Myc modulators and uses thereof

ABSTRACT

The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.

RELATED APPLICATIONS

This application is a divisional of and claims priority under 35 U.S.C.§ 120 to U.S. application, U.S. Ser. No. 14/965,549, filed Dec. 10,2015, which claims priority under 35 U.S.C. § 119 (e) to U.S.Provisional application, U.S. Ser. No. 62/090,290, filed Dec. 10, 2014,each of which is incorporated herein by reference.

GOVERNMENT SUPPORT

This invention was made with government support under grant numberCA160860 awarded by the National Institutes of Health. The governmenthas certain rights in the invention.

BACKGROUND OF THE INVENTION

Activation of c-Myc is one of the most common oncogenic events in humanmalignancies [1, 2]. In normal cells, the Myc family of transcriptionfactors (c-Myc, L-Myc, and N-Myc) regulates a diverse set of biologicalprocesses including DNA replication, gene transcription, and proteintranslation. Consequently, numerous cellular processes are regulated byMyc, including growth, proliferation, apoptosis, metabolism,differentiation, self-renewal, and angiogenesis [3, 4, 5]. It has beenestimated that c-Myc regulates expression of more than 15% of all genesand therefore is considered to be a master regulator [6]. In malignantcells, Myc activation can occur through several mechanisms such as pointmutation, somatic gene amplification, chromosomal translocation,overexpression, enhanced translation, and increased protein stability[2]. One estimate attributes 100,000 cancer deaths annually in theUnited States to deregulation of Myc [6]. Burkitt's lymphoma provides aparadigm for Myc deregulation in malignancy as nearly all cases involvebalanced translocation of the MYC gene and overexpression of theoncoprotein [7, 8]. c-Myc deregulation may result in uncontrolled cellproliferation, alterations in the apoptotic pathway, genomicinstability, escape from immune surveillance, growth factorindependence, and immortalization [2]. The report that the inhibition ofMyc in vivo eradicated lung cancer in mice [9] shows the potential ofMyc as a target in cancer treatment.

SUMMARY OF THE INVENTION

In one aspect, described herein are compounds of Formula (I), andpharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof. The compounds described herein may be modulators(e.g., inhibitors) of Myc (e.g., c-Myc, L-Myc, N-Myc). The compounds maybe useful in modulating (e.g., inhibiting) the activity of Myc in asubject in need thereof, treating diseases associated with Myc (e.g.,diseases associated with aberrant activity (e.g., increased activity) ofMyc) in a subject in need thereof, treating proliferative diseases in asubject in need thereof, preventing diseases associated with Myc (e.g.,diseases associated with aberrant activity (e.g., increased activity) ofMyc) in a subject in need thereof, preventing proliferative diseases ina subject in need thereof, inducing apoptosis of a cell in a subject,biological sample, or tissue, and/or as research tools (e.g., forstudying Myc (e.g., studying the activity of Myc) in a subject,biological sample, tissue, or cell). Also provided are pharmaceuticalcompositions, kits, methods, and uses including a compound describedherein.

In one aspect, the present disclosure provides compounds of Formula(I-a):

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof, wherein R^(A), k, R^(B), W^(a), X^(a)L, Ring A,and R^(D) are as defined herein. Exemplary compounds of Formula (I-a)include, but are not limited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

Exemplary compounds of Formula (I-a) include, but are not limited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

In one aspect, the present disclosure provides compounds of Formula (I):

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof, wherein R^(A), k, R^(B), X, and R^(C) are asdefined herein.

Exemplary compounds of Formula (I) include, but are not limited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

Additional exemplary compounds of Formula (I) include, but are notlimited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

In another aspect, the present disclosure provides compounds of Formula(II):

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof, wherein R^(E), a, and R^(C) are as defined herein.

Exemplary compounds of Formula (II) include, but are not limited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

In another aspect, described herein are pharmaceutical compositionsincluding a compound described herein, and optionally a pharmaceuticallyacceptable excipient. In certain embodiments, a pharmaceuticalcomposition described herein includes an effective amount (e.g.,therapeutically effective amount or prophylactically effective amount)of a compound described herein. In certain embodiments, a pharmaceuticalcomposition described herein further comprises an additionalpharmaceutical agent. The pharmaceutical compositions may be useful inmodulating (e.g., inhibiting) the activity of Myc in a subject in needthereof, treating diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, treating proliferative diseases in a subjectin need thereof, preventing diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, preventing proliferative diseases in asubject in need thereof, inducing apoptosis of a cell in a subject,biological sample, or tissue, and/or as research tools (e.g., forstudying Myc (e.g., studying the activity of Myc) in a subject,biological sample, tissue, or cell).

In certain embodiments, the proliferative disease is associated withaberrant activity (e.g., increased or decreased activity) of Myc. Incertain embodiments, the proliferative disease is associated withincreased activity of Myc. In certain embodiments, the proliferativedisease is cancer, benign neoplasm, or pathological angiogenesis.

In certain embodiments, the subject is a human. In certain embodiments,the subject is a non-human animal. In certain embodiments, the cell isin vitro. In certain embodiments, the cell is in vivo.

In still another aspect, described herein are kits including a containerwith a compound or pharmaceutical composition described herein. A kitdescribed herein may include a single dose or multiple doses of thecompound or pharmaceutical composition. The described kits may be usefulin modulating (e.g., inhibiting) the activity of Myc in a subject inneed thereof, treating diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, treating proliferative diseases in a subjectin need thereof, preventing diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, preventing proliferative diseases in asubject in need thereof, inducing apoptosis of a cell in a subject,biological sample, or tissue, and/or as research tools (e.g., forstudying Myc (e.g., studying the activity of Myc) in a subject,biological sample, tissue, or cell). In certain embodiments, a kitdescribed herein further includes instructions for using the compound orpharmaceutical composition included in the kit.

In another aspect, the present disclosure provides methods of modulating(e.g., inhibiting) the activity of Myc in a subject in need thereof, themethods comprising administering to the subject an effective amount of acompound or pharmaceutical composition described herein.

In another aspect, the present disclosure provides methods of modulating(e.g., inhibiting) the activity of Myc in a biological sample, tissue,or cell, the methods comprising contacting the biological sample,tissue, or cell with an effective amount of a compound or pharmaceuticalcomposition described herein.

In certain embodiments, the compound being administered or usedselectively modulates (e.g., inhibits) the activity of a particular Myc(e.g., c-Myc, L-Myc, and/or N-Myc), compared to a different Myc and/or adifferent transcription factor.

Another aspect of the present disclosure relates to methods of treatinga proliferative disease in a subject in need thereof, the methodscomprising administering to the subject an effective amount of acompound or pharmaceutical composition described herein.

In another aspect, the present disclosure provides methods of preventinga proliferative disease in a subject in need thereof, the methodscomprising administering to the subject an effective amount of acompound or pharmaceutical composition described herein.

In another aspect, the present disclosure provides methods of inducingapoptosis of a cell in a subject, the methods comprising administeringto the subject an effective amount of a compound or pharmaceuticalcomposition described herein.

In another aspect, the present disclosure provides methods of inducingapoptosis of a cell in a biological sample, tissue, or cell, the methodscomprising contacting the biological sample, tissue, or cell with aneffective amount of a compound or pharmaceutical composition describedherein.

Another aspect of the disclosure relates to methods of screening alibrary of compounds to identify a compound that is useful in a methoddescribed herein.

In yet another aspect, the present disclosure provides compounds andpharmaceutical compositions described herein for use in a method of thedisclosure (e.g., a method of modulating (e.g., inhibiting) the activityof Myc, a method of treating a proliferative disease, a method ofpreventing a proliferative disease, a method of inducing apoptosis,and/or a method of screening a library of compounds).

Definitions

Definitions of specific functional groups and chemical terms aredescribed in more detail below. The chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 75^(th) Ed., inside cover, andspecific functional groups are generally defined as described therein.Additionally, general principles of organic chemistry, as well asspecific functional moieties and reactivity, are described in ThomasSorrell, Organic Chemistry, University Science Books, Sausalito, 1999;Smith and March, March's Advanced Organic Chemistry, 5^(th) Edition,John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive OrganicTransformations, VCH Publishers, Inc., New York, 1989; and Carruthers,Some Modern Methods of Organic Synthesis, 3^(rd) Edition, CambridgeUniversity Press, Cambridge, 1987. The disclosure is not intended to belimited in any manner by the exemplary listing of substituents describedherein.

Compounds described herein can comprise one or more asymmetric centers,and thus can exist in various isomeric forms, e.g., enantiomers and/ordiastereomers. For example, the compounds described herein can be in theform of an individual enantiomer, diastereomer or geometric isomer, orcan be in the form of a mixture of stereoisomers, including racemicmixtures and mixtures enriched in one or more stereoisomer. Isomers canbe isolated from mixtures by methods known to those skilled in the art,including chiral high pressure liquid chromatography (HPLC) and theformation and crystallization of chiral salts; or preferred isomers canbe prepared by asymmetric syntheses. See, for example, Jacques et al.,Enantiomers, Racemates and Resolutions (Wiley Interscience, New York,1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistryof Carbon Compounds (McGraw-Hill, N Y, 1962); and Wilen, Tables ofResolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ.of Notre Dame Press, Notre Dame, Ind. 1972). The disclosure additionallyencompasses compounds described herein as individual isomerssubstantially free of other isomers, and alternatively, as mixtures ofvarious isomers.

When a range of values is listed, it is intended to encompass each valueand sub-range within the range. For example “C₁₋₆” is intended toencompass, C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆,C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₅, C₄₋₆, C₄₋₅, and C₅₋₆.

The term “aliphatic” includes both saturated and unsaturated, straightchain (i.e., unbranched), branched, acyclic, cyclic, or polycyclicaliphatic hydrocarbons, which are optionally substituted with one ormore functional groups. As will be appreciated by one of ordinary skillin the art, “aliphatic” is intended herein to include, but is notlimited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, andcycloalkynyl moieties. Thus, the term “alkyl” includes straight,branched and cyclic alkyl groups. An analogous convention applies toother generic terms such as “alkenyl”, “alkynyl”, and the like.Furthermore, the terms “alkyl”, “alkenyl”, “alkynyl”, and the likeencompass both substituted and unsubstituted groups. In certainembodiments, “lower alkyl” is used to indicate those alkyl groups(cyclic, acyclic, substituted, unsubstituted, branched or unbranched)having 1-6 carbon atoms.

In certain embodiments, the alkyl, alkenyl, and alkynyl groups employedin the disclosure contain 1-20 aliphatic carbon atoms. In certain otherembodiments, the alkyl, alkenyl, and alkynyl groups employed in thedisclosure contain 1-10 aliphatic carbon atoms. In yet otherembodiments, the alkyl, alkenyl, and alkynyl groups employed in thedisclosure contain 1-8 aliphatic carbon atoms. In still otherembodiments, the alkyl, alkenyl, and alkynyl groups employed in thedisclosure contain 1-6 aliphatic carbon atoms. In yet other embodiments,the alkyl, alkenyl, and alkynyl groups employed in the disclosurecontain 1-4 carbon atoms. Illustrative aliphatic groups thus include,but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl,cyclopropyl, —CH₂-cyclopropyl, vinyl, allyl, n-butyl, sec-butyl,isobutyl, tert-butyl, cyclobutyl, —CH₂-cyclobutyl, n-pentyl, sec-pentyl,isopentyl, tert-pentyl, cyclopentyl, —CH₂-cyclopentyl, n-hexyl,sec-hexyl, cyclohexyl, —CH₂-cyclohexyl moieties and the like, whichagain, may bear one or more substituents. Alkenyl groups include, butare not limited to, for example, ethenyl, propenyl, butenyl,1-methyl-2-buten-1-yl, and the like. Representative alkynyl groupsinclude, but are not limited to, ethynyl, 2-propynyl (propargyl),1-propynyl, and the like.

The term “alkyl” refers to a radical of a straight-chain or branchedsaturated hydrocarbon group having from 1 to 10 carbon atoms (“C₁₋₁₀alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms(“C₁₋₉ alkyl”). In some embodiments, an alkyl group has 1 to 8 carbonatoms (“C₁₋₈ alkyl”). In some embodiments, an alkyl group has 1 to 7carbon atoms (“C₁₋₇ alkyl”). In some embodiments, an alkyl group has 1to 6 carbon atoms (“C₁₋₆ alkyl”). In some embodiments, an alkyl grouphas 1 to 5 carbon atoms (“C₁₋₅ alkyl”). In some embodiments, an alkylgroup has 1 to 4 carbon atoms (“C₁₋₄ alkyl”). In some embodiments, analkyl group has 1 to 3 carbon atoms (“C₁₋₃ alkyl”). In some embodiments,an alkyl group has 1 to 2 carbon atoms (“C₁₋₂ alkyl”). In someembodiments, an alkyl group has 1 carbon atom (“C₁ alkyl”). In someembodiments, an alkyl group has 2 to 6 carbon atoms (“C₂₋₆ alkyl”).Examples of C₁₋₆ alkyl groups include methyl (C₁), ethyl (C₂), propyl(C₃) (e.g., n-propyl, isopropyl), butyl (C₄) (e.g., n-butyl, tert-butyl,sec-butyl, iso-butyl), pentyl (C₅) (e.g., n-pentyl, 3-pentanyl, amyl,neopentyl, 3-methyl-2-butanyl, tertiary amyl), and hexyl (C₆) (e.g.,n-hexyl). Additional examples of alkyl groups include n-heptyl (C₇),n-octyl (C₈), and the like. Unless otherwise specified, each instance ofan alkyl group is independently unsubstituted (an “unsubstituted alkyl”)or substituted (a “substituted alkyl”) with one or more substituents(e.g., halogen, such as F). In certain embodiments, the alkyl group isan unsubstituted C₁₋₁₀ alkyl (such as unsubstituted C₁₋₆ alkyl, e.g.,—CH₃ (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g.,unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)),unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu),unsubstituted tert-butyl (tert-Bu or t-Bu), unsubstituted sec-butyl(sec-Bu), unsubstituted isobutyl (i-Bu)). In certain embodiments, thealkyl group is a substituted C₁₋₁₀ alkyl (such as substituted C₁₋₆alkyl, e.g., —CF₃, Bn).

“Alkenyl” refers to a radical of a straight-chain or branchedhydrocarbon group having from 2 to 20 carbon atoms, one or morecarbon-carbon double bonds, and no triple bonds (“C₂₋₂₀ alkenyl”). Insome embodiments, an alkenyl group has 2 to 10 carbon atoms (“C₂₋₁₀alkenyl”). In some embodiments, an alkenyl group has 2 to 9 carbon atoms(“C₂₋₉ alkenyl”). In some embodiments, an alkenyl group has 2 to 8carbon atoms (“C₂₋₈ alkenyl”). In some embodiments, an alkenyl group has2 to 7 carbon atoms (“C₂₋₇ alkenyl”). In some embodiments, an alkenylgroup has 2 to 6 carbon atoms (“C₂₋₆ alkenyl”). In some embodiments, analkenyl group has 2 to 5 carbon atoms (“C₂₋₅ alkenyl”). In someembodiments, an alkenyl group has 2 to 4 carbon atoms (“C₂₋₄ alkenyl”).In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C₂₋₃alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C₂alkenyl”). The one or more carbon-carbon double bonds can be internal(such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples ofC₂₋₄ alkenyl groups include ethenyl (C₂), 1-propenyl (C₃), 2-propenyl(C₃), 1-butenyl (C₄), 2-butenyl (C₄), butadienyl (C₄), and the like.Examples of C₂₋₆ alkenyl groups include the aforementioned C₂₋₄ alkenylgroups as well as pentenyl (C₅), pentadienyl (C₅), hexenyl (C₆), and thelike. Additional examples of alkenyl include heptenyl (C₇), octenyl(C₈), octatrienyl (C₈), and the like. Unless otherwise specified, eachinstance of an alkenyl group is independently optionally substituted,i.e., unsubstituted (an “unsubstituted alkenyl”) or substituted (a“substituted alkenyl”) with one or more substituents. In certainembodiments, the alkenyl group is unsubstituted C₂₋₁₀ alkenyl. Incertain embodiments, the alkenyl group is substituted C₂₋₁₀ alkenyl. Inan alkenyl group, a C═C double bond for which the stereochemistry is notspecified (e.g., —CH═CHCH₃ or

may be an (E)- or (Z)-double bond.

“Alkynyl” refers to a radical of a straight-chain or branchedhydrocarbon group having from 2 to 20 carbon atoms, one or morecarbon-carbon triple bonds, and optionally one or more double bonds(“C₂₋₂₀ alkynyl”). In some embodiments, an alkynyl group has 2 to 10carbon atoms (“C₂₋₁₀ alkynyl”). In some embodiments, an alkynyl grouphas 2 to 9 carbon atoms (“C₂₋₉ alkynyl”). In some embodiments, analkynyl group has 2 to 8 carbon atoms (“C₂₋₈ alkynyl”). In someembodiments, an alkynyl group has 2 to 7 carbon atoms (“C₂₋₇ alkynyl”).In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C₂₋₆alkynyl”). In some embodiments, an alkynyl group has 2 to 5 carbon atoms(“C₂₋₅ alkynyl”). In some embodiments, an alkynyl group has 2 to 4carbon atoms (“C₂₋₄ alkynyl”). In some embodiments, an alkynyl group has2 to 3 carbon atoms (“C₂₋₃ alkynyl”). In some embodiments, an alkynylgroup has 2 carbon atoms (“C₂ alkynyl”). The one or more carbon-carbontriple bonds can be internal (such as in 2-butynyl) or terminal (such asin 1-butynyl). Examples of C₂₋₄ alkynyl groups include, withoutlimitation, ethynyl (C₂), 1-propynyl (C₃), 2-propynyl (C₃), 1-butynyl(C₄), 2-butynyl (C₄), and the like. Examples of C₂₋₆ alkenyl groupsinclude the aforementioned C₂₋₄ alkynyl groups as well as pentynyl (C₅),hexynyl (C₆), and the like. Additional examples of alkynyl includeheptynyl (C₇), octynyl (C₈), and the like. Unless otherwise specified,each instance of an alkynyl group is independently optionallysubstituted, i.e., unsubstituted (an “unsubstituted alkynyl”) orsubstituted (a “substituted alkynyl”) with one or more substituents. Incertain embodiments, the alkynyl group is unsubstituted C₂₋₁₀ alkynyl.In certain embodiments, the alkynyl group is substituted C₂₋₁₀ alkynyl.

“Carbocyclyl” or “carbocyclic” refers to a radical of a non-aromaticcyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C₃₋₁₀carbocyclyl”) and zero heteroatoms in the non-aromatic ring system. Insome embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms(“C₃₋₈ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to6 ring carbon atoms (“C₃₋₆ carbocyclyl”). In some embodiments, acarbocyclyl group has 3 to 6 ring carbon atoms (“C₃₋₆ carbocyclyl”). Insome embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms(“C₅₋₁₀ carbocyclyl”). Exemplary C₃₋₆ carbocyclyl groups include,without limitation, cyclopropyl (C₃), cyclopropenyl (C₃), cyclobutyl(C₄), cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅),cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), and the like.Exemplary C₃₋₈ carbocyclyl groups include, without limitation, theaforementioned C₃₋₆ carbocyclyl groups as well as cycloheptyl (C₇),cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇),cyclooctyl (C₈), cyclooctenyl (C₈), bicyclo[2.2.1]heptanyl (C₇),bicyclo[2.2.2]octanyl (C₈), and the like. Exemplary C₃₋₁₀ carbocyclylgroups include, without limitation, the aforementioned C₃₋₈ carbocyclylgroups as well as cyclononyl (C₉), cyclononenyl (C₉), cyclodecyl (C₁₀),cyclodecenyl (C₁₀), octahydro-1H-indenyl (C₉), decahydronaphthalenyl(C₁₀), spiro[4.5]decanyl (C₁₀), and the like. As the foregoing examplesillustrate, in certain embodiments, the carbocyclyl group is eithermonocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged orspiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) andcan be saturated or can be partially unsaturated. “Carbocyclyl” alsoincludes ring systems wherein the carbocyclic ring, as defined above, isfused with one or more aryl or heteroaryl groups wherein the point ofattachment is on the carbocyclic ring, and in such instances, the numberof carbons continue to designate the number of carbons in thecarbocyclic ring system. Unless otherwise specified, each instance of acarbocyclyl group is independently optionally substituted, i.e.,unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a“substituted carbocyclyl”) with one or more substituents. In certainembodiments, the carbocyclyl group is unsubstituted C₃₋₁₀ carbocyclyl.In certain embodiments, the carbocyclyl group is substituted C₃₋₁₀carbocyclyl.

In some embodiments, “carbocyclyl” is a monocyclic, saturatedcarbocyclyl group having from 3 to 10 ring carbon atoms (“C₃₋₁₀cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ringcarbon atoms (“C₃₋₈ cycloalkyl”). In some embodiments, a cycloalkylgroup has 3 to 6 ring carbon atoms (“C₃₋₆ cycloalkyl”). In someembodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C₅₋₆cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ringcarbon atoms (“C₅₋₁₀ cycloalkyl”). Examples of C₅₋₆ cycloalkyl groupsinclude cyclopentyl (C₅) and cyclohexyl (C₅). Examples of C₃₋₆cycloalkyl groups include the aforementioned C₅₋₆ cycloalkyl groups aswell as cyclopropyl (C₃) and cyclobutyl (C₄). Examples of C₃₋₈cycloalkyl groups include the aforementioned C₃₋₆ cycloalkyl groups aswell as cycloheptyl (C₇) and cyclooctyl (C₈). Unless otherwisespecified, each instance of a cycloalkyl group is independentlyunsubstituted (an “unsubstituted cycloalkyl”) or substituted (a“substituted cycloalkyl”) with one or more substituents. In certainembodiments, the cycloalkyl group is unsubstituted C₃₋₁₀ cycloalkyl. Incertain embodiments, the cycloalkyl group is substituted C₃₋₁₀cycloalkyl.

“Heterocyclyl” or “heterocyclic” refers to a radical of a 3- to10-membered non-aromatic ring system having ring carbon atoms and 1 to 4ring heteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 memberedheterocyclyl”). In heterocyclyl groups that contain one or more nitrogenatoms, the point of attachment can be a carbon or nitrogen atom, asvalency permits. A heterocyclyl group can either be monocyclic(“monocyclic heterocyclyl”) or a fused, bridged, or spiro ring system,such as a bicyclic system (“bicyclic heterocyclyl”), and can besaturated or can be partially unsaturated. Heterocyclyl bicyclic ringsystems can include one or more heteroatoms in one or both rings.“Heterocyclyl” also includes ring systems wherein the heterocyclic ring,as defined above, is fused with one or more carbocyclyl groups whereinthe point of attachment is either on the carbocyclyl or heterocyclicring, or ring systems wherein the heterocyclic ring, as defined above,is fused with one or more aryl or heteroaryl groups, wherein the pointof attachment is on the heterocyclic ring, and in such instances, thenumber of ring members continue to designate the number of ring membersin the heterocyclic ring system. Unless otherwise specified, eachinstance of heterocyclyl is independently optionally substituted, i.e.,unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a“substituted heterocyclyl”) with one or more substituents. In certainembodiments, the heterocyclyl group is unsubstituted 3-10 memberedheterocyclyl. In certain embodiments, the heterocyclyl group issubstituted 3-10 membered heterocyclyl.

In some embodiments, a heterocyclyl group is a 5-10 memberednon-aromatic ring system having ring carbon atoms and 1-4 ringheteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 memberedheterocyclyl”). In some embodiments, a heterocyclyl group is a 5-8membered non-aromatic ring system having ring carbon atoms and 1-4 ringheteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In someembodiments, a heterocyclyl group is a 5-6 membered non-aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms, wherein eachheteroatom is independently selected from nitrogen, oxygen, and sulfur(“5-6 membered heterocyclyl”). In some embodiments, the 5-6 memberedheterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen,and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2ring heteroatoms selected from nitrogen, oxygen, and sulfur. In someembodiments, the 5-6 membered heterocyclyl has one ring heteroatomselected from nitrogen, oxygen, and sulfur.

Exemplary 3-membered heterocyclyl groups containing one heteroatominclude, without limitation, azirdinyl, oxiranyl, thiiranyl. Exemplary4-membered heterocyclyl groups containing one heteroatom include,without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary5-membered heterocyclyl groups containing one heteroatom include,without limitation, tetrahydrofuranyl, dihydrofuranyl,tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl,and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groupscontaining two heteroatoms include, without limitation, dioxolanyl,oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-memberedheterocyclyl groups containing three heteroatoms include, withoutlimitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary6-membered heterocyclyl groups containing one heteroatom include,without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl,and thianyl. Exemplary 6-membered heterocyclyl groups containing twoheteroatoms include, without limitation, piperazinyl, morpholinyl,dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groupscontaining two heteroatoms include, without limitation, triazinanyl.Exemplary 7-membered heterocyclyl groups containing one heteroatominclude, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary8-membered heterocyclyl groups containing one heteroatom include,without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary5-membered heterocyclyl groups fused to a C₆ aryl ring (also referred toherein as a 5,6-bicyclic heterocyclic ring) include, without limitation,indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groupsfused to an aryl ring (also referred to herein as a 6,6-bicyclicheterocyclic ring) include, without limitation, tetrahydroquinolinyl,tetrahydroisoquinolinyl, and the like.

“Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclicor tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pielectrons shared in a cyclic array) having 6-14 ring carbon atoms andzero heteroatoms provided in the aromatic ring system (“C₆₋₁₄ aryl”). Insome embodiments, an aryl group has six ring carbon atoms (“C₆ aryl”;e.g., phenyl). In some embodiments, an aryl group has ten ring carbonatoms (“C₁₀ aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). Insome embodiments, an aryl group has fourteen ring carbon atoms (“C₁₄aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein thearyl ring, as defined above, is fused with one or more carbocyclyl orheterocyclyl groups wherein the radical or point of attachment is on thearyl ring, and in such instances, the number of carbon atoms continue todesignate the number of carbon atoms in the aryl ring system. Unlessotherwise specified, each instance of an aryl group is independentlyoptionally substituted, i.e., unsubstituted (an “unsubstituted aryl”) orsubstituted (a “substituted aryl”) with one or more substituents. Incertain embodiments, the aryl group is unsubstituted C₆₋₁₄ aryl. Incertain embodiments, the aryl group is substituted C₆₋₁₄ aryl.

“Aralkyl” is a subset of alkyl and aryl and refers to an optionallysubstituted alkyl group substituted by an optionally substituted arylgroup. In certain embodiments, the aralkyl is optionally substitutedbenzyl. In certain embodiments, the aralkyl is benzyl. In certainembodiments, the aralkyl is optionally substituted phenethyl. In certainembodiments, the aralkyl is phenethyl.

“Heteroaryl” refers to a radical of a 5-10 membered monocyclic orbicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electronsshared in a cyclic array) having ring carbon atoms and 1-4 ringheteroatoms provided in the aromatic ring system, wherein eachheteroatom is independently selected from nitrogen, oxygen and sulfur(“5-10 membered heteroaryl”). In heteroaryl groups that contain one ormore nitrogen atoms, the point of attachment can be a carbon or nitrogenatom, as valency permits. Heteroaryl bicyclic ring systems can includeone or more heteroatoms in one or both rings. “Heteroaryl” includes ringsystems wherein the heteroaryl ring, as defined above, is fused with oneor more carbocyclyl or heterocyclyl groups wherein the point ofattachment is on the heteroaryl ring, and in such instances, the numberof ring members continue to designate the number of ring members in theheteroaryl ring system. “Heteroaryl” also includes ring systems whereinthe heteroaryl ring, as defined above, is fused with one or more arylgroups wherein the point of attachment is either on the aryl orheteroaryl ring, and in such instances, the number of ring membersdesignates the number of ring members in the fused (aryl/heteroaryl)ring system. Bicyclic heteroaryl groups wherein one ring does notcontain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and thelike) the point of attachment can be on either ring, i.e., either thering bearing a heteroatom (e.g., 2-indolyl) or the ring that does notcontain a heteroatom (e.g., 5-indolyl).

In some embodiments, a heteroaryl group is a 5-10 membered aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-8 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-6 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In someembodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatomsselected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen,oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unlessotherwise specified, each instance of a heteroaryl group isindependently optionally substituted, i.e., unsubstituted (an“unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”)with one or more substituents. In certain embodiments, the heteroarylgroup is unsubstituted 5-14 membered heteroaryl. In certain embodiments,the heteroaryl group is substituted 5-14 membered heteroaryl.

Exemplary 5-membered heteroaryl groups containing one heteroatominclude, without limitation, pyrrolyl, furanyl, and thiophenyl.Exemplary 5-membered heteroaryl groups containing two heteroatomsinclude, without limitation, imidazolyl, pyrazolyl, oxazolyl,isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroarylgroups containing three heteroatoms include, without limitation,triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-memberedheteroaryl groups containing four heteroatoms include, withoutlimitation, tetrazolyl. Exemplary 6-membered heteroaryl groupscontaining one heteroatom include, without limitation, pyridinyl.Exemplary 6-membered heteroaryl groups containing two heteroatomsinclude, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.Exemplary 6-membered heteroaryl groups containing three or fourheteroatoms include, without limitation, triazinyl and tetrazinyl,respectively. Exemplary 7-membered heteroaryl groups containing oneheteroatom include, without limitation, azepinyl, oxepinyl, andthiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, withoutlimitation, indolyl, isoindolyl, indazolyl, benzotriazolyl,benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl,benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl,benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, andpurinyl. Exemplary 6,6-bicyclic heteroaryl groups include, withoutlimitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl,cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

“Heteroaralkyl” is a subset of alkyl and heteroaryl and refers to anoptionally substituted alkyl group substituted by an optionallysubstituted heteroaryl group.

“Unsaturated” or “partially unsaturated” refers to a group that includesat least one double or triple bond. A “partially unsaturated” ringsystem is further intended to encompass rings having multiple sites ofunsaturation, but is not intended to include aromatic groups (e.g., arylor heteroaryl groups). Likewise, “saturated” refers to a group that doesnot contain a double or triple bond, i.e., contains all single bonds.

Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroarylgroups, which are divalent bridging groups, are further referred tousing the suffix -ene, e.g., alkylene, alkenylene, alkynylene,carbocyclylene, heterocyclylene, arylene, and heteroarylene.

An atom, moiety, or group described herein may be unsubstituted orsubstituted, as valency permits, unless otherwise provided expressly.The term “optionally substituted” refers to substituted orunsubstituted.

A group is optionally substituted unless expressly provided otherwise.The term “optionally substituted” refers to being substituted orunsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionallysubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted”or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl,“substituted” or “unsubstituted” carbocyclyl, “substituted” or“unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or“substituted” or “unsubstituted” heteroaryl group). In general, the term“substituted”, whether preceded by the term “optionally” or not, meansthat at least one hydrogen present on a group (e.g., a carbon ornitrogen atom) is replaced with a permissible substituent, e.g., asubstituent which upon substitution results in a stable compound, e.g.,a compound which does not spontaneously undergo transformation such asby rearrangement, cyclization, elimination, or other reaction. Unlessotherwise indicated, a “substituted” group has a substituent at one ormore substitutable positions of the group, and when more than oneposition in any given structure is substituted, the substituent iseither the same or different at each position. The term “substituted” iscontemplated to include substitution with all permissible substituentsof organic compounds, any of the substituents described herein thatresults in the formation of a stable compound. The present disclosurecontemplates any and all such combinations in order to arrive at astable compound. For purposes of this disclosure, heteroatoms such asnitrogen may have hydrogen substituents and/or any suitable substituentas described herein which satisfy the valencies of the heteroatoms andresults in the formation of a stable moiety. In certain embodiments, thesubstituent is a carbon atom substituent. In certain embodiments, thesubstituent is a nitrogen atom substituent. In certain embodiments, thesubstituent is an oxygen atom substituent. In certain embodiments, thesubstituent is a sulfur atom substituent.

Exemplary carbon atom substituents include, but are not limited to,halogen, —CN, —NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(aa), —ON(R^(bb))₂,—N(R^(bb))₂, —N(R^(bb))₃ ⁺X⁻, —N(OR^(cc))R^(bb), —SH, —SSR^(cc),—C(═O)R^(aa), —CO₂H, —CHO, —C(OR^(cc))₂, —CO₂R^(aa), —OC(═O)R^(aa),—OCO₂R^(aa), —C(═O)N(R^(bb))₂, —OC(═O)N(R^(bb))₂, —NR^(bb)C(═O)R^(aa),—NR^(bb)CO₂R^(aa), —NR^(bb)C(═O)N(R^(bb))₂, —C(═NR^(bb))R^(aa),—C(═NR^(bb))OR^(aa), —OC(═NR^(bb))R^(aa), —OC(═NR^(bb))OR^(aa),—C(═NR^(bb))N(R^(bb))₂, —OC(═NR^(bb))N(R^(bb))₂,—NR^(bb)C(═NR^(bb))N(R^(bb))₂, —C(═O)NR^(bb)SO₂R^(aa),—NR^(bb)SO₂R^(aa), —SO₂N(R^(bb))₂, —SO₂R^(aa), —SO₂OR^(aa), —OSO₂R^(aa),—S(═O)R^(aa), —OS(═O)R^(aa), —Si(R^(aa))₃,—OSi(R^(aa))₃—C(═S)N(R^(bb))₂, —C(═O)SR^(aa), —C(═S)SR^(aa),—SC(═S)SR^(a), —SC(═O)SR^(aa), —OC(═O)SR^(aa), —SC(═O)OR^(aa),—SC(═O)R^(aa), —P(═O)(R^(aa))₂, —P(═O)(OR^(cc))₂, —OP(═O)(R^(aa))₂,—OP(═O)(OR^(cc))₂, —P(═O)(N(R^(bb))₂)₂, —OP(═O)(N(R^(bb))₂)₂,—NR^(bb)P(═O)(R^(aa))₂, —NR^(bb)P(═O)(OR^(cc))₂,—NR^(bb)P(═O)(N(R^(bb))₂)₂, —P(R^(cc))₂, —P(OR^(cc))₂, —P(R^(cc))₃ ⁺X⁻,—P(OR^(cc))₃ ⁺X⁻, —P(R^(cc))₄, —P(OR^(cc))₄, —OP(R^(cc))₂, —OP(R^(cc))₃⁺X⁻, —OP(OR^(cc))₂, —OP(OR^(cc))₃ ⁺X⁻, —OP(R^(cc))₄, —OP(OR^(cc))₄,—B(R^(aa))₂, —B(OR^(cc))₂, —BR^(aa)(OR^(cc)), C₁₋₁₀ alkyl, C₁₋₁₀perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀ carbocyclyl, 3-14membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, whereineach alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^(dd)groups; wherein X⁻ is a counterion;

or two geminal hydrogens on a carbon atom are replaced with the group═O, ═S, ═NN(R^(bb))₂, ═NNR^(bb)C(═O)R^(aa), ═NNR^(bb)C(═O)OR^(aa),═NNR^(bb)S(═O)₂R^(aa), ═NR^(bb), or ═NOR^(cc);

each instance of R^(aa) is, independently, selected from C₁₋₁₀ alkyl,C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀ carbocyclyl,3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, ortwo R^(aa) groups are joined to form a 3-14 membered heterocyclyl or5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(bb) is, independently, selected from hydrogen, —OH,—OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa), —C(═O)N(R^(cc))₂, —CO₂R^(aa),—SO₂R^(aa), —C(═NR^(cc))OR^(aa), —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂,—SO₂R^(cc), —SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc),—C(═S)SR^(cc), —P(═O)(R^(aa))₂, —P(═O)(OR^(cc))₂, —P(═O)(N(R^(cc))₂)₂,C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂ 10 alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(bb) groups are joined to form a 3-14 memberedheterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl,alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl isindependently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;wherein X⁻ is a counterion;

each instance of R^(cc) is, independently, selected from hydrogen, C₁₋₁₀alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(cc) groups are joined to form a 3-14 memberedheterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl,alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl isindependently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(dd) is, independently, selected from halogen, —CN,—NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(ee), —ON(R^(ff))₂, —N(R^(ff))₂,—N(R^(ff))₃ ⁺X⁻, —N(OR^(ee))R^(ff), —SH, —SR^(ee), —SSR^(ee),—C(═O)R^(ee), —CO₂H, —CO₂R^(ee), —OC(═O)R^(ee), —OCO₂R^(ee),—C(═O)N(R^(ff))₂, —OC(═O)N(R^(ff))₂, —NR^(ff)C(═O)R^(ee),—NR^(ff)CO₂R^(ee), —NR^(ff)C(═O)N(R^(ff))₂, —C(═NR^(ff))OR^(ee),—OC(═NR^(ff))R^(ee), OC(═NR^(ff))OR^(ee), —C(═NR^(ff))N(R^(ff))₂,—OC(═NR^(ff))N(R^(ff))₂, —NR^(ff)C(═NR^(ff))N(R^(ff))₂,—NR^(ff)SO₂R^(ee), —SO₂N(R^(ff))₂, —SO₂R^(ee), —SO₂OR^(ee), —OSO₂R^(ee),—S(═O)R^(ee), —Si(R^(ee))₃, —OSi(R^(ee))₃, —C(═S)N(R^(ff))₂,—C(═O)SR^(ee), —C(═S)SR^(ee), —SC(═S)SR^(ee), —P(═O)(OR^(ee))₂,—P(═O)(R^(ee))₂, —OP(═O)(R^(ee))₂, —OP(═O)(OR^(ee))₂, C₁₋₆ alkyl, C₁₋₆perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl, 3-10membered heterocyclyl, C₆₋₁₀ aryl, 5-10 membered heteroaryl, whereineach alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^(gg)groups, or two geminal R^(dd) substituents can be joined to form ═O or═S; wherein X⁻ is a counterion;

each instance of R^(ee) is, independently, selected from C₁₋₆ alkyl,C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl, C₆₋₁₀aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, whereineach alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, andheteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 R^(gg)groups;

each instance of R^(ff) is, independently, selected from hydrogen, C₁₋₆alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl,3-10 membered heterocyclyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl, ortwo R^(ff) groups are joined to form a 3-14 membered heterocyclyl or5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(gg) groups; and

each instance of R^(gg) is, independently, halogen, —CN, —NO₂, —N₃,—SO₂H, —SO₃H, —OH, —OC₁₋₆ alkyl, —ON(C₁₋₆ alkyl)₂, —N(C₁₋₆ alkyl)₂,—N(C₁₋₆ alkyl)₃ ⁺X⁻, —NH(C₁₋₆ alkyl)₂ ⁺X⁻, —NH₂(C₁₋₆ alkyl)⁺X⁻, —NH₃⁺X⁻, —N(OC₁₋₆ alkyl)(C₁₋₆ alkyl), —N(OH)(C₁₋₆ alkyl), —NH(OH), —SH,—SC₁₋₆ alkyl, —SS(C₁₋₆ alkyl), —C(═O)(C₁₋₆ alkyl), —CO₂H, —CO₂(C₁₋₆alkyl), —OC(═O)(C₁₋₆ alkyl), —OCO₂(C₁₋₆ alkyl), —C(═O)NH₂, —C(═O)N(C₁₋₆alkyl)₂, —OC(═O)NH(C₁₋₆ alkyl), —NHC(═O)(C₁₋₆ alkyl), —N(C₁₋₆alkyl)C(═O)(C₁₋₆ alkyl), —NHCO₂(C₁₋₆ alkyl), —NHC(═O)N(C₁₋₆ alkyl)₂,—NHC(═O)NH(C₁₋₆ alkyl), —NHC(═O)NH₂, —C(═NH)O(C₁₋₆ alkyl), —OC(═NH)(C₁₋₆alkyl), —OC(═NH)OC₁₋₆ alkyl, —C(═NH)N(C₁₋₆ alkyl)₂, —C(═NH)NH(C₁₋₆alkyl), —C(═NH)NH₂, —OC(═NH)N(C₁₋₆ alkyl)₂, —OC(NH)NH(C₁₋₆ alkyl),—OC(NH)NH₂, —NHC(NH)N(C₁₋₆ alkyl)₂, —NHC(═NH)NH₂, —NHSO₂(C₁₋₆ alkyl),—SO₂N(C₁₋₆ alkyl)₂, —SO₂NH(C₁₋₆ alkyl), —SO₂NH₂, —SO₂C₁₋₆ alkyl,—SO₂OC₁₋₆ alkyl, —OSO₂C₁₋₆ alkyl, —SOC₁₋₆ alkyl, —Si(C₁₋₆ alkyl)₃,—OSi(C₁₋₆ alkyl)₃-C(═S)N(C₁₋₆ alkyl)₂, C(═S)NH(C₁₋₆ alkyl), C(═S)NH₂,—C(═O)S(C₁₋₆ alkyl), —C(═S)SC₁₋₆ alkyl, —SC(═S)SC₁₋₆ alkyl, —P(═O)(OC₁₋₆alkyl)₂, —P(═O)(C₁₋₆ alkyl)₂, —OP(═O)(C₁₋₆ alkyl)₂, —OP(═O)(OC₁₋₆alkyl)₂, C₁₋₆ alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ carbocyclyl, C₆₋₁₀ aryl, 3-10 membered heterocyclyl, 5-10 memberedheteroaryl; or two geminal R^(gg) substituents can be joined to form ═Oor ═S; wherein X⁻ is a counterion.

A “counterion” or “anionic counterion” is a negatively charged groupassociated with a positively charged group in order to maintainelectronic neutrality. An anionic counterion may be monovalent (i.e.,including one formal negative charge). An anionic counterion may also bemultivalent (i.e., including more than one formal negative charge), suchas divalent or trivalent. Exemplary counterions include halide ions(e.g., F⁻, Cl⁻, Br⁻, I⁻), NO₃ ⁻, ClO₄ ⁻, OH⁻, H₂PO₄ ⁻, HSO₄ ⁻, sulfonateions (e.g., methansulfonate, trifluoromethanesulfonate,p-toluenesulfonate, benzenesulfonate, 10-camphor sulfonate,naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate,ethan-1-sulfonic acid-2-sulfonate, and the like), carboxylate ions(e.g., acetate, propanoate, benzoate, glycerate, lactate, tartrate,glycolate, gluconate, and the like), BF₄ ⁻, PF₄ ⁻, PF₆ ⁻, AsF₆ ⁻, SbF₆⁻, B[3,5-(CF₃)₂C₆H₃]₄]⁻, BPh₄ ⁻, Al(OC(CF₃)₃)₄ ⁻, and a carborane anion(e.g., CB₁₁H₁₂ ⁻ or (HCB₁₁Me₅Br₆)⁻). Exemplary counterions which may bemultivalent include CO₃ ²⁻, HPO₄ ²⁻, PO₄ ³⁻, B₄O₇ ²⁻, SO₄ ²⁻, S₂O₃ ²⁻,carboxylate anions (e.g., tartrate, citrate, fumarate, maleate, malate,malonate, gluconate, succinate, glutarate, adipate, pimelate, suberate,azelate, sebacate, salicylate, phthalates, aspartate, glutamate, and thelike), and carboranes.

“Halo” or “halogen” refers to fluorine (fluoro, —F), chlorine (chloro,—Cl), bromine (bromo, —Br), or iodine (iodo, —I).

“Acyl” refers to a moiety selected from the group consisting of—C(═O)R^(aa), —CHO, —CO₂R^(aa), —C(═O)N(R^(bb))₂, —C(═NR^(bb))R^(aa),—C(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂, —C(═O)NR^(bb)SO₂R^(aa),—C(═S)N(R^(bb))₂, —C(═O)SR^(aa), or —C(═S)SR^(aa), wherein R^(aa) andR^(bb) are as defined herein.

Nitrogen atoms can be substituted or unsubstituted as valency permits,and include primary, secondary, tertiary, and quaternary nitrogen atoms.Exemplary nitrogen atom substituents include, but are not limited to,hydrogen, —OH, —OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa),—C(═O)N(R^(cc))₂, —CO₂R^(aa), —SO₂R^(aa), —C(═NR^(bb))R^(aa),—C(═NR^(cc))OR^(aa), —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc),—SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc),—P(═O)(OR^(cc))₂, —P(═O)(R^(aa))₂, —P(═O)(N(R^(cc))₂)₂, C₁₋₁₀ alkyl,C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀ carbocyclyl,3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 membered heteroaryl, ortwo R^(cc) groups attached to a nitrogen atom are joined to form a 3-14membered heterocyclyl or 5-14 membered heteroaryl ring, wherein eachalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroarylis independently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups, andwherein R^(aa), R^(bb), R^(cc), and R^(dd) are as defined above.

In certain embodiments, the substituent present on a nitrogen atom is anitrogen protecting group (also referred to as an amino protectinggroup). Nitrogen protecting groups include, but are not limited to, —OH,—OR^(aa), —N(R^(cc))₂, —C(═O)R^(aa), —C(═O)N(R^(cc))₂, —CO₂R^(aa),—SO₂R^(aa), —C(═NR^(cc))R^(aa), —C(═NR^(cc))OR^(aa),—C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc), —SO₂OR^(cc),—SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc), C₁₋₁₀ alkyl(e.g., aralkyl, heteroaralkyl), C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aralkyl, aryl, and heteroaryl is independently substitutedwith 0, 1, 2, 3, 4, or 5 R^(dd) groups, and wherein R^(aa), R^(bb),R^(cc) and R^(dd) are as defined herein. Nitrogen protecting groups arewell known in the art and include those described in detail inProtecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts,3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

For example, nitrogen protecting groups such as amide groups (e.g.,—C(═O)R^(aa)) include, but are not limited to, formamide, acetamide,chloroacetamide, trichloroacetamide, trifluoroacetamide,phenylacetamide, 3-phenylpropanamide, picolinamide,3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide,p-phenylbenzamide, o-nitophenylacetamide, o-nitrophenoxyacetamide,acetoacetamide, (N′-dithiobenzyloxyacylamino)acetamide,3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide,2-methyl-2-(o-nitrophenoxy)propanamide,2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide,3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethioninederivative, o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide.

Nitrogen protecting groups such as carbamate groups (e.g.,—C(═O)OR^(aa)) include, but are not limited to, methyl carbamate, ethylcarbamate, 9-fluorenylmethyl carbamate (Fmoc),9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethylcarbamate,2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methylcarbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc),2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate(Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethylcarbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate,1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC),1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC),1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc),1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2′- and4′-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethylcarbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc),vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallylcarbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate(Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz),p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzylcarbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzylcarbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate,2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate,2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methylcarbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc),2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate(Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc),1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate,p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate,2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenylcarbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate,3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methylcarbamate, t-amyl S-benzyl thiocarbamate, p-cyanobenzyl carbamate,cyclobutyl carbamate, cyclohexyl cyclopentyl carbamate,cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate,2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzylcarbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate,1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate,2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate,isobutyl carbamate, isonicotinyl carbamate,p-(p′-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate,1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate,1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate,1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethylcarbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate,p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate,4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzylcarbamate.

Nitrogen protecting groups such as sulfonamide groups (e.g.,—S(═O)₂R^(aa)) include, but are not limited to, p-toluenesulfonamide(Ts), benzenesulfonamide, 2,3,6,-trimethyl-4-methoxybenzenesulfonamide(Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb),2,6-dimethyl-4-methoxybenzenesulfonamide (Pme),2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte),4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide(Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds),2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide(Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide,4-(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS),benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.

Other nitrogen protecting groups include, but are not limited to,phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacylderivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanylderivative, N-acetylmethionine derivative,4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts),N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole,N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE),5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted3,5-dinitro-4-pyridone, N-methylamine, N-allylamine,N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine,N-(1-isopropyl-4-nitro-2-oxo-3-pyroolin-3-yl)amine, quaternary ammoniumsalts, N-benzylamine, N-di(4-methoxyphenyl)methylamine,N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr),N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr),N-9-phenylfluorenylamine (PhF),N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm),N-2-picolylamino N′-oxide, N-1,1-dimethylthiomethyleneamine,N-benzylideneamine, N-p-methoxybenzylideneamine,N-diphenylmethyleneamine, N-[(2-N—(N′,N′-dimethylaminomethylene)amine,N,N′-isopropylidenediamine, N-p-nitrobenzylideneamine,N-salicylideneamine, N-5-chlorosalicylideneamine,N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine,N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine,N-borane derivative, N-diphenylborinic acid derivative,N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate,N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide,diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzylphosphoramidate, diphenyl phosphoramidate, benzenesulfenamide,o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide,pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide,triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

Exemplary oxygen atom substituents include, but are not limited to,—R^(aa), —C(═O)SR^(aa), —C(═O)R^(aa), —CO₂R^(aa), —C(═O)N(R^(bb))₂,—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂,—S(═O)R^(aa), —SO₂R, —Si(R^(aa))₃, —P(R^(cc))₂, —P(R^(cc))₃ ⁺X⁻,—P(OR^(cc))₂, —P(OR^(cc))₃ ⁺X⁻, —P(═O)(R^(aa))₂, —P(═O)(OR^(cc))₂, and—P(═O)(N(R^(bb))₂)₂, wherein X⁻, R^(aa), R^(bb), and R^(cc) are asdefined herein. In certain embodiments, the oxygen atom substituentpresent on an oxygen atom is an oxygen protecting group (also referredto as a hydroxyl protecting group). Oxygen protecting groups are wellknown in the art and include those described in detail in ProtectingGroups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3^(rd)edition, John Wiley & Sons, 1999, incorporated herein by reference.Exemplary oxygen protecting groups include, but are not limited to,methyl, t-butyloxycarbonyl (BOC or Boc), methoxylmethyl (MOM),methylthiomethyl (MTM), t-butylthiomethyl,(phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM),p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM),guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM),siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl,bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR),tetrahydropyranyl (THP), 3-bromotetrahydropyranyl,tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl(MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranylS,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl(CTMP), 1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl,2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl,1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl,1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl,t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl,benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl,p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl,p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido,diphenylmethyl, p,p′-dinitrobenzhydryl, 5-dibenzosuberyl,triphenylmethyl, ca-naphthyldiphenylmethyl,p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl,tri(p-methoxyphenyl)methyl, 4-(4′-bromophenacyloxyphenyl)diphenylmethyl,4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl,4,4′,4″-tris(levulinoyloxyphenyl)methyl,4,4′,4″-tris(benzoyloxyphenyl)methyl,3-(imidazol-1-yl)bis(4′,4″-dimethoxyphenyl)methyl,1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl,9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,1,3-benzodisulfuran-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl(TMS), triethylsilyl (TES), triisopropylsilyl (TIPS),dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS),dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl(TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl,diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate,benzoylformate, acetate, chloroacetate, dichloroacetate,trichloroacetate, trifluoroacetate, methoxyacetate,triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate,3-phenylpropionate, 4-oxopentanoate (levulinate),4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate,adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate,2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate,9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate(TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec),2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutylcarbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkylp-nitrophenyl carbonate, alkyl benzyl alkyl p-methoxybenzyl carbonate,alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate,alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate,4-ethoxy-1-napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate,4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate,2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl,4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate,2,6-dichloro-4-methylphenoxyacetate,2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate,o-(methoxyacyl)benzoate, o-naphthoate, nitrate, alkylN,N,N′,N′-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate,borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate,sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate(Ts).

Exemplary sulfur atom substituents include, but are not limited to,—R^(aa), —C(═O)SR^(aa), —C(═O)R^(aa), —CO₂R^(aa), —C(═O)N(R^(bb))₂,—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂,—S(═O)R^(aa), —SO₂R^(aa), —Si(R^(aa))₃, —P(R^(cc))₂, —P(R^(cc))₃ ⁺X⁻,—P(OR^(cc))₂, —P(OR^(cc))₃ ⁺X⁻, —P(═O)(R^(aa))₂, —P(═O)(OR^(cc))₂, and—P(═O)(N(R^(bb))₂)₂, wherein R^(aa), R^(bb), and R^(cc) are as definedherein. In certain embodiments, the sulfur atom substituent present on asulfur atom is a sulfur protecting group (also referred to as a thiolprotecting group). Sulfur protecting groups are well known in the artand include those described in detail in Protecting Groups in OrganicSynthesis, T. W. Greene and P. G. M. Wuts, 3^(rd) edition, John Wiley &Sons, 1999, incorporated herein by reference.

The term “leaving group” is given its ordinary meaning in the art ofsynthetic organic chemistry and refers to an atom or a group capable ofbeing displaced by a nucleophile. See, for example, Smith, MarchAdvanced Organic Chemistry 6th ed. (501-502). Examples of suitableleaving groups include, but are not limited to, halogen (such as F, Cl,Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy,alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy),arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxylamino, pixyl, andhaloformates. In some cases, the leaving group is an activatedsubstituted hydroxyl group (e.g., —OC(═O)SR^(aa), —OC(═O)R^(aa),—OCO₂R^(aa), —OC(═O)N(R^(bb))₂, —OC(═NR^(bb))R^(aa),—OC(═NR^(bb))OR^(aa), —OC(═NR^(bb))N(R^(bb))₂, —OS(═O)R^(aa),—OSO₂R^(aa), —OP(R^(cc))₂, —OP(R^(cc))₃, —OP(═O)₂R^(aa),—OP(═O)(R^(aa))₂, —OP(═O)(OR^(cc))₂, —OP(═O)₂N(R^(bb))₂, and—OP(═O)(NR^(bb))₂, wherein R^(aa), R^(bb), and R^(cc) are as definedherein). In some cases, the leaving group is a sulfonic acid ester, suchas toluenesulfonate (tosylate, —OTs), methanesulfonate (mesylate, —OMs),p-bromobenzenesulfonyloxy (brosylate, —OBs), —OS(═O)₂(CF₂)₃CF₃(nonaflate, —ONf), or trifluoromethanesulfonate (triflate, —OTf). Insome cases, the leaving group is a brosylate, such asp-bromobenzenesulfonyloxy. In some cases, the leaving group is anosylate, such as 2-nitrobenzenesulfonyloxy. In some embodiments, theleaving group is a sulfonate-containing group. In some embodiments, theleaving group is a tosylate group. The leaving group may also be aphosphineoxide (e.g., formed during a Mitsunobu reaction) or an internalleaving group such as an epoxide or cyclic sulfate. Other non-limitingexamples of leaving groups are water, ammonia, alcohols, ether moieties,thioether moieties, zinc halides, magnesium moieties, diazonium salts,and copper moieties.

The term “pharmaceutically acceptable salt” refers to those salts whichare, within the scope of sound medical judgment, suitable for use incontact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, Berge et al.,describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein byreference. Pharmaceutically acceptable salts of the compounds describedherein include those derived from suitable inorganic and organic acidsand bases. Examples of pharmaceutically acceptable, nontoxic acidaddition salts are salts of an amino group formed with inorganic acidssuch as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuricacid, and perchloric acid or with organic acids such as acetic acid,oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, ormalonic acid or by using other methods known in the art such as ionexchange. Other pharmaceutically acceptable salts include adipate,alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N⁺(C₁₋₄ alkyl)₄ ⁻ salts.Representative alkali or alkaline earth metal salts include sodium,lithium, potassium, calcium, magnesium, and the like. Furtherpharmaceutically acceptable salts include, when appropriate, nontoxicammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate,nitrate, lower alkyl sulfonate, and aryl sulfonate.

The term “solvate” refers to forms of the compound, or a salt thereof,that are associated with a solvent, usually by a solvolysis reaction.This physical association may include hydrogen bonding. Conventionalsolvents include water, methanol, ethanol, acetic acid, DMSO, THF,diethyl ether, and the like. The compounds described herein may beprepared, e.g., in crystalline form, and may be solvated. Suitablesolvates include pharmaceutically acceptable solvates and furtherinclude both stoichiometric solvates and non-stoichiometric solvates. Incertain instances, the solvate will be capable of isolation, forexample, when one or more solvent molecules are incorporated in thecrystal lattice of a crystalline solid. “Solvate” encompasses bothsolution-phase and isolatable solvates. Representative solvates includehydrates, ethanolates, and methanolates.

The term “hydrate” refers to a compound that is associated with water.Typically, the number of the water molecules contained in a hydrate of acompound is in a definite ratio to the number of the compound moleculesin the hydrate. Therefore, a hydrate of a compound may be represented,for example, by the general formula R.x H₂O, wherein R is the compound,and x is a number greater than 0. A given compound may form more thanone type of hydrate, including, e.g., monohydrates (x is 1), lowerhydrates (x is a number greater than 0 and smaller than 1, e.g.,hemihydrates (R.0.5H₂O)), and polyhydrates (x is a number greater than1, e.g., dihydrates (R.2H₂O) and hexahydrates (R.6H₂O)).

The term “tautomers” or “tautomeric” refers to two or moreinterconvertible compounds resulting from at least one formal migrationof a hydrogen atom and at least one change in valency (e.g., a singlebond to a double bond, a triple bond to a single bond, or vice versa).The exact ratio of the tautomers depends on several factors, includingtemperature, solvent, and pH. Tautomerizations (i.e., the reactionproviding a tautomeric pair) may catalyzed by acid or base. Exemplarytautomerizations include keto-to-enol, amide-to-imide, lactam-to-lactim,enamine-to-imine, and enamine-to-(a different enamine) tautomerizations.

It is also to be understood that compounds that have the same molecularformula but differ in the nature or sequence of bonding of their atomsor the arrangement of their atoms in space are termed “isomers”. Isomersthat differ in the arrangement of their atoms in space are termed“stereoisomers”.

Stereoisomers that are not mirror images of one another are termed“diastereomers” and those that are non-superimposable mirror images ofeach other are termed “enantiomers”. When a compound has an asymmetriccenter, for example, it is bonded to four different groups, a pair ofenantiomers is possible. An enantiomer can be characterized by theabsolute configuration of its asymmetric center and is described by theR- and S-sequencing rules of Cahn and Prelog, or by the manner in whichthe molecule rotates the plane of polarized light and designated asdextrorotatory or levorotatory (i.e., as (+) or (−)-isomersrespectively). A chiral compound can exist as either individualenantiomer or as a mixture thereof. A mixture containing equalproportions of the enantiomers is called a “racemic mixture”.

The term “polymorphs” refers to a crystalline form of a compound (or asalt, hydrate, or solvate thereof). All polymorphs have the sameelemental composition. Different crystalline forms usually havedifferent X-ray diffraction patterns, infrared spectra, melting points,density, hardness, crystal shape, optical and electrical properties,stability, and solubility. Recrystallization solvent, rate ofcrystallization, storage temperature, and other factors may cause onecrystal form to dominate. Various polymorphs of a compound can beprepared by crystallization under different conditions.

The term “prodrugs” refers to compounds that have cleavable groups andbecome by solvolysis or under physiological conditions the compoundsdescribed herein, which are pharmaceutically active in vivo. Suchexamples include, but are not limited to, choline ester derivatives andthe like, N-alkylmorpholine esters and the like. Other derivatives ofthe compounds described herein have activity in both their acid and acidderivative forms, but in the acid sensitive form often offer advantagesof solubility, tissue compatibility, or delayed release in the mammalianorganism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24,Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well knownto practitioners of the art, such as, for example, esters prepared byreaction of the parent acid with a suitable alcohol, or amides preparedby reaction of the parent acid compound with a substituted orunsubstituted amine, or acid anhydrides, or mixed anhydrides. Simplealiphatic or aromatic esters, amides, and anhydrides derived from acidicgroups pendant on the compounds described herein are particularprodrugs. In some cases it is desirable to prepare double ester typeprodrugs such as (acyloxy)alkyl esters or((alkoxycarbonyl)oxy)alkylesters. C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈alkynyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl esters ofthe compounds described herein may be preferred.

The term “small molecule” refers to molecules, whethernaturally-occurring or artificially created (e.g., via chemicalsynthesis) that have a relatively low molecular weight. Typically, asmall molecule is an organic compound (i.e., it contains carbon). Thesmall molecule may contain multiple carbon-carbon bonds, stereocenters,and other functional groups (e.g., amines, hydroxyl, carbonyls, andheterocyclic rings, etc.). In certain embodiments, the molecular weightof a small molecule is not more than about 1,000 g/mol, not more thanabout 900 g/mol, not more than about 800 g/mol, not more than about 700g/mol, not more than about 600 g/mol, not more than about 500 g/mol, notmore than about 400 g/mol, not more than about 300 g/mol, not more thanabout 200 g/mol, or not more than about 100 g/mol. In certainembodiments, the molecular weight of a small molecule is at least about100 g/mol, at least about 200 g/mol, at least about 300 g/mol, at leastabout 400 g/mol, at least about 500 g/mol, at least about 600 g/mol, atleast about 700 g/mol, at least about 800 g/mol, or at least about 900g/mol, or at least about 1,000 g/mol. Combinations of the above ranges(e.g., at least about 200 g/mol and not more than about 500 g/mol) arealso possible. In certain embodiments, the small molecule is atherapeutically active agent such as a drug (e.g., a molecule approvedby the U.S. Food and Drug Administration as provided in the Code ofFederal Regulations (C.F.R.)). The small molecule may also be complexedwith one or more metal atoms and/or metal ions. Preferred smallmolecules are biologically active in that they produce a biologicaleffect in animals, preferably mammals, more preferably humans. Smallmolecules include, but are not limited to, radionuclides and imagingagents. In certain embodiments, the small molecule is a drug.Preferably, though not necessarily, the drug is one that has alreadybeen deemed safe and effective for use in humans or animals by theappropriate governmental agency or regulatory body. For example, drugsapproved for human use are listed by the FDA under 21 C.F.R. §§ 330.5,331 through 361, and 440 through 460, incorporated herein by reference;drugs for veterinary use are listed by the FDA under 21 C.F.R. §§ 500through 589, incorporated herein by reference. All listed drugs areconsidered acceptable for use in accordance with the present invention.

The term “small molecule label” refers to a small molecule that iscapable of being detected, or a radical of such a small molecule.Exemplary small molecule labels include, but are not limited to, biotin,radioactive isotopes, enzymes, luminescent agents, precipitating agents,fluorophores, and dyes.

The term “small molecule fluorophore” refers to a small molecule that isfluorescent, e.g., being able to re-emit light upon light excitation.Exemplary small molecule fluorophores include, but are not limited to,fluorescein, rhodamine, coumarin, cyanine, and derivatives thereof.

The term “inhibition”, “inhibiting”, “inhibit,” or “inhibitor” refer tothe ability of a compound to reduce, slow, halt or prevent activity of aparticular biological process (e.g., activity of Myc) in a cell relativeto vehicle.

When a compound, pharmaceutical composition, method, use, or kit isreferred to as “selectively,” “specifically,” or “competitively”inhibiting a Myc, the compound, pharmaceutical composition, method, use,or kit inhibits the Myc to a greater extent (e.g., not less than 2-fold,not less than 5-fold, not less than 10-fold, not less than 30-fold, notless than 100-fold, not less than 1,000-fold, or not less than10,000-fold; and/or: not more than 2-fold, not more than 5-fold, notmore than 10-fold, not more than 30-fold, not more than 100-fold, notmore than 1,000-fold, or not more than 10,000-fold) than inhibiting adifferent Myc and/or a different transcription factor.

The term “aberrant activity” refers to activity deviating from normalactivity. In certain embodiments, the aberrant activity is increasedactivity. In certain embodiments, the aberrant activity is decreasedactivity. The term “increased activity” refers to activity higher thannormal activity. The term “decreased activity” refers to activity lowerthan normal activity.

The terms “composition” and “formulation” are used interchangeably.

A “subject” to which administration is contemplated refers to a human(i.e., male or female of any age group, e.g., pediatric subject (e.g.,infant, child, or adolescent) or adult subject (e.g., young adult,middle-aged adult, or senior adult)) or non-human animal. In certainembodiments, the non-human animal is a mammal (e.g., primate (e.g.,cynomolgus monkey or rhesus monkey), commercially relevant mammal (e.g.,cattle, pig, horse, sheep, goat, cat, or dog), or bird (e.g.,commercially relevant bird, such as chicken, duck, goose, or turkey)).In certain embodiments, the non-human animal is a fish, reptile, oramphibian. The non-human animal may be a male or female at any stage ofdevelopment. The non-human animal may be a transgenic animal orgenetically engineered animal. A “patient” refers to a human subject inneed of treatment of a proliferative disease.

The term “biological sample” refers to any sample including tissuesamples (such as tissue sections and needle biopsies of a tissue); cellsamples (e.g., cytological smears (such as Pap or blood smears) orsamples of cells obtained by microdissection); samples of wholeorganisms (such as samples of yeasts or bacteria); or cell fractions,fragments or organelles (such as obtained by lysing cells and separatingthe components thereof by centrifugation or otherwise). Other examplesof biological samples include blood, serum, urine, semen, fecal matter,cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus,biopsied tissue (e.g., obtained by a surgical biopsy or needle biopsy),nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccalswabs), or any material containing biomolecules that is derived from afirst biological sample.

The terms “administer,” “administering,” or “administration” refers toimplanting, absorbing, ingesting, injecting, inhaling, or otherwiseintroducing a compound described herein, or a composition thereof, in oron a subject.

The terms “treatment,” “treat,” and “treating” refer to reversing,alleviating, delaying the onset of, or inhibiting the progress of aproliferative disease described herein. In some embodiments, treatmentmay be administered after one or more signs or symptoms of theproliferative disease have developed or have been observed. In otherembodiments, treatment may be administered in the absence of signs orsymptoms of the proliferative disease. For example, treatment may beadministered to a susceptible subject prior to the onset of symptoms(e.g., in light of a history of symptoms and/or in light of exposure toa pathogen). Treatment may also be continued after symptoms haveresolved, for example, to delay or prevent recurrence.

The term “prevent,” “preventing,” or “prevention” refers to aprophylactic treatment of a subject who is not and was not with aproliferative disease but is at risk of developing the proliferativedisease or who was with a proliferative disease, is not with theproliferative disease, but is at risk of regression of the proliferativedisease. In certain embodiments, the subject is at a higher risk ofdeveloping the proliferative disease or at a higher risk of regressionof the proliferative disease than an average healthy member of apopulation.

The terms “condition,” “disease,” and “disorder” are usedinterchangeably.

An “effective amount” of a compound described herein refers to an amountsufficient to elicit the desired biological response. An effectiveamount of a compound described herein may vary depending on such factorsas the desired biological endpoint, the pharmacokinetics of thecompound, the condition being treated, the mode of administration, andthe age and health of the subject. In certain embodiments, an effectiveamount is a therapeutically effective amount. In certain embodiments, aneffective amount is a prophylactic treatment. In certain embodiments, aneffective amount is the amount of a compound described herein in asingle dose. In certain embodiments, an effective amount is the combinedamounts of a compound described herein in multiple doses.

A “therapeutically effective amount” of a compound described herein isan amount sufficient to provide a therapeutic benefit in the treatmentof a condition or to delay or minimize one or more symptoms associatedwith the condition. A therapeutically effective amount of a compoundmeans an amount of therapeutic agent, alone or in combination with othertherapies, which provides a therapeutic benefit in the treatment of thecondition. The term “therapeutically effective amount” can encompass anamount that improves overall therapy, reduces or avoids symptoms, signs,or causes of the condition, and/or enhances the therapeutic efficacy ofanother therapeutic agent. In certain embodiments, a therapeuticallyeffective amount is effective for modulating (e.g., inhibiting) theactivity of Myc. In certain embodiments, a therapeutically effectiveamount is effective for treating a proliferative disease. In certainembodiments, a therapeutically effective amount is effective formodulating (e.g., inhibiting) the activity of Myc and effective fortreating a proliferative disease. In certain embodiments, atherapeutically effective amount is effective for inducing apoptosis.

A “prophylactically effective amount” of a compound described herein isan amount sufficient to prevent a condition, or one or more symptomsassociated with the condition or prevent its recurrence. Aprophylactically effective amount of a compound means an amount of atherapeutic agent, alone or in combination with other agents, whichprovides a prophylactic benefit in the prevention of the condition. Theterm “prophylactically effective amount” can encompass an amount thatimproves overall prophylaxis or enhances the prophylactic efficacy ofanother prophylactic agent. In certain embodiments, a prophylacticallyeffective amount is effective for modulating (e.g., inhibiting) theactivity of Myc. In certain embodiments, a prophylactically effectiveamount is effective for preventing a proliferative disease. In certainembodiments, a prophylactically effective amount is effective formodulating (e.g., inhibiting) the activity of Myc and effective forpreventing a proliferative disease. In certain embodiments, aprophylactically effective amount is effective for inducing apoptosis.

The term “transcription factor” refers to is a protein that binds tospecific DNA sequences, thereby controlling the rate of transcription ofgenetic information from DNA to messenger RNA. Transcription factorsperform their functions alone or with other proteins in a complex, bypromoting (as an activator), or blocking (as a repressor) therecruitment of RNA polymerase to specific genes. A feature oftranscription factors is that they contain one or more DNA-bindingdomains (DBDs), which attach to specific sequences of DNA adjacent tothe genes that they regulate. Additional proteins such as coactivators,chromatin remodelers, histone acetylases, deacetylases, kinases, andmethylases, while also playing crucial roles in gene regulation, lackDNA-binding domains, and, therefore, are not classified as transcriptionfactors. In certain embodiments, a transcription factor described hereinis Myc. In certain embodiments, a transcription factor described hereinis c-Myc. In certain embodiments, a transcription factor describedherein is SP1, AP-1, C/EBP, heat shock factor, ATF/CREB, Oct-1, or NF-1.

The term “Myc” refers to the Myc family of transcription factors and thegenes encoding the Myc family of transcription factors. In certainembodiments, the Myc is c-Myc (encoded by the MYC gene (HomoloGene:31092; ChEMBL: 1250348; GeneCards: MYC Gene)). In certain embodiments,the Myc is L-Myc (encoded by the MYCL gene (HomoloGene: 3921; GeneCards:MYCL Gene)) or N-Myc (encoded by the MYCN gene (HomoloGene: 3922;GeneCards: MYCN Gene)). In certain embodiments, the Myc is MYC. Incertain embodiments, the Myc is MYCL or MYCN.

A “proliferative disease” refers to a disease that occurs due toabnormal growth or extension by the multiplication of cells (Walker,Cambridge Dictionary of Biology; Cambridge University Press: Cambridge,UK, 1990). A proliferative disease may be associated with: 1) thepathological proliferation of normally quiescent cells; 2) thepathological migration of cells from their normal location (e.g.,metastasis of neoplastic cells); 3) the pathological expression ofproteolytic enzymes such as the matrix metalloproteinases (e.g.,collagenases, gelatinases, and elastases); or 4) the pathologicalangiogenesis as in proliferative retinopathy and tumor metastasis.Exemplary proliferative diseases include cancers (i.e., “malignantneoplasms”), benign neoplasms, angiogenesis, inflammatory diseases, andautoimmune diseases.

The term “angiogenesis” refers to the physiological process throughwhich new blood vessels form from pre-existing vessels. Angiogenesis isdistinct from vasculogenesis, which is the de novo formation ofendothelial cells from mesoderm cell precursors. The first vessels in adeveloping embryo form through vasculogenesis, after which angiogenesisis responsible for most blood vessel growth during normal or abnormaldevelopment. Angiogenesis is a vital process in growth and development,as well as in wound healing and in the formation of granulation tissue.However, angiogenesis is also a fundamental step in the transition oftumors from a benign state to a malignant one, leading to the use ofangiogenesis inhibitors in the treatment of cancer. Angiogenesis may bechemically stimulated by angiogenic proteins, such as growth factors(e.g., VEGF). “Pathological angiogenesis” refers to abnormal (e.g.,excessive or insufficient) angiogenesis that amounts to and/or isassociated with a disease.

The terms “neoplasm” and “tumor” are used herein interchangeably andrefer to an abnormal mass of tissue wherein the growth of the masssurpasses and is not coordinated with the growth of a normal tissue. Aneoplasm or tumor may be “benign” or “malignant,” depending on thefollowing characteristics: degree of cellular differentiation (includingmorphology and functionality), rate of growth, local invasion, andmetastasis. A “benign neoplasm” is generally well differentiated, hascharacteristically slower growth than a malignant neoplasm, and remainslocalized to the site of origin. In addition, a benign neoplasm does nothave the capacity to infiltrate, invade, or metastasize to distantsites. Exemplary benign neoplasms include, but are not limited to,lipoma, chondroma, adenomas, acrochordon, senile angiomas, seborrheickeratoses, lentigos, and sebaceous hyperplasias. In some cases, certain“benign” tumors may later give rise to malignant neoplasms, which mayresult from additional genetic changes in a subpopulation of the tumor'sneoplastic cells, and these tumors are referred to as “pre-malignantneoplasms.” An exemplary pre-malignant neoplasm is a teratoma. Incontrast, a “malignant neoplasm” is generally poorly differentiated(anaplasia) and has characteristically rapid growth accompanied byprogressive infiltration, invasion, and destruction of the surroundingtissue. Furthermore, a malignant neoplasm generally has the capacity tometastasize to distant sites. The term “metastasis,” “metastatic,” or“metastasize” refers to the spread or migration of cancerous cells froma primary or original tumor to another organ or tissue and is typicallyidentifiable by the presence of a “secondary tumor” or “secondary cellmass” of the tissue type of the primary or original tumor and not ofthat of the organ or tissue in which the secondary (metastatic) tumor islocated. For example, a prostate cancer that has migrated to bone issaid to be metastasized prostate cancer and includes cancerous prostatecancer cells growing in bone tissue.

The term “cancer” refers to a class of diseases characterized by thedevelopment of abnormal cells that proliferate uncontrollably and havethe ability to infiltrate and destroy normal body tissues. See, e.g.,Stedman's Medical Dictionary, 25th ed.; Hensyl ed.; Williams & Wilkins:Philadelphia, 1990. Exemplary cancers include, but are not limited to,hematological malignancies. Additional exemplary cancers include, butare not limited to, lung cancer (e.g., bronchogenic carcinoma, smallcell lung cancer (SCLC), non-small cell lung cancer (NSCLC),adenocarcinoma of the lung); kidney cancer (e.g., nephroblastoma, a.k.a.Wilms' tumor, renal cell carcinoma); acoustic neuroma; adenocarcinoma;adrenal gland cancer; anal cancer; angiosarcoma (e.g.,lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma);appendix cancer; benign monoclonal gammopathy; biliary cancer (e.g.,cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinomaof the breast, papillary carcinoma of the breast, mammary cancer,medullary carcinoma of the breast); brain cancer (e.g., meningioma,glioblastomas, glioma (e.g., astrocytoma, oligodendroglioma),medulloblastoma); bronchus cancer; carcinoid tumor; cervical cancer(e.g., cervical adenocarcinoma); choriocarcinoma; chordoma;craniopharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer,colorectal adenocarcinoma); connective tissue cancer; epithelialcarcinoma; ependymoma; endotheliosarcoma (e.g., Kaposi's sarcoma,multiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g.,uterine cancer, uterine sarcoma); esophageal cancer (e.g.,adenocarcinoma of the esophagus, Barrett's adenocarcinoma); Ewing'ssarcoma; ocular cancer (e.g., intraocular melanoma, retinoblastoma);familiar hypereosinophilia; gall bladder cancer; gastric cancer (e.g.,stomach adenocarcinoma); gastrointestinal stromal tumor (GIST); germcell cancer; head and neck cancer (e.g., head and neck squamous cellcarcinoma, oral cancer (e.g., oral squamous cell carcinoma), throatcancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngealcancer, oropharyngeal cancer)); heavy chain disease (e.g., alpha chaindisease, gamma chain disease, mu chain disease; hemangioblastoma;hypopharynx cancer; inflammatory myofibroblastic tumors; immunocyticamyloidosis; liver cancer (e.g., hepatocellular cancer (HCC), malignanthepatoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemicmastocytosis); muscle cancer; myelodysplastic syndrome (MDS);mesothelioma; myeloproliferative disorder (MPD) (e.g., polycythemia vera(PV), essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM)a.k.a. myelofibrosis (MF), chronic idiopathic myelofibrosis, chronicmyelocytic leukemia (CML), chronic neutrophilic leukemia (CNL),hypereosinophilic syndrome (HES)); neuroblastoma; neurofibroma (e.g.,neurofibromatosis (NF) type 1 or type 2, schwannomatosis);neuroendocrine cancer (e.g., gastroenteropancreatic neuroendoctrinetumor (GEP-NET), carcinoid tumor); osteosarcoma (e.g., bone cancer);ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma,ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer(e.g., pancreatic andenocarcinoma, intraductal papillary mucinousneoplasm (IPMN), Islet cell tumors); penile cancer (e.g., Paget'sdisease of the penis and scrotum); pinealoma; primitive neuroectodermaltumor (PNT); plasma cell neoplasia; paraneoplastic syndromes;intraepithelial neoplasms; prostate cancer (e.g., prostateadenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer;skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA),melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g.,appendix cancer); soft tissue sarcoma (e.g., malignant fibroushistiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor(MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous glandcarcinoma; small intestine cancer; sweat gland carcinoma; synovioma;testicular cancer (e.g., seminoma, testicular embryonal carcinoma);thyroid cancer (e.g., papillary carcinoma of the thyroid, papillarythyroid carcinoma (PTC), medullary thyroid cancer); urethral cancer;vaginal cancer; and vulvar cancer (e.g., Paget's disease of the vulva).The term “hematological malignancy” refers to tumors that affect blood,bone marrow, and/or lymph nodes. Exemplary hematological malignanciesinclude, but are not limited to, leukemia, such as acute lymphocyticleukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myelocytic leukemia(AML) (e.g., B-cell AML, T-cell AML), chronic myelocytic leukemia (CML)(e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL)(e.g., B-cell CLL, T-cell CLL)); lymphoma, such as Hodgkin lymphoma (HL)(e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g.,B-cell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuselarge B-cell lymphoma (DLBCL, e.g., activated B-cell (ABC) DLBCL(ABC-DLBCL))), follicular lymphoma, chronic lymphocytic leukemia/smalllymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), marginalzone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT)lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zoneB-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt'slymphoma, Waldenström's macroglobulinemia (WM, lymphoplasmacyticlymphoma), hairy cell leukemia (HCL), immunoblastic large cell lymphoma,precursor B-lymphoblastic lymphoma, central nervous system (CNS)lymphoma (e.g., primary CNS lymphoma and secondary CNS lymphoma); andT-cell NHL, such as precursor T-lymphoblastic lymphomalleukemia,peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma(CTCL) (e.g., mycosis fungoides, Sezary syndrome), angioimmunoblasticT-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathytype T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma,and anaplastic large cell lymphoma); lymphoma of an immune privilegedsite (e.g., cerebral lymphoma, ocular lymphoma, lymphoma of theplacenta, lymphoma of the fetus, testicular lymphoma); a mixture of oneor more leukemia/lymphoma as described above; myelodysplasia; andmultiple myeloma (MM).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows the chemical structure of compound 1. FIG. 1B showsexemplary results of compound 1 in an initial reporter assay. Compound1's activity against Myc was measured as a Firefly/Renilla ratio, usingthe Myc reporter assay (Qiagen) in HEK293T cells after treatment withcompound 1 for 16 hours. Results are expressed as a mean+/−SD (n=3). SD:standard deviation.

FIGS. 2A to 2E show exemplary results of cell viability assay ofcompound 1. Compound 1 affected cell viability after treatment withcompound 1 for 3 days, as measured using CELL TITER GLO (Promega) in 5different cancer cell lines: NCIH1975 (lung; FIG. 2A), SNUC5 (colon;FIG. 2B), Namalwa (Burkitt's lymphoma; FIG. 2C), KLP1 (breast; FIG. 2D),and Hela (cervix; FIG. 2E). Results were expressed as a mean+/−SEM(n=3). RLU: Relative Luminescence Units.

FIGS. 3A to 3B show CTD² viability data profile of cancer cell linestreated with compound 1. FIG. 3A: dose response curves of 789 cell linestreated with compound 1 for 72 hours. FIG. 3B: relative percentcomposition of cell lineages and enrichment analysis after treatmentwith compound 1.

FIG. 4 shows exemplary reagents to enable experiments for demonstratingengagement of Myc in a cellular setting and evaluating the selectivityof the compounds described herein for other proteins in a cellularsetting.

FIGS. 5A and 5B shows exemplary Western blotting results of compound1-mediated pull downs of Myc where free compound 1 is used as a solublecompetitor. Compound 19 beads (FIG. 5A) and compound 55 beads (FIG. 5B)were used. Results are expressed as a mean+/−SEM (n=3). Compound 55beads were formed by a method analogous to the method shown in FIG. 4,where beads were linked to the —NH₂ moiety of compound 55 by forming aurea moiety.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

The present disclosure provides, in one aspect, compounds of Formula(I), and pharmaceutically acceptable salts, solvates, hydrates,polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeledderivatives, and prodrugs thereof. The compounds described herein may bebinders and/or modulators (e.g., inhibitors or activators) of Myc (e.g.,c-Myc, L-Myc, and/or N-Myc). Also provided are pharmaceuticalcompositions, kits, methods, and uses including a compound describedherein.

Compounds

One aspect of the present disclosure relates to the compounds describedherein. The compounds described herein may be Myc modulators (e.g., Mycinhibitors) and/or Myc binders. In certain embodiments, a compounddescribed herein is a compound of Formula (I-a), or a pharmaceuticallyacceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer,stereoisomer, isotopically labeled derivative, or prodrug thereof. Incertain embodiments, a compound described herein is a compound ofFormula (I), or a pharmaceutically acceptable salt, solvate, hydrate,polymorph, co-crystal, tautomer, stereoisomer, isotopically labeledderivative, or prodrug thereof. In certain embodiments, a compounddescribed herein is a compound of Formula (I), or a pharmaceuticallyacceptable salt thereof. In certain embodiments, a compound describedherein is a compound of Formula (II), or a pharmaceutically acceptablesalt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer,isotopically labeled derivative, or prodrug thereof.

Compounds of Formula (I-a)

In certain embodiments, the compound of Formula (I-a) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof, wherein:

each instance of R^(A) is independently hydrogen, halogen, substitutedor unsubstituted alkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, substituted or unsubstitutedcarbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, —OR^(a),—N(R^(a))₂, —SR^(a), —CN, —SCN, —C(═NR^(a))R^(a), —C(═NR^(a))OR^(a),—C(═NR^(a))N(R^(a))₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂, —NO₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)N(R^(a))₂,—N(R^(a))S(═O)R^(a), —N(R^(a))S(═O)OR^(a), —N(R^(a))S(═O)N(R^(a))₂,—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂OR^(a), —N(R^(a))S(═O)₂N(R^(a))₂,—OC(═O)R^(a), —OC(═O)OR^(a), or —OC(═O)N(R^(a))₂, or two instances ofR^(A) are joined to form a substituted or unsubstituted, carbocyclicring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted, aryl ring, or substituted or unsubstituted, heteroarylring;

k is 0, 1, 2, or 3;

L is —N—, —O—, —S—, or a bond;

X^(a) is —NR^(B)—, —O—, or —S—;

W^(a) is —CR^(A)═ or —N═;

R^(B) is hydrogen, substituted or unsubstituted C₁₋₆ alkyl, or anitrogen protecting group;

R^(D) is hydrogen, substituted or unsubstituted acyl, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, —OR^(d1), —N(R^(d1))₂,—NO₂, —NR^(d1)C(═O)R^(d1), —NR^(d1)C(═O)OR^(d1),—NR^(d1)C(═O)N(R^(d1))₂, —OC(═O)R^(d1), —OC(═O)OR^(d1),—OC(═O)N(R^(d1))₂, —C(═O)R^(d1), —C(═O)OR^(d1), —C(═O)N(R^(d1))₂,—CH₂N(R^(d1))₂, or —CH₂OR^(d1);

each instance of R^(a) is independently hydrogen, substituted orunsubstituted acyl, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(a) are joined to form a substituted or unsubstituted carbocyclylring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted aryl ring, or substituted or unsubstituted, heteroarylring;

each instance of R^(d1) is independently hydrogen, substituted orunsubstituted acyl, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(d1) are joined to form a substituted or unsubstituted carbocyclylring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted aryl ring, or substituted or unsubstituted, heteroarylring; and

Ring A is a substituted or unsubstituted aryl, or substituted orunsubstituted heteroaryl.

Formula (I-a) may include one or more instances of substituent R^(A).When Formula (I-a) includes two or more instances of R^(A), any twoinstances of R^(A) may be the same or different from each other. Incertain embodiments, at least one instance of R^(A) is halogen (e.g., F,Cl, Br, or I). In certain embodiments, at least one instance of R^(A) isF. In certain embodiments, at least one instance of R^(A) is Cl. Incertain embodiments, at least one instance of R^(A) is substituted orunsubstituted alkyl. In certain embodiments, at least one instance ofR^(A) is substituted or unsubstituted C₁₋₆ alkyl. In certainembodiments, at least one instance of R^(A) is Me. In certainembodiments, at least one instance of R^(A) is substituted methyl (e.g.,—CF₃, —CH₂OH, or Bn). In certain embodiments, at least one instance ofR^(A) is Et, substituted ethyl (e.g., perfluoroethyl), Pr (e.g., n-Pr ori-Pr), substituted propyl (e.g., perfluoropropyl), Bu, or substitutedbutyl (e.g., perfluorobutyl). In certain embodiments, at least oneinstance of R^(A) is substituted or unsubstituted alkenyl (e.g.,substituted or unsubstituted C₂₋₆ alkenyl). In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted alkynyl(e.g., substituted or unsubstituted C₂₋₆ alkynyl). In certainembodiments, at least one instance of R^(A) is substituted orunsubstituted carbocyclyl (e.g., substituted or unsubstituted, 3- to7-membered, monocyclic carbocyclyl comprising zero, one, or two doublebonds in the carbocyclic ring system). In certain embodiments, at leastone instance of R^(A) is substituted or unsubstituted cyclopropyl,substituted or unsubstituted cyclobutyl, substituted or unsubstitutedcyclopentyl, or substituted or unsubstituted cyclohexyl. In certainembodiments, at least one instance of R^(A) is substituted orunsubstituted heterocyclyl (e.g., substituted or unsubstituted, 3- to7-membered, monocyclic heterocyclyl comprising zero, one, or two doublebonds in the heterocyclic ring system, wherein one, two, or three atomsin the heterocyclic ring system are independently nitrogen, oxygen, orsulfur). In certain embodiments, at least one instance of R^(A) issubstituted or unsubstituted oxetanyl, substituted or unsubstitutedtetrahydrofuranyl, substituted or unsubstituted pyrrolidinyl,substituted or unsubstituted tetrahydropyranyl, substituted orunsubstituted piperidinyl, substituted or unsubstituted morpholinyl, orsubstituted or unsubstituted piperazinyl. In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted aryl (e.g.,substituted or unsubstituted, 6- to 10-membered aryl). In certainembodiments, at least one instance of R^(A) is unsubstituted phenyl. Incertain embodiments, at least one instance of R^(A) is substitutedphenyl. In certain embodiments, at least one instance of R^(A) issubstituted or unsubstituted naphthyl. In certain embodiments, at leastone instance of R^(A) is substituted or unsubstituted heteroaryl. Incertain embodiments, at least one instance of R^(A) is substituted orunsubstituted, 5- to 6-membered, monocyclic heteroaryl, wherein one,two, three, or four atoms in the heteroaryl ring system areindependently nitrogen, oxygen, or sulfur. In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted, 9- to10-membered, bicyclic heteroaryl, wherein one, two, three, or four atomsin the heteroaryl ring system are independently nitrogen, oxygen, orsulfur. In certain embodiments, at least one instance of R^(A) is—OR^(a) (e.g., —OH, —O(substituted or unsubstituted C₁₋₆ alkyl) (e.g.,—OMe, —OCF₃, —OEt, —OPr, —OBu, or —OBn), or —O(substituted orunsubstituted phenyl) (e.g., —OPh)). In certain embodiments, at leastone instance of R^(A) is —SR^(a) (e.g., —SH, —S(substituted orunsubstituted C₁₋₆ alkyl) (e.g., —SMe, —SEt, —SPr, —SBu, or —SBn), or—S(substituted or unsubstituted phenyl) (e.g., —SPh)). In certainembodiments, at least one instance of R^(A) is —N(R^(a))₂ (e.g., —NH₂,—NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g., —NHMe), or—N(substituted or unsubstituted C₁₋₆ alkyl)-(substituted orunsubstituted C₁₋₆ alkyl) (e.g., —NMe₂)). In certain embodiments, atleast one instance of R^(A) is —CN or —SCN. In certain embodiments, atleast one instance of R^(A) is —NO₂. In certain embodiments, at leastone instance of R^(A) is —C(═NR^(a))R^(a), —C(═NR^(a))OR^(a), or—C(═NR^(a))N(R^(a))₂. In certain embodiments, at least one instance ofR^(A) is —C(═O)R^(a) (e.g., —C(═O)(substituted or unsubstituted alkyl)(e.g., —C(═O)Me) or —C(═O)(substituted or unsubstituted phenyl)). Incertain embodiments, at least one instance of R^(A) is —C(═O)OR^(a)(e.g., —C(═O)OH, —C(═O)O(substituted or unsubstituted alkyl) (e.g.,—C(═O)OMe), or —C(═O)O(substituted or unsubstituted phenyl)). In certainembodiments, at least one instance of R^(A) is —C(═O)N(R^(a))₂ (e.g.,—C(═O)NH₂, —C(═O)NH(substituted or unsubstituted alkyl) (e.g.,—C(═O)NHMe), —C(═O)NHPh, —C(═O)NH(substituted phenyl),—C(═O)N(substituted or unsubstituted alkyl)-(substituted orunsubstituted alkyl), —C(═O)N(substituted or unsubstitutedphenyl)-(substituted or unsubstituted alkyl)). In certain embodiments,at least one instance of R^(A) is —C(═O)N(R^(a))₂, wherein two instancesof R^(a) are joined to form a substituted or unsubstituted, 3- to7-membered, monocyclic heterocyclic ring comprising zero, one, or twodouble bonds in the heterocyclic ring system, wherein one, two, or threeatoms in the heterocyclic ring system are independently nitrogen,oxygen, or sulfur. In certain embodiments, at least one instance ofR^(A) is —C(═O)-(1-morpholinyl). In certain embodiments, at least oneinstance of R^(A) is —NR^(a)C(═O)R^(a)(e.g., —NHC(═O)(substituted orunsubstituted C₁₋₆ alkyl) (e.g., —NHC(═O)Me), —NHC(═O)Ph, or—NHC(═O)(substituted phenyl)). In certain embodiments, at least oneinstance of R^(A) is —NR^(a)C(═O)OR^(a). In certain embodiments, atleast one instance of R^(A) is —NR^(a)C(═O)N(R^(a))₂ (e.g., —NHC(═O)NH₂,—NHC(═O)NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g., —NHC(═O)NHMeor —NHC(═O)NH(i-Pr)), —NHC(═O)NHPh, or —NHC(═O)NH(substituted phenyl)).In certain embodiments, at least one instance of R^(A) is —OC(═O)R^(a),—OC(═O)OR^(a), or —OC(═O)N(R^(a))₂. In certain embodiments, at least oneinstance of R^(A) is —NR^(a)S(═O)R^(a) (e.g., —NHS(═O)(substituted orunsubstituted C₁₋₆ alkyl) (e.g., —NHS(═O)Me), —NHS(═O)Ph, or—NHS(═O)(substituted phenyl)). In certain embodiments, at least oneinstance of R^(A) is —NR^(a)S(═O)OR^(a). In certain embodiments, atleast one instance of R^(A) is —NR^(a)S(═O)N(R^(a))₂ (e.g., —NHS(═O)NH₂,—NHS(═O)NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g.,—NHS(═O)NHMe), —NHS(═O)NHPh, or —NHS(═O)NH(substituted phenyl)). Incertain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)₂R^(a) (e.g., —NHS(═O)₂ (substituted or unsubstituted C₁₋₆alkyl) (e.g., —NHS(═O)₂Me), —NHS(═O)₂Ph, or —NHS(═O)₂ (substitutedphenyl)). In certain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)₂OR^(a). In certain embodiments, at least one instance ofR^(A) is —NR^(a)S(═O)₂N(R^(a))₂ (e.g., —NHS(═O)₂NH₂,—NHS(═O)₂NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g.,—NHS(═O)₂NHMe), —NHS(═O)₂NHPh, or —NHS(═O)₂NH(substituted phenyl)). Incertain embodiments, at least one instance of R^(A) is halogen, —OR^(a),—N(R^(a))₂, —NO₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)N(R^(a))₂, or —N(R^(a))S(═O)₂R^(a).In certain embodiments, at least one instance of R^(A) is Cl, —OMe,—OCF₃, —NH₂, —NHMe, —NMe₂, —NO₂, —C(═O)Me, —C(═O)OH, —C(═O)OMe,—C(═O)NH₂, —C(═O)NHMe, —C(═O)NHPh, —C(═O)-(1-morpholinyl), —NHC(═O)Me,—NHC(═O)Ph, —NHC(═O)NH(i-Pr), —NHC(═O)NHPh, —NHS(═O)₂Me, or —NHS(═O)₂Ph.In certain embodiments, at least one instance of R^(A) is —CF₃, —CH₂OH,or i-Pr.

When Formula (I-a) include two or more instances of R^(A), any twoinstances of R^(A) may be joined to form a substituted or unsubstitutedring. In certain embodiments, two instances of R^(A) are joined to forma substituted or unsubstituted, carbocyclic ring (e.g., substituted orunsubstituted, 3- to 7-membered, monocyclic carbocyclic ring comprisingzero, one, or two double bonds in the carbocyclic ring system). Incertain embodiments, two instances of R^(A) are joined to form asubstituted or unsubstituted, heterocyclic ring (e.g., substituted orunsubstituted, 3- to 7-membered, monocyclic heterocyclic ring comprisingzero, one, or two double bonds in the heterocyclic ring system, whereinone, two, or three atoms in the heterocyclic ring system areindependently nitrogen, oxygen, or sulfur). In certain embodiments, twoinstances of R^(A) are joined to form a substituted or unsubstituted,aryl ring (e.g., substituted or unsubstituted phenyl ring). In certainembodiments, two instances of R^(A) are joined to form a substituted orunsubstituted, heteroaryl ring (e.g., substituted or unsubstituted, 5-to 6-membered, monocyclic heteroaryl ring, wherein one, two, or threeatoms in the heteroaryl ring system are independently nitrogen, oxygen,or sulfur).

In certain embodiments, k is 0. In certain embodiments, k is 1. Incertain embodiments, k is 2. In certain embodiments, k is 3.

In certain embodiments, k is 1; and R^(A) is halogen, —OR^(a),—N(R^(a))₂, —NO₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)N(R^(a))₂, or —N(R^(a))S(═O)₂R^(a).In certain embodiments, k is 1; and R^(A) is Cl, —OMe, —OCF₃, —NH₂,—NHMe, —NMe₂, —NO₂, —C(═O)Me, —C(═O)OH, —C(═O)OMe, —C(═O)NH₂,—C(═O)NHMe, —C(═O)NHPh, —C(═O)-(1-morpholinyl), —NHC(═O)Me, —NHC(═O)Ph,—NHC(═O)NH(i-Pr), —NHC(═O)NHPh, —NHS(═O)₂Me, or —NHS(═O)₂Ph. In certainembodiments, k is 1; and R^(A) is halogen. In certain embodiments, k is1; and R^(A) is Cl. In certain embodiments, k is 2; and each instance ofR^(A) is independently halogen. In certain embodiments, k is 2; and eachinstance of R^(A) is Cl.

Formula (I-a) includes W^(a) and X^(a) in a fused bicyclic heterocyclicring. In certain embodiments, W^(a) is —CR^(A)═ or —N═. In certainembodiments, W^(a) is —C(R^(A))═. In certain embodiments, W^(a) is —CH═.In certain embodiments, W^(a) is —N═. In certain embodiments, X^(a) is—NR^(B)—, —O—, or —S—. In certain embodiments, X^(a) is —NH—. In certainembodiments, W^(a) is —CH═, and X^(a) is —NH—. In certain embodiments,W^(a) is —CH═, and X^(a) is —S—. In certain embodiments, W^(a) is —CH═,and X^(a) is —O—. In certain embodiments, W^(a) is —N═, and X^(a) is—NH—.

In certain embodiments, when X^(a) is N, Formula (I-a) includessubstituent R^(B) on atom X^(a) of the fused bicyclic heterocyclic ring.In certain embodiments, R^(B) is hydrogen. In certain embodiments, R^(B)is substituted or unsubstituted C₁₋₆ alkyl. In certain embodiments,R^(B) is Me. In certain embodiments, R^(B) is substituted methyl (e.g.,—CF₃ or Bn). In certain embodiments, R^(B) is Et, substituted ethyl(e.g., perfluoroethyl), Pr, substituted propyl (e.g., perfluoropropyl or—(CH₂)₃NH₂), Bu, or substituted butyl (e.g., perfluorobutyl). In certainembodiments, R^(B) is of the formula: —(CH₂)^(a)N(R^(a1))₂, wherein amay be 1, 2, 3, or 4, and each instance of R^(a1) may be independentlyH, substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl. In certain embodiments, a is 3. In certain embodiments,R^(a1) is hydrogen.

In certain embodiments, R^(B) is of the formula:—(CH₂)_(a)NHC(═O)(CH₂)_(b)R^(b1), wherein: each instance of a and b isindependently 1, 2, or 3, or 4; R^(b1) is H, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, or —N(R^(b2))C(═O)R^(b3);and each instance of R^(b2) and R^(b3) is independently H, substitutedor unsubstituted acyl, substituted or unsubstituted alkyl, substitutedor unsubstituted alkenyl, substituted or unsubstituted alkynyl,substituted or unsubstituted carbocyclyl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted aryl, substituted orunsubstituted heteroaryl. In certain embodiments, a is 1. In certainembodiments, a is 2. In certain embodiments, a is 3. In certainembodiments, b is 1. In certain embodiments, b is 2. In certainembodiments, b is 3.

In certain embodiments, R^(b1) is of the formula: —N(R^(b2))C(═O)R^(b3).In certain embodiments, R^(b2) is alkynl (e.g., propyne). In certainembodiments, R^(b3) is acyl.

In certain embodiments, R^(B) is of the formula:

In certain embodiments, R^(b1) is a heterocyclic ring (e.g., substitutedor unsubstituted, 5- to 10-membered bicyclic heterocyclic ring, wherein1, 2, or 3 atoms in the heterocyclic ring are independently nitrogen,oxygen, or sulfur). In certain embodiments, R^(b1) is of the formula:

In certain embodiments, R^(B) is of the formula:—(CH₂)_(a)C(═O)NHR^(c1), wherein R^(c1) is H, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, or substituted or unsubstituted heteroaryl. In certainembodiments, R^(c1) is substituted or unsubstituted C₁₋₆ alkyl. Incertain embodiments, R^(c1) is of the formula:—(CH₂)_(d)O(CH₂)_(e)O(CH₂)_(f)C(═O)NHR^(e1), wherein R^(e1) isindependently H, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl; and each instance of d, e, or f is independently 1, 2, 3, 4,5, or 6. In certain embodiments, all instances of d, e, and f are 2. Incertain embodiments, R^(e1) is a heterocyclic ring (e.g., substituted orunsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclicring, wherein one or two atoms in the heterocyclic ring areindependently nitrogen, oxygen, or sulfur).

In certain embodiments, R^(B) is of the formula:

In certain embodiments, R^(B) is of the formula:—(CH₂)_(a)NHC(═O)R^(f1), wherein R^(f1) is independently H, substitutedor unsubstituted alkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, substituted or unsubstitutedcarbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl. In certainembodiments, a is 3. In certain embodiments, R^(f1) is substitutedphenyl. In certain embodiments, R^(B) is of the formula:

In certain embodiments, R^(B) is a nitrogen protecting group (e.g.,benzyl (Bn), t-butyl carbonate (BOC or Boc), benzyl carbamate (Cbz),9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl, triphenylmethyl,acetyl, or p-toluenesulfonamide (Ts)).

Formula (I-a) includes a linker L connecting the fused bicyclicheterocyclic ring with Ring A. In certain embodiments, L is —N—. Incertain embodiments, L is —O—. In certain embodiments, L is —S—. Incertain embodiments, L is a bond. In certain embodiments, L is anoptionally substituted C₁₋₄ hydrocarbon chain.

Formula (I-a) includes Ring A. In certain embodiments, Ring A issubstituted or unsubstituted aryl ring (e.g., phenyl). In certainembodiments, Ring A is a heteroaryl ring (e.g., a substituted orunsubstituted, 5- to 6-membered, monocyclic or bicyclic heteroaryl ring,wherein one or two atoms in the heteroaryl ring are independentlynitrogen, oxygen, or sulfur). In certain embodiments, Ring A is of theformula:

wherein: W is —NH—, —O— or —S—. In certain embodiments, W is —N—. Incertain embodiments, W is —O—. In certain embodiments, W is —S—. Incertain embodiments, Ring A is of the formula:

wherein: Y is —O— or —S—. In certain embodiments, Y is —O—. In certainembodiments, Y is —S—. In certain embodiments, Ring A is of the formula:

Formula (I-a) includes substituent R^(D) on Ring A. In certainembodiments, R^(D) is hydrogen. In certain embodiments, R^(D) is acyl.In certain embodiments, R^(D) is substituted or unsubstituted alkyl. Incertain embodiments, R^(D) is substituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, substituted or unsubstitutedcarbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Incertain embodiments, R^(D) is substituted alkenyl. In certainembodiments, R^(D) is unsubstituted alkenyl. In certain embodiments, Ris of the formula:

wherein X¹ may be —S—, —NR^(C)—, or —CH₂—. In certain embodiments, X¹ is—S—. In certain embodiments, X¹ is —NR^(C)—. In certain embodiments, X¹is —CH₂—. In certain embodiments, R^(D) is of the formula:

In certain embodiments, R^(D) may include substituent R^(C). In certainembodiments, R^(C) is hydrogen. In certain embodiments, R^(C) issubstituted or unsubstituted alkyl. In certain embodiments, R^(C) issubstituted or unsubstituted C₁₋₆ alkyl. In certain embodiments, R^(C)is Me. In certain embodiments, R^(C) is substituted methyl. In certainembodiments, R^(C) is —CF₃ or Bn. In certain embodiments, R^(C) is—C(R^(a))₂—C(═O)OR^(a), optionally wherein each instance of R^(a) isindependently H, substituted or unsubstituted C₁₋₆ alkyl, or substitutedor unsubstituted phenyl. In certain embodiments, R^(C) is —CH₂—CO₂H,—CH₂—CO₂Me, —CH₂—CO₂(t-Bu), —CH(Me)-CO₂Me, or —CH(Me)-CO₂Et.

In certain embodiments, R^(D) is of the formula: —OR^(d1), —N(R^(d1))₂,—NO₂, —NR^(d1)C(═O)R^(d1), —NR^(d1)C(═O)OR^(d1),—NR^(d1)C(═O)N(R^(d1))₂, —OC(═O)R^(d1), —OC(═O)OR^(d1),—OC(═O)N(R^(d1))₂, —C(═O)R^(d1), —C(═O)OR^(d1), —C(═O)N(R^(d1))₂,—CH₂N(R^(d1))₂, or —CH₂OR^(d1). In certain embodiments, R^(D) is—OR^(d1) (e.g., —OH, —O(substituted or unsubstituted C₁₋₆ alkyl)). Incertain embodiments, R^(D) is —N(R^(d1))₂ (e.g., —NH₂, —NH(substitutedor unsubstituted C₁₋₆ alkyl) (e.g., —NHMe)). In certain embodiments,R^(D) is —CH₂OR^(d1) (e.g., —CH₂OH, —CH₂O (substituted or unsubstitutedC₁₋₆ alkyl)). In certain embodiments, R^(D) is —CH₂N(R^(d1))₂ (e.g.,—CH₂NH(substituted or unsubstituted C₁₋₆ alkyl), or —CH₂NH(phenyl)). Incertain embodiments, R^(D) is —CH₂N(R^(d1))₂, wherein two instances ofR^(d1) are combined to form a substituted or unsubstituted, 5- to6-membered, monocyclic or bicyclic heterocyclic ring, wherein one or twoatoms in the heterocyclic ring are independently nitrogen, oxygen, orsulfur). In certain embodiments, R^(D) is —C(═O)OR^(d1) (e.g., —C(═O)OH,—C(═O)O(substituted or unsubstituted C₁₋₆ alkyl)). In certainembodiments, R^(D) is —C(═O)N(R^(d1))₂ (e.g., —C(═O)NH(phenyl)),—C(═O)NH(substituted or unsubstituted C₁₋₆ alkyl). In certainembodiments, R^(D) is —C(═O)N(R^(d1))₂, wherein two instances of R^(d1)are combined to form a substituted or unsubstituted, 5- to 6-membered,monocyclic or bicyclic heterocyclic ring, wherein one or two atoms inthe heterocyclic ring are independently nitrogen, oxygen, or sulfur).

Formula (I-a) may include one or more instances of substituent R^(a) orsubstituent R^(d1). When Formula (I-a) includes two or more instances ofR^(a), any two instances of R^(a) may be the same or different from eachother. When Formula (I-a) includes two or more instances of R^(d1), anytwo instances of R^(d1) may be the same or different from each other. Incertain embodiments, at least one instance of R^(a) or R^(d1) ishydrogen. In certain embodiments, each instance of R^(a) or R^(d1) ishydrogen. In certain embodiments, at least one instance of R^(a) orR^(d1) is substituted or unsubstituted alkyl (e.g., substituted orunsubstituted C₁₋₆ alkyl). In certain embodiments, at least one instanceof R^(a) or R^(d1) is substituted or unsubstituted acyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl (e.g., substituted or unsubstitutedphenyl), substituted or unsubstituted heteroaryl, a nitrogen protectinggroup (e.g., benzyl (Bn), t-butyl carbonate (BOC or Boc), benzylcarbamate (Cbz), 9-fluorenylmethyl carbonate (Fmoc), trifluoroacetyl,triphenylmethyl, acetyl, or p-toluenesulfonamide (Ts)) when attached toa nitrogen atom, an oxygen protecting group (e.g., silyl,t-butyldiphenylsilyl (TBDPS), t-butyldimethylsilyl (TBDMS),triisopropylsilyl (TIPS), trimethylsilyl (TMS), triethylsilyl (TES),methoxylmethyl (MOM), tetrahydropyranyl (THP), t-Bu, benzyl (Bn), allyl,acetyl, pivaloyl, or benzoyl) when attached to an oxygen atom, or asulfur protecting group (e.g., acetamidomethyl, t-Bu, 3-nitro-2-pyridinesulfenyl, 2-pyridine-sulfenyl, or triphenylmethyl) when attached to asulfur atom. In certain embodiments, two instances of R^(a), or twoinstances of R^(d1), are joined to form a substituted or unsubstitutedcarbocyclyl ring, substituted or unsubstituted, heterocyclic ring,substituted or unsubstituted aryl ring, or substituted or unsubstituted,heteroaryl ring.

In certain embodiments, R^(d1) is hydrogen. In certain embodiments,R^(d1) is substituted or unsubstituted alkyl (e.g., substituted orunsubstituted C₁₋₆ alkyl). In certain embodiments, R^(d1) is methyl. Incertain embodiments, R^(d1) is isopropyl. In certain embodiments, R^(d1)is substituted or unsubstituted alkenyl (e.g., substituted orunsubstituted C₂₋₆ alkenyl). In certain embodiments, R^(d1) issubstituted or unsubstituted aryl (e.g., substituted or unsubstitutedphenyl). In certain embodiments, two instances of R^(d1) are joined toform a heterocyclic ring (e.g., substituted or unsubstituted, 5- to6-membered monocyclic heterocyclic ring, wherein one or two atoms in theheterocyclic ring are independently nitrogen, oxygen, or sulfur). Incertain embodiments, R^(D) is of the formula:

In certain embodiments, the compound of Formula (I-a) is of one of thefollowing formulae:

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the compound of Formula (I-a) is of the formula:

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the compound of Formula (I-a) is of the formula:

or a pharmaceutically acceptable salt thereof.

Compounds of Formula (I)

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof, wherein:

each instance of R^(A) is independently halogen, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, —OR^(a), —N(R^(a))₂,—SR^(a), —CN, —SCN, —C(═NR^(a))R^(a), —C(═NR^(a))OR^(a),—C(═NR^(a))N(R^(a))₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂, —NO₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)N(R^(a))₂,—N(R^(a))S(═O)R^(a), —N(R^(a))S(═O)OR^(a), —N(R^(a))S(═O)N(R^(a))₂,—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂OR^(a), —N(R^(a))S(═O)₂N(R^(a))₂,—OC(═O)R^(a), —OC(═O)OR^(a), or —OC(═O)N(R^(a))₂, or two instances ofR^(A) are joined to form a substituted or unsubstituted, carbocyclicring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted, aryl ring, or substituted or unsubstituted, heteroarylring;

each instance of R^(a) is independently H, substituted or unsubstitutedacyl, substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(a) are joined to form a substituted or unsubstituted, heterocyclicring, or substituted or unsubstituted, heteroaryl ring;

k is 0, 1, 2, 3, or 4;

R^(B) is H, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogenprotecting group;

X is —O— or —S—;

the double bond labeled with “a” is in the (E)- or (Z)-configuration;and

R^(C) is hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂, or a nitrogenprotecting group.

Formula (I) may include one or more instances of substituent R^(A) onthe benzimidazolyl moiety. When Formula (I) includes two or moreinstances of R^(A), any two instances of R^(A) may be the same ordifferent from each other. In certain embodiments, at least one instanceof R^(A) is halogen (e.g., F, Cl, Br, or I). In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted alkyl. Incertain embodiments, at least one instance of R^(A) is substituted orunsubstituted C₁₋₆ alkyl. In certain embodiments, at least one instanceof R^(A) is Me. In certain embodiments, at least one instance of R^(A)is substituted methyl (e.g., —CF₃, —CH₂OH, or Bn). In certainembodiments, at least one instance of R^(A) is Et, substituted ethyl(e.g., perfluoroethyl), Pr (e.g., n-Pr or i-Pr), substituted propyl(e.g., perfluoropropyl), Bu, or substituted butyl (e.g.,perfluorobutyl). In certain embodiments, at least one instance of R^(A)is substituted or unsubstituted alkenyl (e.g., substituted orunsubstituted C₂₋₆ alkenyl). In certain embodiments, at least oneinstance of R^(A) is substituted or unsubstituted alkynyl (e.g.,substituted or unsubstituted C₂₋₆ alkynyl). In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted carbocyclyl(e.g., substituted or unsubstituted, 3- to 7-membered, monocycliccarbocyclyl comprising zero, one, or two double bonds in the carbocyclicring system). In certain embodiments, at least one instance of R^(A) issubstituted or unsubstituted cyclopropyl, substituted or unsubstitutedcyclobutyl, substituted or unsubstituted cyclopentyl, or substituted orunsubstituted cyclohexyl. In certain embodiments, at least one instanceof R^(A) is substituted or unsubstituted heterocyclyl (e.g., substitutedor unsubstituted, 3- to 7-membered, monocyclic heterocyclyl comprisingzero, one, or two double bonds in the heterocyclic ring system, whereinone, two, or three atoms in the heterocyclic ring system areindependently nitrogen, oxygen, or sulfur). In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted oxetanyl,substituted or unsubstituted tetrahydrofuranyl, substituted orunsubstituted pyrrolidinyl, substituted or unsubstitutedtetrahydropyranyl, substituted or unsubstituted piperidinyl, substitutedor unsubstituted morpholinyl, or substituted or unsubstitutedpiperazinyl. In certain embodiments, at least one instance of R^(A) issubstituted or unsubstituted aryl (e.g., substituted or unsubstituted,6- to 10-membered aryl). In certain embodiments, at least one instanceof R^(A) is unsubstituted phenyl. In certain embodiments, at least oneinstance of R^(A) is substituted phenyl. In certain embodiments, atleast one instance of R^(A) is substituted or unsubstituted naphthyl. Incertain embodiments, at least one instance of R^(A) is substituted orunsubstituted heteroaryl. In certain embodiments, at least one instanceof R^(A) is substituted or unsubstituted, 5- to 6-membered, monocyclicheteroaryl, wherein one, two, three, or four atoms in the heteroarylring system are independently nitrogen, oxygen, or sulfur. In certainembodiments, at least one instance of R^(A) is substituted orunsubstituted, 9- to 10-membered, bicyclic heteroaryl, wherein one, two,three, or four atoms in the heteroaryl ring system are independentlynitrogen, oxygen, or sulfur. In certain embodiments, at least oneinstance of R^(A) is —OR^(a) (e.g., —OH, —O(substituted or unsubstitutedC₁₋₆ alkyl) (e.g., —OMe, —OCF₃, —OEt, —OPr, —OBu, or —OBn), or—O(substituted or unsubstituted phenyl) (e.g., —OPh)). In certainembodiments, at least one instance of R^(A) is —SR^(a) (e.g., —SH,—S(substituted or unsubstituted C₁₋₆ alkyl) (e.g., —SMe, —SEt, —SPr,—SBu, or —SBn), or —S(substituted or unsubstituted phenyl) (e.g.,—SPh)). In certain embodiments, at least one instance of R^(A) is—N(R^(a))₂ (e.g., —NH₂, —NH(substituted or unsubstituted C₁₋₆ alkyl)(e.g., —NHMe), or —N(substituted or unsubstituted C₁₋₆alkyl)-(substituted or unsubstituted C₁₋₆ alkyl) (e.g., —NMe₂)). Incertain embodiments, at least one instance of R^(A) is —CN or —SCN. Incertain embodiments, at least one instance of R^(A) is —NO₂. In certainembodiments, at least one instance of R^(A) is —C(═NR^(a))R^(a),—C(═NR^(a))OR^(a), or —C(═NR^(a))N(R^(a))₂. In certain embodiments, atleast one instance of R^(A) is —C(═O)R^(a) (e.g., —C(═O)(substituted orunsubstituted alkyl) (e.g., —C(═O)Me) or —C(═O)(substituted orunsubstituted phenyl)). In certain embodiments, at least one instance ofR^(A) is —C(═O)OR^(a) (e.g., —C(═O)OH, —C(═O)O(substituted orunsubstituted alkyl) (e.g., —C(═O)OMe), or —C(═O)O(substituted orunsubstituted phenyl)). In certain embodiments, at least one instance ofR^(A) is —C(═O)N(R^(a))₂ (e.g., —C(═O)NH₂, —C(═O)NH(substituted orunsubstituted alkyl) (e.g., —C(═O)NHMe), —C(═O)NHPh,—C(═O)NH(substituted phenyl), —C(═O)N(substituted or unsubstitutedalkyl)-(substituted or unsubstituted alkyl), —C(═O)N(substituted orunsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certainembodiments, at least one instance of R^(A) is —C(═O)N(R^(a))₂, whereintwo instances of R^(a) are joined to form a substituted orunsubstituted, 3- to 7-membered, monocyclic heterocyclic ring comprisingzero, one, or two double bonds in the heterocyclic ring system, whereinone, two, or three atoms in the heterocyclic ring system areindependently nitrogen, oxygen, or sulfur. In certain embodiments, atleast one instance of R^(A) is —C(═O)-(1-morpholinyl). In certainembodiments, at least one instance of R^(A) is —NR^(a)C(═O)R^(a)(e.g.,—NHC(═O)(substituted or unsubstituted C₁₋₆ alkyl) (e.g., —NHC(═O)Me),—NHC(═O)Ph, or —NHC(═O)(substituted phenyl)). In certain embodiments, atleast one instance of R^(A) is —NR^(a)C(═O)OR^(a). In certainembodiments, at least one instance of R^(A) is —NR^(a)C(═O)N(R^(a))₂(e.g., —NHC(═O)NH₂, —NHC(═O)NH(substituted or unsubstituted C₁₋₆ alkyl)(e.g., —NHC(═O)NHMe or —NHC(═O)NH(i-Pr)), —NHC(═O)NHPh, or—NHC(═O)NH(substituted phenyl)). In certain embodiments, at least oneinstance of R^(A) is —OC(═O)R^(a), —OC(═O)OR^(a), or —OC(═O)N(R^(a))₂.In certain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)R^(a) (e.g., —NHS(═O)(substituted or unsubstituted C₁₋₆alkyl) (e.g., —NHS(═O)Me), —NHS(═O)Ph, or —NHS(═O)(substituted phenyl)).In certain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)OR^(a). In certain embodiments, at least one instance ofR^(A) is —NR^(a)S(═O)N(R^(a))₂ (e.g., —NHS(═O)NH₂,—NHS(═O)NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g.,—NHS(═O)NHMe), —NHS(═O)NHPh, or —NHS(═O)NH(substituted phenyl)). Incertain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)₂R^(a) (e.g., —NHS(═O)₂ (substituted or unsubstituted C₁₋₆alkyl) (e.g., —NHS(═O)₂Me), —NHS(═O)₂Ph, or —NHS(═O)₂ (substitutedphenyl)). In certain embodiments, at least one instance of R^(A) is—NR^(a)S(═O)₂OR^(a). In certain embodiments, at least one instance ofR^(A) is —NR^(a)S(═O)₂N(R^(a))₂ (e.g., —NHS(═O)₂NH₂,—NHS(═O)₂NH(substituted or unsubstituted C₁₋₆ alkyl) (e.g.,—NHS(═O)₂NHMe), —NHS(═O)₂NHPh, or —NHS(═O)₂NH(substituted phenyl)). Incertain embodiments, at least one instance of R^(A) is halogen, —OR^(a),—N(R^(a))₂, —NO₂, —C(═O)R^(a), C(═O)OR^(a), —C(═O)N(R^(a))₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)N(R^(a))₂, or —N(R^(a))S(═O)₂R^(a).In certain embodiments, at least one instance of R^(A) is Cl, —OMe,—OCF₃, —NH₂, —NHMe, —NMe₂, —NO₂, —C(═O)Me, —C(═O)OH, —C(═O)OMe,—C(═O)NH₂, —C(═O)NHMe, —C(═O)NHPh, —C(═O)-(1-morpholinyl), —NHC(═O)Me,—NHC(═O)Ph, —NHC(═O)NH(i-Pr), —NHC(═O)NHPh, —NHS(═O)₂Me, or —NHS(═O)₂Ph.In certain embodiments, at least one instance of R^(A) is —CF₃, —CH₂OH,or i-Pr.

When Formula (I) include two or more instances of R^(A), any twoinstances of R^(A) may be joined to form a substituted or unsubstitutedring. In certain embodiments, two instances of R^(A) are joined to forma substituted or unsubstituted, carbocyclic ring (e.g., substituted orunsubstituted, 3- to 7-membered, monocyclic carbocyclic ring comprisingzero, one, or two double bonds in the carbocyclic ring system). Incertain embodiments, two instances of R^(A) are joined to form asubstituted or unsubstituted, heterocyclic ring (e.g., substituted orunsubstituted, 3- to 7-membered, monocyclic heterocyclic ring comprisingzero, one, or two double bonds in the heterocyclic ring system, whereinone, two, or three atoms in the heterocyclic ring system areindependently nitrogen, oxygen, or sulfur). In certain embodiments, twoinstances of R^(A) are joined to form a substituted or unsubstituted,aryl ring (e.g., substituted or unsubstituted phenyl ring). In certainembodiments, two instances of R^(A) are joined to form a substituted orunsubstituted, heteroaryl ring (e.g., substituted or unsubstituted, 5-to 6-membered, monocyclic heteroaryl ring, wherein one, two, or threeatoms in the heteroaryl ring system are independently nitrogen, oxygen,or sulfur).

Formula (I) may include one or more instances of substituent R^(a). WhenFormula (I) includes two or more instances of R^(a), any two instancesof R^(a) may be the same or different from each other. In certainembodiments, at least one instance of R^(a) is H. In certainembodiments, each instance of R^(a) is H. In certain embodiments, atleast one instance of R^(a) is substituted or unsubstituted alkyl (e.g.,substituted or unsubstituted C₁₋₆ alkyl). In certain embodiments, atleast one instance of R^(a) is substituted or unsubstituted acyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl (e.g.,substituted or unsubstituted phenyl), substituted or unsubstitutedheteroaryl, a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc,trifluoroacetyl, triphenylmethyl, acetyl, or Ts) when attached to anitrogen atom, an oxygen protecting group (e.g., silyl, TBDPS, TBDMS,TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl)when attached to an oxygen atom, or a sulfur protecting group (e.g.,acetamidomethyl, t-Bu, 3-nitro-2-pyridine sulfenyl, 2-pyridine-sulfenyl,or triphenylmethyl) when attached to a sulfur atom. In certainembodiments, two instances of R^(a) are joined to form a substituted orunsubstituted, heterocyclic ring, or substituted or unsubstituted,heteroaryl ring.

In certain embodiments, k is 0. In certain embodiments, k is 1. Incertain embodiments, k is 2. In certain embodiments, k is 3. In certainembodiments, k is 4.

In certain embodiments, k is 1; and R^(A) is halogen, —OR^(a),—N(R^(a))₂, —NO₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)N(R^(a))₂, or —N(R^(a))S(═O)₂R^(a).In certain embodiments, k is 1; and R^(A) is Cl, —OMe, —OCF₃, —NH₂,—NHMe, —NMe₂, —NO₂, —C(═O)Me, —C(═O)OH, —C(═O)OMe, —C(═O)NH₂,—C(═O)NHMe, —C(═O)NHPh, —C(═O)-(1-morpholinyl), —NHC(═O)Me, —NHC(═O)Ph,—NHC(═O)NH(i-Pr), —NHC(═O)NHPh, —NHS(═O)₂Me, or —NHS(═O)₂Ph. In certainembodiments, k is 2; and each instance of R^(A) is independentlyhalogen. In certain embodiments, k is 2; and each instance of R^(A) isCl.

Formula (I) includes substituent R^(B) on a nitrogen atom of thebenzimidazolyl moiety. In certain embodiments, R^(B) is H. In certainembodiments, R^(B) is substituted or unsubstituted C₁₋₆ alkyl. Incertain embodiments, R^(B) is Me. In certain embodiments, R^(B) issubstituted methyl (e.g., —CF₃ or Bn). In certain embodiments, R^(B) isEt, substituted ethyl (e.g., perfluoroethyl), Pr, substituted propyl(e.g., perfluoropropyl or —(CH₂)₃NH₂), Bu, or substituted butyl (e.g.,perfluorobutyl). In certain embodiments, R^(B) is a nitrogen protectinggroup (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl,acetyl, or Ts).

Formula (I) includes an unsubstituted furanyl ring (when X is —O—) orunsubstituted thienyl ring (when X is —S—).

Formula (I) includes a double bond that is labeled with “a.” When thedouble bond that is labeled with “a” is attached to a substituentthrough a wavy bond (e.g.,

), both the (E)- and (Z)-configurations of the double bond arecontemplated. When the double bond that is labeled with “a” is notattached to any substituent through a wavy bond, the configuration ofthe double bond is either the (E)- or (Z)-configuration, as determinedby the way in which the double bond and any substituents thereon aredrawn.

Formula (I) includes substituent R^(C) on the thiazolidine-2,4-dionemoiety. In certain embodiments, R^(C) is H. In certain embodiments,R^(C) is substituted or unsubstituted alkyl. In certain embodiments,R^(C) is substituted or unsubstituted C₁₋₆ alkyl. In certainembodiments, R^(C) is Me. In certain embodiments, R^(C) is substitutedmethyl. In certain embodiments, R^(C) is —CF₃ or Bn. In certainembodiments, R^(C) is —C(R^(a))₂—C(═O)OR^(a), optionally wherein eachinstance of R^(a) is independently H, substituted or unsubstituted C₁₋₆alkyl, or substituted or unsubstituted phenyl. In certain embodiments,R^(C) is —CH₂—CO₂H, —CH₂—CO₂Me, —CH₂—CO₂(t-Bu), —CH(Me)-CO₂Me, or—CH(Me)-CO₂Et. In certain embodiments, R^(C) is—C(R^(a))₂—C(═O)N(R^(a))₂, optionally wherein each instance of R^(a) isindependently H, substituted or unsubstituted C₁₋₆ alkyl, or substitutedor unsubstituted phenyl, or two instances of R^(a) on the nitrogen atomare joined to form a substituted or unsubstituted heterocyclic ring orsubstituted or unsubstituted heteroaryl ring. In certain embodiments,R^(C) is of the formula:

In certain embodiments, R^(C) is Et or substituted ethyl (e.g.,perfluoroethyl). In certain embodiments, R^(C) is n-Pr. In certainembodiments, R^(C) is i-Pr. In certain embodiments, R^(C) is substitutedpropyl (e.g., perfluoropropyl). In certain embodiments, R^(C) is n-Bu,i-Bu, or t-Bu. In certain embodiments, R^(C) is sec-Bu. In certainembodiments, R^(C) is substituted butyl (e.g., perfluorobutyl). Incertain embodiments, R^(C) is —(CH₂)—N(R^(a))₂,—(CH₂)—N(R^(a))C(═O)R^(a), —(CH₂)—C(═O)N(R^(a))₂, or—(CH₂)_(n)—N(R^(a))C(═O)N(R^(a))₂, wherein each instance of n isindependently 2, 3, 4, 5, or 6 (e.g., 3); and optionally wherein eachinstance of R^(a) is independently H, substituted or unsubstituted C₁₋₆alkyl, substituted or unsubstituted phenyl, a nitrogen protecting groupwhen attached to a nitrogen atom, or a small molecule label (e.g., abiotin moiety (e.g.,

or a small molecule fluorophore), or two instances of R^(a) on the samenitrogen atom are joined to form a substituted or unsubstitutedheterocyclic ring or substituted or unsubstituted heteroaryl ring. Incertain embodiments, R^(C) is —(CH₂)₃—NH₂, —(CH₂)₃—NHC(═O)NHEt,—(CH₂)₃—NHC(═O)NHPh, or

In certain embodiments, R^(C) is substituted or unsubstituted alkenyl(e.g., substituted or unsubstituted C₂₋₆ alkenyl). In certainembodiments, R^(C) is substituted or unsubstituted alkynyl (e.g.,substituted or unsubstituted C₂₋₆ alkynyl). In certain embodiments,R^(C) is substituted or unsubstituted carbocyclyl (e.g., substituted orunsubstituted, 3- to 7-membered, monocyclic carbocyclyl comprising zero,one, or two double bonds in the carbocyclic ring system). In certainembodiments, R^(C) is substituted or unsubstituted cyclopropyl,substituted or unsubstituted cyclobutyl, substituted or unsubstitutedcyclopentyl, or substituted or unsubstituted cyclohexyl. In certainembodiments, R^(C) is substituted or unsubstituted heterocyclyl (e.g.,substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclylcomprising zero, one, or two double bonds in the heterocyclic ringsystem, wherein one, two, or three atoms in the heterocyclic ring systemare independently nitrogen, oxygen, or sulfur). In certain embodiments,R^(C) is substituted or unsubstituted oxetanyl, substituted orunsubstituted tetrahydrofuranyl, substituted or unsubstitutedpyrrolidinyl, substituted or unsubstituted tetrahydropyranyl,substituted or unsubstituted piperidinyl, substituted or unsubstitutedmorpholinyl, or substituted or unsubstituted piperazinyl. In certainembodiments, R^(C) is substituted or unsubstituted aryl (e.g.,substituted or unsubstituted, 6- to 10-membered aryl). In certainembodiments, R^(C) is unsubstituted phenyl. In certain embodiments,R^(C) is substituted phenyl. In certain embodiments, R^(C) issubstituted or unsubstituted naphthyl. In certain embodiments, R^(C) issubstituted or unsubstituted heteroaryl. In certain embodiments, R^(C)is substituted or unsubstituted, 5- to 6-membered, monocyclicheteroaryl, wherein one, two, three, or four atoms in the heteroarylring system are independently nitrogen, oxygen, or sulfur. In certainembodiments, R^(C) is substituted or unsubstituted, 9- to 10-membered,bicyclic heteroaryl, wherein one, two, three, or four atoms in theheteroaryl ring system are independently nitrogen, oxygen, or sulfur. Incertain embodiments, R^(C) is —C(═O)R^(a) (e.g., —C(═O)(substituted orunsubstituted alkyl) (e.g., —C(═O)Me) or —C(═O)(substituted orunsubstituted phenyl)). In certain embodiments, R^(C) is —C(═O)OR^(a)(e.g., —C(═O)OH, —C(═O)O(substituted or unsubstituted alkyl) (e.g.,—C(═O)OMe), or —C(═O)O(substituted or unsubstituted phenyl)). In certainembodiments, R^(C) is —C(═O)N(R^(a))₂ (e.g., —C(═O)NH₂,—C(═O)NH(substituted or unsubstituted alkyl) (e.g., —C(═O)NHMe),—C(═O)NH(substituted or unsubstituted phenyl), —C(═O)N(substituted orunsubstituted alkyl)-(substituted or unsubstituted alkyl),—C(═O)N(substituted or unsubstituted phenyl)-(substituted orunsubstituted alkyl)). In certain embodiments, R^(C) is —C(═O)N(R^(a))₂,wherein two instances of R^(a) are joined to form a substituted orunsubstituted, 3- to 7-membered, monocyclic heterocyclic ring comprisingzero, one, or two double bonds in the heterocyclic ring system, whereinone, two, or three atoms in the heterocyclic ring system areindependently nitrogen, oxygen, or sulfur. In certain embodiments, R^(C)is a nitrogen protecting group (e.g., Bn, Boc, Cbz, Fmoc,trifluoroacetyl, triphenylmethyl, acetyl, or Ts).

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, the compound of Formula (I) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof.

In certain embodiments, when X is —O—, then k is 1, 2, 3, or 4, and noinstance of R^(A) is Me. In certain embodiments, when X is —O—, then kis 1, 2, 3, or 4, and no instance of R^(A) is unsubstituted C₁₋₆ alkyl.In certain embodiments, wherein when X is —O—, and k is 1, then noinstance of R^(A) is Me. In certain embodiments, wherein when X is —O—,and k is 1, then no instance of R^(A) is unsubstituted C₁₋₆ alkyl. Incertain embodiments, the compound of Formula (I) is not of the formula:

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the compound of Formula (I) is not of theformula:

Exemplary compounds of Formula (I) include, but are not limited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

Additional exemplary compounds of Formula (I) include, but are notlimited to:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

Further exemplary compounds of Formula (I) include, but are not limitedto:

and pharmaceutically acceptable salts, solvates, hydrates, polymorphs,co-crystals, tautomers, stereoisomers, isotopically labeled derivatives,and prodrugs thereof.

Compounds of Formula (II)

In certain embodiments, the compound of Formula (II) is of the formula:

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph,co-crystal, tautomer, stereoisomer, isotopically labeled derivative, orprodrug thereof, wherein:

the double bond labeled with “a” is in the (E)- or (Z)-configuration;and

R^(C) is hydrogen, substituted or unsubstituted acyl, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)N(R^(a))₂, or a nitrogen protecting group;

each instance of R^(a) is independently hydrogen, substituted orunsubstituted acyl, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(a) are joined to form a substituted or unsubstituted, heterocyclicring, or substituted or unsubstituted, heteroaryl ring; and

R^(E) is a substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl.

Formula (II) includes substituent R^(E). In certain embodiments, R^(E)is substituted or unsubstituted alkyl (e.g., substituted orunsubstituted C₁₋₆ alkyl). In certain embodiments, R^(E) is substitutedor unsubstituted alkenyl (e.g., substituted or unsubstituted C₂₋₆alkenyl). In certain embodiments, R^(E) is of the formula:

wherein R^(f) is H, or substituted or unsubstituted alkyl. In certainembodiments R^(f) is substituted or unsubstituted C₁₋₆ alkyl. In certainembodiments R^(f) is methyl. In certain embodiments, R^(E) issubstituted or unsubstituted aryl (e.g., substituted or unsubstitutedphenyl). In certain embodiments, R^(E) is a heterocyclic ring (e.g.,substituted or unsubstituted, 5- to 10-membered monocyclic or bicyclicheterocyclic ring, wherein 1, 2, or 3 atoms in the heterocyclic ring areindependently nitrogen, oxygen, or sulfur). In certain embodiments,R^(E) is substituted or unsubstituted heteroaryl (e.g., substituted orunsubstituted, 5- to 6-membered heteroaryl ring, wherein one or twoatoms in the heteroaryl ring are independently nitrogen, oxygen, orsulfur). In certain embodiments, R^(E) is of the formula:

wherein X is —O— or —S—; and R^(X) is H, substituted or unsubstitutedalkyl, substituted or unsubstituted acyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, or substituted or unsubstitutedheteroaryl. In certain embodiments, Rx is substituted or unsubstitutedalkyl (e.g., substituted or unsubstituted C₁₋₆ alkyl). In certainembodiments, R^(E) is of the formula:

In certain embodiments, R^(E) is of the formula:

wherein X is —O— or —S—; and Ring B is a substituted or unsubstitutedcarbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, or substituted or unsubstituted heteroaryl. Incertain embodiments Ring B is a heterocyclic ring (e.g., substituted orunsubstituted, 5- to 10-membered monocyclic or bicyclic heterocyclicring, wherein one or two atoms in the heterocyclic ring areindependently nitrogen, oxygen, or sulfur). In certain embodiments, RingB is substituted or unsubstituted aryl (e.g., substituted orunsubstituted phenyl). In certain embodiments, Ring B is of the formula:

wherein W¹ and Y¹ are independently —N—, or —NR^(W)—, as valencypermits, and R^(W) is H, substituted or unsubstituted alkyl, substitutedor unsubstituted acyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, or a nitrogen protectinggroup. In certain embodiments, Ring B is of the formula:

wherein Z is —N—, or —CH—; and R^(G) is H, or substituted orunsubstituted alkyl. In certain embodiments, R^(G) is substituted orunsubstituted alkyl (e.g., substituted or unsubstituted C₁₋₆ alkyl).

In certain embodiments, Ring B is of the formula:

wherein Y¹ and Z¹ are independently —NR^(g)—, —CH—, or —O—; and R^(g) isH, or substituted or unsubstituted alkyl.

In certain embodiments, Ring B is of the formula:

In certain embodiments, the compound of Formula (II) is of one of thefollowing formulae:

or a pharmaceutically acceptable salt thereof.

In certain embodiments, the compound of Formula (II) is of the formula:

or a pharmaceutically acceptable salt thereof.

The compounds described herein may be capable of binding (e.g.,reversibly binding or irreversibly binding, through covalent and/ornon-covalent interactions) Myc. The compounds described herein may alsobe capable of preventing or reducing the interaction or binding of Mycwith another molecule (e.g., peptide or protein). The compoundsdescribed herein may be useful in modulating (e.g., inhibiting) theactivity of Myc in a subject in need thereof, treating diseasesassociated with Myc (e.g., diseases associated with aberrant activity(e.g., increased activity) of Myc) in a subject in need thereof,treating proliferative diseases in a subject in need thereof, preventingdiseases associated with Myc (e.g., diseases associated with aberrantactivity (e.g., increased activity) of Myc) in a subject in needthereof, preventing proliferative diseases in a subject in need thereof,and/or inducing apoptosis of a cell in a subject, biological sample, ortissue. The compounds described herein may also be useful as researchtools, e.g., for studying Myc (e.g., studying the activity of Myc) in asubject, biological sample, tissue, or cell.

Pharmaceutical Compositions, Kits, and Administration

The present disclosure also provides pharmaceutical compositionscomprising a compound described herein and optionally a pharmaceuticallyacceptable excipient. The pharmaceutical compositions may be useful inmodulating (e.g., inhibiting) the activity of Myc in a subject in needthereof, treating diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, treating proliferative diseases in a subjectin need thereof, preventing diseases associated with Myc (e.g., diseasesassociated with aberrant activity (e.g., increased activity) of Myc) ina subject in need thereof, preventing proliferative diseases in asubject in need thereof, and/or inducing apoptosis of a cell in asubject, biological sample, or tissue. The pharmaceutical compositionsdescribed herein may also be useful as research tools, e.g., forstudying Myc (e.g., studying the activity of Myc) in a subject,biological sample, tissue, or cell.

In certain embodiments, the Myc is c-Myc. In certain embodiments, theMyc is L-Myc or N-Myc.

In certain embodiments, the subject is an animal. The animal may be ofeither sex and may be at any stage of development. In certainembodiments, the subject described herein is a human. In certainembodiments, the subject is a non-human animal. In certain embodiments,the subject is a mammal. In certain embodiments, the subject is anon-human mammal. In certain embodiments, the subject is a domesticatedanimal, such as a dog, cat, cow, pig, horse, sheep, or goat. In certainembodiments, the subject is a companion animal, such as a dog or cat. Incertain embodiments, the subject is a livestock animal, such as a cow,pig, horse, sheep, or goat. In certain embodiments, the subject is a zooanimal. In another embodiment, the subject is a research animal, such asa rodent (e.g., mouse, rat), dog, pig, or non-human primate. In certainembodiments, the animal is a genetically engineered animal. In certainembodiments, the animal is a transgenic animal (e.g., transgenic miceand transgenic pigs). In certain embodiments, the subject is a fish orreptile.

In certain embodiments, the cell is in vitro. In certain embodiments,the cell is in vivo.

In certain embodiments, the compound described herein is provided in aneffective amount in the pharmaceutical composition. In certainembodiments, the effective amount is a therapeutically effective amount.In certain embodiments, the effective amount is a prophylacticallyeffective amount. In certain embodiments, a therapeutically effectiveamount is an amount effective for modulating (e.g., inhibiting) theactivity of Myc. In certain embodiments, a therapeutically effectiveamount is an amount effective for treating a proliferative disease. Incertain embodiments, a therapeutically effective amount is an amounteffective for modulating (e.g., inhibiting) the activity of Myc andtreating a proliferative disease. In certain embodiments, atherapeutically effective amount is an amount effective for inducingapoptosis of a cell. In certain embodiments, a prophylacticallyeffective amount is an amount effective for modulating (e.g.,inhibiting) the activity of Myc. In certain embodiments, aprophylactically effective amount is an amount effective for preventinga proliferative disease. In certain embodiments, a prophylacticallyeffective amount is an amount effective for modulating (e.g.,inhibiting) the activity of Myc and preventing a proliferative disease.In certain embodiments, a prophylactically effective amount is an amounteffective for inducing apoptosis of a cell.

In certain embodiments, the effective amount is an amount effective formodulating (e.g., inhibiting) the activity of Myc by at least 10%, atleast 20%, at least 30%, at least 40%, at least 50%, at least 60%, atleast 70%, at least 80%, at least 90%, at least 95%, or at least 98%. Incertain embodiments, the effective amount is an amount effective formodulating (e.g., inhibiting) the activity of Myc by not more than 10%,not more than 20%, not more than 30%, not more than 40%, not more than50%, not more than 60%, not more than 70%, not more than 80%, not morethan 90%, not more than 95%, or not more than 98%.

Pharmaceutical compositions described herein can be prepared by anymethod known in the art of pharmacology. In general, such preparatorymethods include bringing the compound described herein (i.e., the“active ingredient”) into association with a carrier or excipient,and/or one or more other accessory ingredients, and then, if necessaryand/or desirable, shaping, and/or packaging the product into a desiredsingle- or multi-dose unit.

Pharmaceutical compositions can be prepared, packaged, and/or sold inbulk, as a single unit dose, and/or as a plurality of single unit doses.A “unit dose” is a discrete amount of the pharmaceutical compositioncomprising a predetermined amount of the active ingredient. The amountof the active ingredient is generally equal to the dosage of the activeingredient which would be administered to a subject and/or a convenientfraction of such a dosage, such as one-half or one-third of such adosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition described herein will vary, depending uponthe identity, size, and/or condition of the subject treated and furtherdepending upon the route by which the composition is to be administered.The composition may comprise between 0.1% and 100% (w/w) activeingredient.

Pharmaceutically acceptable excipients used in the manufacture ofprovided pharmaceutical compositions include inert diluents, dispersingand/or granulating agents, surface active agents and/or emulsifiers,disintegrating agents, binding agents, preservatives, buffering agents,lubricating agents, and/or oils. Excipients such as cocoa butter andsuppository waxes, coloring agents, coating agents, sweetening,flavoring, and perfuming agents may also be present in the composition.

Exemplary diluents include calcium carbonate, sodium carbonate, calciumphosphate, dicalcium phosphate, calcium sulfate, calcium hydrogenphosphate, sodium phosphate lactose, sucrose, cellulose,microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodiumchloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

Exemplary granulating and/or dispersing agents include potato starch,corn starch, tapioca starch, sodium starch glycolate, clays, alginicacid, guar gum, citrus pulp, agar, bentonite, cellulose, and woodproducts, natural sponge, cation-exchange resins, calcium carbonate,silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone)(crospovidone), sodium carboxymethyl starch (sodium starch glycolate),carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose(croscarmellose), methylcellulose, pregelatinized starch (starch 1500),microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate,quaternary ammonium compounds, and mixtures thereof.

Exemplary surface active agents and/or emulsifiers include naturalemulsifiers (e.g., acacia, agar, alginic acid, sodium alginate,tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk,casein, wool fat, cholesterol, wax, and lecithin), colloidal clays(e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminumsilicate)), long chain amino acid derivatives, high molecular weightalcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetinmonostearate, ethylene glycol distearate, glyceryl monostearate, andpropylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.,carboxy polymethylene, polyacrylic acid, acrylic acid polymer, andcarboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.,carboxymethylcellulose sodium, powdered cellulose, hydroxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylenesorbitan monolaurate (Tween® 20), polyoxyethylene sorbitan (Tween® 60),polyoxyethylene sorbitan monooleate (Tween® 80), sorbitan monopalmitate(Span® 40), sorbitan monostearate (Span® 60), sorbitan tristearate(Span® 65), glyceryl monooleate, sorbitan monooleate (Span® 80),polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj® 45),polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil,polyoxymethylene stearate, and Solutol®), sucrose fatty acid esters,polyethylene glycol fatty acid esters (e.g., Cremophor®),polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether (Brij® 30)),poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamineoleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyllaurate, sodium lauryl sulfate, Pluronic® F-68, poloxamer P-188,cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride,docusate sodium, and/or mixtures thereof.

Exemplary binding agents include starch (e.g., cornstarch and starchpaste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin,molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums(e.g., acacia, sodium alginate, extract of Irish moss, panwar gum,ghatti gum, mucilage of isapol husks, carboxymethylcellulose,methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose,cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate(Veegum®), and larch arabogalactan), alginates, polyethylene oxide,polyethylene glycol, inorganic calcium salts, silicic acid,polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.

Exemplary preservatives include antioxidants, chelating agents,antimicrobial preservatives, antifungal preservatives, antiprotozoanpreservatives, alcohol preservatives, acidic preservatives, and otherpreservatives. In certain embodiments, the preservative is anantioxidant. In other embodiments, the preservative is a chelatingagent.

Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbylpalmitate, butylated hydroxyanisole, butylated hydroxytoluene,monothioglycerol, potassium metabisulfite, propionic acid, propylgallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, andsodium sulfite.

Exemplary chelating agents include ethylenediaminetetraacetic acid(EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodiumedetate, trisodium edetate, calcium disodium edetate, dipotassiumedetate, and the like), citric acid and salts and hydrates thereof(e.g., citric acid monohydrate), fumaric acid and salts and hydratesthereof, malic acid and salts and hydrates thereof, phosphoric acid andsalts and hydrates thereof, and tartaric acid and salts and hydratesthereof. Exemplary antimicrobial preservatives include benzalkoniumchloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide,cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol,chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea,phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate,propylene glycol, and thimerosal.

Exemplary antifungal preservatives include butyl paraben, methylparaben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoicacid, potassium benzoate, potassium sorbate, sodium benzoate, sodiumpropionate, and sorbic acid.

Exemplary alcohol preservatives include ethanol, polyethylene glycol,phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate,and phenylethyl alcohol.

Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E,beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbicacid, sorbic acid, and phytic acid.

Other preservatives include tocopherol, tocopherol acetate, deteroximemesylate, cetrimide, butylated hydroxyanisol (BHA), butylatedhydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS),sodium lauryl ether sulfate (SLES), sodium bisulfite, sodiummetabisulfite, potassium sulfite, potassium metabisulfite, Glydant®Plus, Phenonip®, methylparaben, Germall® 115, Germaben® II, Neolone®,Kathon®, and Euxyl®.

Exemplary buffering agents include citrate buffer solutions, acetatebuffer solutions, phosphate buffer solutions, ammonium chloride, calciumcarbonate, calcium chloride, calcium citrate, calcium glubionate,calcium gluceptate, calcium gluconate, D-gluconic acid, calciumglycerophosphate, calcium lactate, propanoic acid, calcium levulinate,pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasiccalcium phosphate, calcium hydroxide phosphate, potassium acetate,potassium chloride, potassium gluconate, potassium mixtures, dibasicpotassium phosphate, monobasic potassium phosphate, potassium phosphatemixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodiumcitrate, sodium lactate, dibasic sodium phosphate, monobasic sodiumphosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide,aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline,Ringer's solution, ethyl alcohol, and mixtures thereof.

Exemplary lubricating agents include magnesium stearate, calciumstearate, stearic acid, silica, talc, malt, glyceryl behanate,hydrogenated vegetable oils, polyethylene glycol, sodium benzoate,sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate,sodium lauryl sulfate, and mixtures thereof.

Exemplary natural oils include almond, apricot kernel, avocado, babassu,bergamot, black current seed, borage, cade, camomile, canola, caraway,carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee,corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed,geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate,jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademianut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange,orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed,pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood,sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, andwheat germ oils. Exemplary synthetic oils include, but are not limitedto, butyl stearate, caprylic triglyceride, capric triglyceride,cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate,mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixturesthereof.

Liquid dosage forms for oral and parenteral administration includepharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active ingredients,the liquid dosage forms may comprise inert diluents commonly used in theart such as, for example, water or other solvents, solubilizing agentsand emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed,groundnut, corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, the oralcompositions can include adjuvants such as wetting agents, emulsifyingand suspending agents, sweetening, flavoring, and perfuming agents. Incertain embodiments for parenteral administration, the conjugatesdescribed herein are mixed with solubilizing agents such as Cremophor®,alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins,polymers, and mixtures thereof.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation can be a sterile injectable solution,suspension, or emulsion in a nontoxic parenterally acceptable diluent orsolvent, for example, as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that can be employed are water,Ringer's solution, U.S.P., and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or di-glycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of a drug, it is often desirable to slowthe absorption of the drug from subcutaneous or intramuscular injection.This can be accomplished by the use of a liquid suspension ofcrystalline or amorphous material with poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolution,which, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform may be accomplished by dissolving or suspending the drug in an oilvehicle.

Compositions for rectal or vaginal administration are typicallysuppositories which can be prepared by mixing the conjugates describedherein with suitable non-irritating excipients or carriers such as cocoabutter, polyethylene glycol, or a suppository wax which are solid atambient temperature but liquid at body temperature and therefore melt inthe rectum or vaginal cavity and release the active ingredient.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activeingredient is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or (a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, (b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, (c) humectants such as glycerol, (d) disintegratingagents such as agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, (e) solutionretarding agents such as paraffin, (f) absorption accelerators such asquaternary ammonium compounds, (g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolinand bentonite clay, and (i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets, and pills, thedosage form may include a buffering agent.

Solid compositions of a similar type can be employed as fillers in softand hard-filled gelatin capsules using such excipients as lactose ormilk sugar as well as high molecular weight polyethylene glycols and thelike. The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the art of pharmacology. Theymay optionally comprise opacifying agents and can be of a compositionthat they release the active ingredient(s) only, or preferentially, in acertain part of the intestinal tract, optionally, in a delayed manner.Examples of encapsulating compositions which can be used includepolymeric substances and waxes. Solid compositions of a similar type canbe employed as fillers in soft and hard-filled gelatin capsules usingsuch excipients as lactose or milk sugar as well as high molecularweight polethylene glycols and the like.

The active ingredient can be in a micro-encapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings, and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active ingredient can be admixed with at least oneinert diluent such as sucrose, lactose, or starch. Such dosage forms maycomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms may comprise bufferingagents. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of encapsulating agents which can be usedinclude polymeric substances and waxes.

Dosage forms for topical and/or transdermal administration of a compounddescribed herein may include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants, and/or patches. Generally, theactive ingredient is admixed under sterile conditions with apharmaceutically acceptable carrier or excipient and/or any neededpreservatives and/or buffers as can be required. Additionally, thepresent disclosure contemplates the use of transdermal patches, whichoften have the added advantage of providing controlled delivery of anactive ingredient to the body. Such dosage forms can be prepared, forexample, by dissolving and/or dispensing the active ingredient in theproper medium. Alternatively or additionally, the rate can be controlledby either providing a rate controlling membrane and/or by dispersing theactive ingredient in a polymer matrix and/or gel.

Suitable devices for use in delivering intradermal pharmaceuticalcompositions described herein include short needle devices. Intradermalcompositions can be administered by devices which limit the effectivepenetration length of a needle into the skin. Alternatively oradditionally, conventional syringes can be used in the classical mantouxmethod of intradermal administration. Jet injection devices whichdeliver liquid formulations to the dermis via a liquid jet injectorand/or via a needle which pierces the stratum corneum and produces a jetwhich reaches the dermis are suitable. Ballistic powder/particledelivery devices which use compressed gas to accelerate the compound inpowder form through the outer layers of the skin to the dermis aresuitable.

Formulations suitable for topical administration include, but are notlimited to, liquid and/or semi-liquid preparations such as liniments,lotions, oil-in-water and/or water-in-oil emulsions such as creams,ointments, and/or pastes, and/or solutions and/or suspensions. Topicallyadministrable formulations may, for example, comprise from about 1% toabout 10% (w/w) active ingredient, although the concentration of theactive ingredient can be as high as the solubility limit of the activeingredient in the solvent. Formulations for topical administration mayfurther comprise one or more of the additional ingredients describedherein.

A pharmaceutical composition described herein can be prepared, packaged,and/or sold in a formulation suitable for pulmonary administration viathe buccal cavity. Such a formulation may comprise dry particles whichcomprise the active ingredient and which have a diameter in the rangefrom about 0.5 to about 7 nanometers, or from about 1 to about 6nanometers. Such compositions are conveniently in the form of drypowders for administration using a device comprising a dry powderreservoir to which a stream of propellant can be directed to dispersethe powder and/or using a self-propelling solvent/powder dispensingcontainer such as a device comprising the active ingredient dissolvedand/or suspended in a low-boiling propellant in a sealed container. Suchpowders comprise particles wherein at least 98% of the particles byweight have a diameter greater than 0.5 nanometers and at least 95% ofthe particles by number have a diameter less than 7 nanometers.Alternatively, at least 95% of the particles by weight have a diametergreater than 1 nanometer and at least 90% of the particles by numberhave a diameter less than 6 nanometers. Dry powder compositions mayinclude a solid fine powder diluent such as sugar and are convenientlyprovided in a unit dose form.

Low boiling propellants generally include liquid propellants having aboiling point of below 65° F. at atmospheric pressure. Generally thepropellant may constitute 50 to 99.9% (w/w) of the composition, and theactive ingredient may constitute 0.1 to 20% (w/w) of the composition.The propellant may further comprise additional ingredients such as aliquid non-ionic and/or solid anionic surfactant and/or a solid diluent(which may have a particle size of the same order as particlescomprising the active ingredient).

Pharmaceutical compositions described herein formulated for pulmonarydelivery may provide the active ingredient in the form of droplets of asolution and/or suspension. Such formulations can be prepared, packaged,and/or sold as aqueous and/or dilute alcoholic solutions and/orsuspensions, optionally sterile, comprising the active ingredient, andmay conveniently be administered using any nebulization and/oratomization device. Such formulations may further comprise one or moreadditional ingredients including, but not limited to, a flavoring agentsuch as saccharin sodium, a volatile oil, a buffering agent, a surfaceactive agent, and/or a preservative such as methylhydroxybenzoate. Thedroplets provided by this route of administration may have an averagediameter in the range from about 0.1 to about 200 nanometers.

Formulations described herein as being useful for pulmonary delivery areuseful for intranasal delivery of a pharmaceutical composition describedherein. Another formulation suitable for intranasal administration is acoarse powder comprising the active ingredient and having an averageparticle from about 0.2 to 500 micrometers. Such a formulation isadministered by rapid inhalation through the nasal passage from acontainer of the powder held close to the nares.

Formulations for nasal administration may, for example, comprise fromabout as little as 0.1% (w/w) to as much as 100% (w/w) of the activeingredient, and may comprise one or more of the additional ingredientsdescribed herein. A pharmaceutical composition described herein can beprepared, packaged, and/or sold in a formulation for buccaladministration. Such formulations may, for example, be in the form oftablets and/or lozenges made using conventional methods, and maycontain, for example, 0.1 to 20% (w/w) active ingredient, the balancecomprising an orally dissolvable and/or degradable composition and,optionally, one or more of the additional ingredients described herein.Alternately, formulations for buccal administration may comprise apowder and/or an aerosolized and/or atomized solution and/or suspensioncomprising the active ingredient. Such powdered, aerosolized, and/oraerosolized formulations, when dispersed, may have an average particleand/or droplet size in the range from about 0.1 to about 200 nanometers,and may further comprise one or more of the additional ingredientsdescribed herein.

A pharmaceutical composition described herein can be prepared, packaged,and/or sold in a formulation for ophthalmic administration. Suchformulations may, for example, be in the form of eye drops including,for example, a 0.1-1.0% (w/w) solution and/or suspension of the activeingredient in an aqueous or oily liquid carrier or excipient. Such dropsmay further comprise buffering agents, salts, and/or one or more otherof the additional ingredients described herein. Otheropthalmically-administrable formulations which are useful include thosewhich comprise the active ingredient in microcrystalline form and/or ina liposomal preparation. Ear drops and/or eye drops are alsocontemplated as being within the scope of this disclosure.

Although the descriptions of pharmaceutical compositions provided hereinare principally directed to pharmaceutical compositions which aresuitable for administration to humans, it will be understood by theskilled artisan that such compositions are generally suitable foradministration to animals of all sorts. Modification of pharmaceuticalcompositions suitable for administration to humans in order to renderthe compositions suitable for administration to various animals is wellunderstood, and the ordinarily skilled veterinary pharmacologist candesign and/or perform such modification with ordinary experimentation.

Compounds provided herein are typically formulated in dosage unit formfor ease of administration and uniformity of dosage. It will beunderstood, however, that the total daily usage of the compositionsdescribed herein will be decided by a physician within the scope ofsound medical judgment. The specific therapeutically effective doselevel for any particular subject or organism will depend upon a varietyof factors including the proliferative disease being treated and theseverity of the disorder; the activity of the specific active ingredientemployed; the specific composition employed; the age, body weight,general health, sex, and diet of the subject; the time ofadministration, route of administration, and rate of excretion of thespecific active ingredient employed; the duration of the treatment;drugs used in combination or coincidental with the specific activeingredient employed; and like factors well known in the medical arts.

The compounds and compositions provided herein can be administered byany route, including enteral (e.g., oral), parenteral, intravenous,intramuscular, intra-arterial, intramedullary, intrathecal,subcutaneous, intraventricular, transdermal, interdermal, rectal,intravaginal, intraperitoneal, topical (as by powders, ointments,creams, and/or drops), mucosal, nasal, bucal, sublingual; byintratracheal instillation, bronchial instillation, and/or inhalation;and/or as an oral spray, nasal spray, and/or aerosol. Specificallycontemplated routes are oral administration, intravenous administration(e.g., systemic intravenous injection), regional administration viablood and/or lymph supply, and/or direct administration to an affectedsite. In general, the most appropriate route of administration willdepend upon a variety of factors including the nature of the agent(e.g., its stability in the environment of the gastrointestinal tract),and/or the condition of the subject (e.g., whether the subject is ableto tolerate oral administration). In certain embodiments, the compoundor pharmaceutical composition described herein is suitable for topicaladministration to the eye of a subject.

The exact amount of a compound required to achieve an effective amountwill vary from subject to subject, depending, for example, on species,age, and general condition of a subject, severity of the side effects ordisorder, identity of the particular compound, mode of administration,and the like. An effective amount may be included in a single dose(e.g., single oral dose) or multiple doses (e.g., multiple oral doses).In certain embodiments, when multiple doses are administered to asubject or applied to a biological sample, tissue, or cell, any twodoses of the multiple doses include different or substantially the sameamounts of a compound described herein. In certain embodiments, whenmultiple doses are administered to a subject or applied to a biologicalsample, tissue, or cell, the frequency of administering the multipledoses to the subject or applying the multiple doses to the biologicalsample, tissue, or cell is three doses a day, two doses a day, one dosea day, one dose every other day, one dose every third day, one doseevery week, one dose every two weeks, one dose every three weeks, or onedose every four weeks. In certain embodiments, the frequency ofadministering the multiple doses to the subject or applying the multipledoses to the biological sample, tissue, or cell is one dose per day. Incertain embodiments, the frequency of administering the multiple dosesto the subject or applying the multiple doses to the biological sample,tissue, or cell is two doses per day. In certain embodiments, thefrequency of administering the multiple doses to the subject or applyingthe multiple doses to the biological sample, tissue, or cell is threedoses per day. In certain embodiments, when multiple doses areadministered to a subject or applied to a biological sample, tissue, orcell, the duration between the first dose and last dose of the multipledoses is one day, two days, four days, one week, two weeks, three weeks,one month, two months, three months, four months, six months, ninemonths, one year, two years, three years, four years, five years, sevenyears, ten years, fifteen years, twenty years, or the lifetime of thesubject, tissue, or cell. In certain embodiments, the duration betweenthe first dose and last dose of the multiple doses is three months, sixmonths, or one year. In certain embodiments, the duration between thefirst dose and last dose of the multiple doses is the lifetime of thesubject, tissue, or cell. In certain embodiments, a dose (e.g., a singledose, or any dose of multiple doses) described herein includesindependently between 0.1 μg and 1 μg, between 0.001 mg and 0.01 mg,between 0.01 mg and 0.1 mg, between 0.1 mg and 1 mg, between 1 mg and 3mg, between 3 mg and 10 mg, between 10 mg and 30 mg, between 30 mg and100 mg, between 100 mg and 300 mg, between 300 mg and 1,000 mg, orbetween 1 g and 10 g, inclusive, of a compound described herein. Incertain embodiments, a dose described herein includes independentlybetween 1 mg and 3 mg, inclusive, of a compound described herein. Incertain embodiments, a dose described herein includes independentlybetween 3 mg and 10 mg, inclusive, of a compound described herein. Incertain embodiments, a dose described herein includes independentlybetween 10 mg and 30 mg, inclusive, of a compound described herein. Incertain embodiments, a dose described herein includes independentlybetween 30 mg and 100 mg, inclusive, of a compound described herein.

Dose ranges as described herein provide guidance for the administrationof provided pharmaceutical compositions to an adult. The amount to beadministered to, for example, a child or an adolescent can be determinedby a medical practitioner or person skilled in the art and can be loweror the same as that administered to an adult.

A compound or composition, as described herein, can be administered incombination with one or more additional pharmaceutical agents (e.g.,therapeutically and/or prophylactically active agents). The compounds orcompositions can be administered in combination with additionalpharmaceutical agents that improve their activity (e.g., activity (e.g.,potency and/or efficacy) in treating a proliferative disease in asubject in need thereof, in preventing a proliferative disease in asubject in need thereof, in modulating (e.g., inhibiting) the activityof Myc in a subject, biological sample, tissue, or cell, or in inducingapoptosis of a cell in a subject, biological sample, or tissue), improvebioavailability, improve safety, reduce drug resistance, reduce and/ormodify metabolism, inhibit excretion, and/or modify distribution in asubject, biological sample, tissue, or cell. It will also be appreciatedthat the therapy employed may achieve a desired effect for the samedisorder, and/or it may achieve different effects. In certainembodiments, a pharmaceutical composition described herein including acompound described herein and an additional pharmaceutical agent shows asynergistic effect that is absent in a pharmaceutical compositionincluding one of the compound and the additional pharmaceutical agent,but not both.

The compound or composition can be administered concurrently with, priorto, or subsequent to one or more additional pharmaceutical agents, whichmay be useful as, e.g., combination therapies. Pharmaceutical agentsinclude therapeutically active agents. Pharmaceutical agents alsoinclude prophylactically active agents. Pharmaceutical agents includesmall organic molecules such as drug compounds (e.g., compounds approvedfor human or veterinary use by the U.S. Food and Drug Administration asprovided in the Code of Federal Regulations (CFR)), peptides, proteins,carbohydrates, monosaccharides, oligosaccharides, polysaccharides,nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides orproteins, small molecules linked to proteins, glycoproteins, steroids,nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides,antisense oligonucleotides, lipids, hormones, vitamins, and cells. Eachadditional pharmaceutical agent may be administered at a dose and/or ona time schedule determined for that pharmaceutical agent. The additionalpharmaceutical agents may also be administered together with each otherand/or with the compound or composition described herein in a singledose or administered separately in different doses. The particularcombination to employ in a regimen will take into account compatibilityof the compound described herein with the additional pharmaceuticalagent(s) and/or the desired therapeutic and/or prophylactic effect to beachieved. In general, it is expected that the additional pharmaceuticalagent(s) in combination be utilized at levels that do not exceed thelevels at which they are utilized individually. In some embodiments, thelevels utilized in combination will be lower than those utilizedindividually.

The additional pharmaceutical agents include, but are not limited to,anti-proliferative agents, anti-cancer agents, anti-angiogenesis agents,anti-inflammatory agents, immunosuppressants, anti-bacterial agents,anti-viral agents, cardiovascular agents, cholesterol-lowering agents,anti-diabetic agents, anti-allergic agents, contraceptive agents,pain-relieving agents, and a combination thereof. In certainembodiments, the additional pharmaceutical agent is ananti-proliferative agent (e.g., anti-cancer agent). In certainembodiments, the additional pharmaceutical agent is an anti-leukemiaagent. In certain embodiments, the additional pharmaceutical agent isABITREXATE (methotrexate), ADE, Adriamycin RDF (doxorubicinhydrochloride), Ambochlorin (chlorambucil), ARRANON (nelarabine),ARZERRA (ofatumumab), BOSULIF (bosutinib), BUSULFEX (busulfan), CAMPATH(alemtuzumab), CERUBIDINE (daunorubicin hydrochloride), CLAFEN(cyclophosphamide), CLOFAREX (clofarabine), CLOLAR (clofarabine), CVP,CYTOSAR-U (cytarabine), CYTOXAN (cyclophosphamide), ERWINAZE(Asparaginase Erwinia Chrysanthemi), FLUDARA (fludarabine phosphate),FOLEX (methotrexate), FOLEX PFS (methotrexate), GAZYVA (obinutuzumab),GLEEVEC (imatinib mesylate), Hyper-CVAD, ICLUSIG (ponatinibhydrochloride), IMBRUVICA (ibrutinib), LEUKERAN (chlorambucil),LINFOLIZIN (chlorambucil), MARQIBO (vincristine sulfate liposome),METHOTREXATE LPF (methorexate), MEXATE (methotrexate), MEXATE-AQ(methotrexate), mitoxantrone hydrochloride, MUSTARGEN (mechlorethaminehydrochloride), MYLERAN (busulfan), NEOSAR (cyclophosphamide), ONCASPAR(Pegaspargase), PURINETHOL (mercaptopurine), PURIXAN (mercaptopurine),Rubidomycin (daunorubicin hydrochloride), SPRYCEL (dasatinib), SYNRIBO(omacetaxine mepesuccinate), TARABINE PFS (cytarabine), TASIGNA(nilotinib), TREANDA (bendamustine hydrochloride), TRISENOX (arsenictrioxide), VINCASAR PFS (vincristine sulfate), ZYDELIG (idelalisib), ora combination thereof. In certain embodiments, the additionalpharmaceutical agent is an anti-lymphoma agent. In certain embodiments,the additional pharmaceutical agent is ABITREXATE (methotrexate), ABVD,ABVE, ABVE-PC, ADCETRIS (brentuximab vedotin), ADRIAMYCIN PFS(doxorubicin hydrochloride), ADRIAMYCIN RDF (doxorubicin hydrochloride),AMBOCHLORIN (chlorambucil), AMBOCLORIN (chlorambucil), ARRANON(nelarabine), BEACOPP, BECENUM (carmustine), BELEODAQ (belinostat),BEXXAR (tositumomab and iodine I 131 tositumomab), BICNU (carmustine),BLENOXANE (bleomycin), CARMUBRIS (carmustine), CHOP, CLAFEN(cyclophosphamide), COPP, COPP-ABV, CVP, CYTOXAN (cyclophosphamide),DEPOCYT (liposomal cytarabine), DTIC-DOME (dacarbazine), EPOCH, FOLEX(methotrexate), FOLEX PFS (methotrexate), FOLOTYN (pralatrexate),HYPER-CVAD, ICE, IMBRUVICA (ibrutinib), INTRON A (recombinant interferonalfa-2b), ISTODAX (romidepsin), LEUKERAN (chlorambucil), LINFOLIZIN(chlorambucil), Lomustine, MATULANE (procarbazine hydrochloride),METHOTREXATE LPF (methotrexate), MEXATE (methotrexate), MEXATE-AQ(methotrexate), MOPP, MOZOBIL (plerixafor), MUSTARGEN (mechlorethaminehydrochloride), NEOSAR (cyclophosphamide), OEPA, ONTAK (denileukindiftitox), OPPA, R-CHOP, REVLIMID (lenalidomide), RITUXAN (rituximab),STANFORD V, TREANDA (bendamustine hydrochloride), VAMP, VELBAN(vinblastine sulfate), VELCADE (bortezomib), VELSAR (vinblastinesulfate), VINCASAR PFS (vincristine sulfate), ZEVALIN (ibritumomabtiuxetan), ZOLINZA (vorinostat), ZYDELIG (idelalisib), or a combinationthereof. In certain embodiments, the additional pharmaceutical agent isREVLIMID (lenalidomide), DACOGEN (decitabine), VIDAZA (azacitidine),CYTOSAR-U (cytarabine), IDAMYCIN (idarubicin), CERUBIDINE(daunorubicin), LEUKERAN (chlorambucil), NEOSAR (cyclophosphamide),FLUDARA (fludarabine), LEUSTATIN (cladribine), or a combination thereof.In certain embodiments, the additional pharmaceutical agent isABITREXATE (methotrexate), ABRAXANE (paclitaxel albumin-stabilizednanoparticle formulation), AC, AC-T, ADE, ADRIAMYCIN PFS (doxorubicinhydrochloride), ADRUCIL (fluorouracil), AFINITOR (everolimus), AFINITORDISPERZ (everolimus), ALDARA (imiquimod), ALIMTA (pemetrexed disodium),AREDIA (pamidronate disodium), ARIMIDEX (anastrozole), AROMASIN(exemestane), AVASTIN (bevacizumab), BECENUM (carmustine), BEP, BICNU(carmustine), BLENOXANE (bleomycin), CAF, CAMPTOSAR (irinotecanhydrochloride), CAPOX, CAPRELSA (vandetanib), CARBOPLATIN-TAXOL,CARMUBRIS (carmustine), CASODEX (bicalutamide), CEENU (lomustine),CERUBIDINE (daunorubicin hydrochloride), CERVARIX (recombinant HPVbivalent vaccine), CLAFEN (cyclophosphamide), CMF, COMETRIQ(cabozantinib-s-malate), COSMEGEN (dactinomycin), CYFOS (ifosfamide),CYRAMZA (ramucirumab), CYTOSAR-U (cytarabine), CYTOXAN(cyclophosphamide), DACOGEN (decitabine), DEGARELIX, DOXIL (doxorubicinhydrochloride liposome), DOXORUBICIN HYDROCHLORIDE, DOX-SL (doxorubicinhydrochloride liposome), DTIC-DOME (dacarbazine), EFUDEX (fluorouracil),ELLENCE (epirubicin hydrochloride), ELOXATIN (oxaliplatin), ERBITUX(cetuximab), ERIVEDGE (vismodegib), ETOPOPHOS (etoposide phosphate),EVACET (doxorubicin hydrochloride liposome), FARESTON (toremifene),FASLODEX (fulvestrant), FEC, FEMARA (letrozole), FLUOROPLEX(fluorouracil), FOLEX (methotrexate), FOLEX PFS (methotrexate), FOLFIRI,FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, FU-LV,GARDASIL (recombinant human papillomavirus (HPV) quadrivalent vaccine),GEMCITABINE-CISPLATIN, GEMCITABINE-OXALIPLATIN, GEMZAR (gemcitabinehydrochloride), GILOTRIF (afatinib dimaleate), GLEEVEC (imatinibmesylate), GLIADEL (carmustine implant), GLIADEL WAFER (carmustineimplant), HERCEPTIN (trastuzumab), HYCAMTIN (topotecan hydrochloride),IFEX (ifosfamide), IFOSFAMIDUM (ifosfamide), INLYTA (axitinib), INTRON A(recombinant interferon alfa-2b), IRESSA (gefitinib), IXEMPRA(ixabepilone), JAKAFI (ruxolitinib phosphate), JEVTANA (cabazitaxel),KADCYLA (ado-trastuzumab emtansine), KEYTRUDA (pembrolizumab), KYPROLIS(carfilzomib), LIPODOX (doxorubicin hydrochloride liposome), LUPRON(leuprolide acetate), LUPRON DEPOT (leuprolide acetate), LUPRON DEPOT-3MONTH (leuprolide acetate), LUPRON DEPOT-4 MONTH (leuprolide acetate),LUPRON DEPOT-PED (leuprolide acetate), MEGACE (megestrol acetate),MEKINIST (trametinib), METHAZOLASTONE (temozolomide), METHOTREXATE LPF(methotrexate), MEXATE (methotrexate), MEXATE-AQ (methotrexate),MITOXANTRONE HYDROCHLORIDE, MITOZYTREX (mitomycin c), MOZOBIL(plerixafor), MUSTARGEN (mechlorethamine hydrochloride), MUTAMYCIN(mitomycin c), MYLOSAR (azacitidine), NAVELBINE (vinorelbine tartrate),NEOSAR (cyclophosphamide), NEXAVAR (sorafenib tosylate), NOLVADEX(tamoxifen citrate), NOVALDEX (tamoxifen citrate), OFF, PAD, PARAPLAT(carboplatin), PARAPLATIN (carboplatin), PEG-INTRON (peginterferonalfa-2b), PEMETREXED DISODIUM, PERJETA (pertuzumab), PLATINOL(cisplatin), PLATINOL-AQ (cisplatin), POMALYST (pomalidomide),prednisone, PROLEUKIN (aldesleukin), PROLIA (denosumab), PROVENGE(sipuleucel-t), REVLIMID (lenalidomide), RUBIDOMYCIN (daunorubicinhydrochloride), SPRYCEL (dasatinib), STIVARGA (regorafenib), SUTENT(sunitinib malate), SYLATRON (peginterferon alfa-2b), SYLVANT(siltuximab), SYNOVIR (thalidomide), TAC, TAFINLAR (dabrafenib),TARABINE PFS (cytarabine), TARCEVA (erlotinib hydrochloride), TASIGNA(nilotinib), TAXOL (paclitaxel), TAXOTERE (docetaxel), TEMODAR(temozolomide), THALOMID (thalidomide), TOPOSAR (etoposide), TORISEL(temsirolimus), TPF, TRISENOX (arsenic trioxide), TYKERB (lapatinibditosylate), VECTIBIX (panitumumab), VEIP, VELBAN (vinblastine sulfate),VELCADE (bortezomib), VELSAR (vinblastine sulfate), VEPESID (etoposide),VIADUR (leuprolide acetate), VIDAZA (azacitidine), VINCASAR PFS(vincristine sulfate), VOTRIENT (pazopanib hydrochloride), WELLCOVORIN(leucovorin calcium), XALKORI (crizotinib), XELODA (capecitabine),XELOX, XGEVA (denosumab), XOFIGO (radium 223 dichloride), XTANDI(enzalutamide), YERVOY (ipilimumab), ZALTRAP (ziv-aflibercept), ZELBORAF(vemurafenib), ZOLADEX (goserelin acetate), ZOMETA (zoledronic acid),ZYKADIA (ceritinib), ZYTIGA (abiraterone acetate), or a combinationthereof. In certain embodiments, the additional pharmaceutical agent isa binder or modulator (e.g., inhibitor or activator) of Myc. In certainembodiments, the additional pharmaceutical agent is a protein kinaseinhibitor (e.g., tyrosine protein kinase inhibitor). In certainembodiments, the additional pharmaceutical agent is selected from thegroup consisting of epigenetic or transcriptional modulators (e.g., DNAmethyltransferase inhibitors, histone deacetylase inhibitors (HDACinhibitors), lysine methyltransferase inhibitors), antimitotic drugs(e.g., taxanes and vinca alkaloids), hormone receptor modulators (e.g.,estrogen receptor modulators and androgen receptor modulators), cellsignaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors),modulators of protein stability (e.g., proteasome inhibitors), Hsp90inhibitors, glucocorticoids, all-trans retinoic acids, and other agentsthat promote differentiation. In certain embodiments, the compoundsdescribed herein or pharmaceutical compositions can be administered incombination with an anti-cancer therapy including, but not limited to,surgery, radiation therapy, transplantation (e.g., stem celltransplantation, bone marrow transplantation), immunotherapy, andchemotherapy.

Also encompassed by the disclosure are kits (e.g., pharmaceuticalpacks). The kits provided may comprise a pharmaceutical composition orcompound described herein and a container (e.g., a vial, ampule, bottle,syringe, and/or dispenser package, or other suitable container). In someembodiments, provided kits may optionally further include a secondcontainer comprising a pharmaceutical excipient for dilution orsuspension of a pharmaceutical composition or compound described herein.In some embodiments, the pharmaceutical composition or compounddescribed herein provided in the first container and the secondcontainer are combined to form one unit dosage form.

Thus, in one aspect, provided are kits including a first containercomprising a compound or pharmaceutical composition described herein.The kits described herein may be useful in modulating (e.g., inhibiting)the activity of Myc in a subject in need thereof, treating diseasesassociated with Myc (e.g., diseases associated with aberrant activity(e.g., increased activity) of Myc) in a subject in need thereof,treating proliferative diseases in a subject in need thereof, preventingdiseases associated with Myc (e.g., diseases associated with aberrantactivity (e.g., increased activity) of Myc) in a subject in needthereof, preventing proliferative diseases in a subject in need thereof,and/or inducing apoptosis of a cell in a subject, biological sample, ortissue. The kits described herein may also be useful as research tools,e.g., for studying Myc (e.g., studying the activity of Myc) in asubject, biological sample, tissue, or cell.

In certain embodiments, a kit described herein further includesinstructions for using the compound or pharmaceutical compositionincluded in the kit. A kit described herein may also include informationas required by a regulatory agency such as the U.S. Food and DrugAdministration (FDA). In certain embodiments, the information includedin the kits is prescribing information. In certain embodiments, the kitsand instructions provide for treating a proliferative disease in asubject in need thereof. In certain embodiments, the kits andinstructions provide for preventing a proliferative disease in a subjectin need thereof. In certain embodiments, the kits and instructionsprovide for modulating (e.g., inhibiting) the activity of Myc in asubject, biological sample, tissue, or cell. In certain embodiments, thekits and instructions provide for inducing apoptosis of a cell in asubject, biological sample, or tissue. A kit described herein mayinclude one or more additional pharmaceutical agents described herein asa separate composition.

Methods of Treatment and Uses

Myc is associated with a wide range of proliferative diseases. Thecompounds described herein may be capable of binding (e.g., reversiblybinding or irreversibly binding) Myc and modulating (e.g., inhibiting orincreasing) the activity (e.g., aberrant activity, such as increased ordecreased activity) of the Myc. In certain embodiments, the aberrantactivity of Myc is increased activity of Myc. Modulation of Myc usingthe compounds described herein may be an effective approach to treatand/or prevent the proliferative disease. Compounds described hereinthat include a small-molecule label may also be useful in identifyingthe association of Myc with a proliferative disease. The presentdisclosure thus provides methods of modulating (e.g., inhibiting orincreasing) the activity of Myc in a subject, biological sample, tissue,or cell, methods of treating and/or preventing proliferative diseases ina subject in need thereof, and methods of inducing apoptosis of a cellin a subject, biological sample, or tissue.

In another aspect, the present disclosure provides methods of modulating(e.g., inhibiting) the activity of Myc (e.g., c-Myc, L-Myc, or N-Myc) ina subject in need thereof, the methods comprising administering to thesubject an effective amount of a compound or pharmaceutical compositiondescribed herein.

In another aspect, the present disclosure provides methods of modulating(e.g., inhibiting) the activity of Myc (e.g., c-Myc, L-Myc, or N-Myc) ina biological sample, tissue, or cell, the methods comprising contactingthe biological sample, tissue, or cell with an effective amount of acompound or pharmaceutical composition described herein.

In certain embodiments, the activity of Myc in a subject, biologicalsample, tissue, or cell is inhibited by a compound, pharmaceuticalcomposition, kit, use, or method described herein by at least 1%, atleast 3%, at least 10%, at least 20%, at least 30%, at least 40%, atleast 50%, at least 60%, at least 70%, at least 80%, or at least 90%. Incertain embodiments, the activity of Myc in a subject, biologicalsample, tissue, or cell is inhibited by a compound, pharmaceuticalcomposition, kit, use, or method described herein by not more than 1%,not more than 3%, not more than 10%, not more than 20%, not more than30%, not more than 40%, not more than 50%, not more than 60%, not morethan 70%, not more than 80%, or not more than 90%. In some embodiments,the activity of Myc in a subject, biological sample, tissue, or cell isselectively inhibited by the compound, pharmaceutical composition, kit,use, or method. In some embodiments, the activity of Myc in a subject,biological sample, tissue, or cell is selectively inhibited by thecompound, pharmaceutical composition, kit, use, or method, compared to adifferent transcription factor (e.g., SP1, AP-1, C/EBP, heat shockfactor, ATF/CREB, Oct-1, NF-1). In some embodiments, the activity ofc-Myc in a subject, biological sample, tissue, or cell is selectivelyinhibited by the compound, pharmaceutical composition, kit, use, ormethod, compared to a different Myc (e.g., L-Myc, N-Myc) and/or adifferent transcription factor (e.g., SP1, AP-1, C/EBP, heat shockfactor, ATF/CREB, Oct-1, NF-1). In some embodiments, the activity of Mycin a subject, biological sample, tissue, or cell is reversibly inhibitedby the compound, pharmaceutical composition, kit, use, or method. Insome embodiments, the activity of Myc in a subject, biological sample,tissue, or cell is irreversibly inhibited by the compound,pharmaceutical composition, kit, use, or method. In certain embodiments,the compound, pharmaceutical composition, kit, use, or method inhibitsthe activity of a mutant (e.g., point mutant) form of Myc (e.g., MYC,MYCL, and/or MYCN). In certain embodiments, the compound, pharmaceuticalcomposition, kit, use, or method modulates (e.g., inhibits) somaticamplification of Myc (e.g., MYC, MYCL, and/or MYCN). In certainembodiments, the compound, pharmaceutical composition, kit, use, ormethod modulates (e.g., inhibits) chromosomal translocation. In certainembodiments, the compound, pharmaceutical composition, kit, use, ormethod regulates (e.g., down-regulates) the expression of Myc (e.g.,MYC, MYCL, and/or MYCN). In certain embodiments, the compound,pharmaceutical composition, kit, use, or method modulates (e.g.,inhibits) translation of Myc (e.g., MYC, MYCL, and/or MYCN). In certainembodiments, the compound, pharmaceutical composition, kit, use, ormethod modulates (e.g., decreases) the stability of a protein thatencodes Myc (e.g., MYC, MYCL, and/or MYCN). In certain embodiments, thecompound, pharmaceutical composition, kit, use, or method modulates(e.g., decreases) the stability of Myc.

Another aspect of the present disclosure relates to methods of treatinga disease associated with Myc (e.g., a disease associated with aberrantactivity (e.g., increased activity) of Myc) in a subject in needthereof, the methods comprising administering to the subject aneffective amount (e.g., therapeutically effective amount) of a compoundor pharmaceutical composition described herein.

Another aspect of the present disclosure relates to methods of treatinga proliferative disease in a subject in need thereof, the methodscomprising administering to the subject an effective amount (e.g.,therapeutically effective amount) of a compound or pharmaceuticalcomposition described herein.

In certain embodiments, a disease described herein is associated withMyc. In certain embodiments, a disease described herein is associatedwith aberrant activity (e.g., increased or decreased activity) of Myc.In certain embodiments, a disease described herein is associated withincreased activity of Myc. In certain embodiments, a disease describedherein is associated with a mutant (e.g., point mutant) form of Myc(e.g., MYC, MYCL, and/or MYCN). In certain embodiments, a diseasedescribed herein is associated with aberrant (e.g., increased) somaticamplification of Myc (e.g., MYC, MYCL, and/or MYCN). In certainembodiments, a disease described herein is associated with aberrantchromosomal translocation. In certain embodiments, a disease describedherein is associated with overexpression of Myc (e.g., MYC, MYCL, and/orMYCN). In certain embodiments, a disease described herein is associatedwith aberrant translation of Myc. In certain embodiments, a diseasedescribed herein is associated with the increased stability of a proteinthat encodes Myc (e.g., MYC, MYCL, and/or MYCN). In certain embodiments,a disease described herein is associated with the increased stability ofMyc. In certain embodiments, a disease described herein is aproliferative disease. In certain embodiments, a disease describedherein is cancer. In certain embodiments, a disease described herein islung cancer (e.g., bronchogenic carcinoma, small cell lung cancer(SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung).In certain embodiments, a disease described herein is cervical cancer.In certain embodiments, a disease described herein is breast cancer(e.g., adenocarcinoma of the breast, papillary carcinoma of the breast,mammary cancer, medullary carcinoma of the breast). In certainembodiments, a disease described herein is colorectal cancer (e.g.,colon cancer, rectal cancer, colorectal adenocarcinoma). In certainembodiments, a disease described herein is ovarian cancer, pancreaticcancer, gastric cancer, or uterine cancer. In certain embodiments, adisease described herein is hematological malignancy. In certainembodiments, a disease described herein is lymphoma (e.g., Hodgkinlymphoma, non-Hodgkin lymphoma (e.g., Burkitt's lymphoma)). In certainembodiments, a disease described herein is leukemia. In certainembodiments, a disease described herein is a benign neoplasm. In certainembodiments, a disease described herein is pathological angiogenesis.

A method of treating a disease (e.g., a disease associated with Myc or aproliferative disease) may further comprise, prior to the step ofadministering, steps of identifying the subject in need thereof (e.g.,subject in need of treatment of the disease). In certain embodiments,the steps of identifying comprise:

optionally, obtaining a biological sample from a subject; and

determining Myc activity of the biological sample;

wherein:

if the Myc activity is higher than a control Myc activity, then thesubject is identified to be a subject in need thereof; or

if the Myc activity is not higher than a control Myc activity, then thesubject is identified not to be a subject in need thereof.

In certain embodiments, a control Myc activity described herein is theMyc activity of a biological sample of a normal subject.

Another aspect of the present disclosure relates to methods ofpreventing a disease associated with Myc (e.g., a disease associatedwith aberrant activity (e.g., increased activity) of Myc) in a subjectin need thereof, the methods comprising administering to the subject aneffective amount (e.g., prophylactically effective amount) of a compoundor pharmaceutical composition described herein.

In another aspect, the present disclosure provides methods of preventinga proliferative disease described herein in a subject in need thereof,the methods comprising administering to the subject an effective amount(e.g., prophylactically effective amount) of a compound orpharmaceutical composition described herein.

In another aspect, the present disclosure provides methods of inducingapoptosis of a cell in a subject in need thereof, the methods comprisingadministering to the subject an effective amount (e.g., therapeuticallyeffective amount) of a compound or pharmaceutical composition describedherein.

In another aspect, the present disclosure provides methods of inducingapoptosis of a cell in a biological sample, tissue, or cell, the methodscomprising contacting the biological sample, tissue, or cell with aneffective amount of a compound or pharmaceutical composition describedherein.

In another aspect, the present disclosure provides the compoundsdescribed herein for use in a method described herein (e.g., a method ofmodulating (e.g., inhibiting) the activity of Myc, a method of treatinga disease associated with Myc (e.g., disease associated with aberrantactivity (e.g., increased activity) of Myc), a method of treating aproliferative disease, a method of preventing a disease associated withMyc (e.g., disease associated with aberrant activity (e.g., increasedactivity) of Myc), a method of preventing a proliferative disease, amethod of inducing apoptosis, and/or a method of screening a library ofcompounds).

In still another aspect, the present disclosure provides thepharmaceutical compositions described herein for use in a methoddescribed herein (e.g., a method of modulating (e.g., inhibiting) theactivity of Myc, a method of treating a disease associated with Myc(e.g., disease associated with aberrant activity (e.g., increasedactivity) of Myc), a method of treating a proliferative disease, amethod of preventing a disease associated with Myc (e.g., diseaseassociated with aberrant activity (e.g., increased activity) of Myc), amethod of preventing a proliferative disease, a method of inducingapoptosis, and/or a method of screening a library of compounds).

Methods of Screening a Library of Compounds

Another aspect of the disclosure relates to methods of screening alibrary of compounds, and pharmaceutical acceptable salts thereof, toidentify a compound, or a pharmaceutical acceptable salt thereof, thatis useful in a method described herein. In certain embodiments, themethods of screening a library include obtaining at least two differentcompounds described herein; and performing at least one assay using thedifferent compounds described herein. In certain embodiments, at leastone assay is useful in identifying a compound that is useful in a methoddescribed herein.

Typically, the methods of screening a library of compounds involve atleast one assay. In certain embodiments, the assay is performed todetect one or more characteristics associated with the treatment and/orprevention of a proliferative disease described herein or with themodulation (e.g., inhibition) of the activity of Myc (e.g., c-Myc,L-Myc, N-Myc). The characteristics may be desired characteristics (e.g.,the activity of Myc having been modulated (e.g., inhibited), a diseaseassociated with Myc (e.g., disease associated with aberrant activity(e.g., increased activity) of Myc) having been treated, a proliferativedisease having been treated, a disease associated with Myc (e.g.,disease associated with aberrant activity (e.g., increased activity) ofMyc) having been prevented, a proliferative disease having beenprevented, and/or apoptosis having been induced). The characteristicsmay be undesired characteristics (e.g., the activity of Myc not havingbeen modulated (e.g., inhibited), a disease associated with Myc (e.g.,disease associated with aberrant activity (e.g., increased activity) ofMyc) not having been treated, a proliferative disease not having beentreated, a disease associated with Myc (e.g., disease associated withaberrant activity (e.g., increased activity) of Myc) not having beenprevented, a proliferative disease not having been prevented, and/orapoptosis not having been induced). The assay may be an immunoassay,such as a sandwich-type assay, competitive binding assay, one-stepdirect test, two-step test, or blot assay. The step of performing atleast one assay may be performed robotically or manually. In certainembodiments, the assay comprises (a) contacting a library of compoundswith Myc; and (b) detecting the binding of the library of compounds tothe Myc. In certain embodiments, the assay comprises detecting thespecific binding of the library of compounds to the Myc. In certainembodiments, the detected binding of the library of compounds to the Mycis useful in identifying the compound that is useful in a methoddescribed herein. In certain embodiments, the step of detecting thebinding comprises using differential scanning fluorimetry (DSF),isothermal titration calorimetry (ITC), and/or an amplified luminescenceproximity homogeneous assay (ALPHA). The step of performing at least oneassay may be performed in a cell in vitro or in vivo.

EXAMPLES

In order that the present disclosure may be more fully understood, thefollowing examples are set forth. The synthetic and biological examplesdescribed in this application are offered to illustrate the compounds,pharmaceutical compositions, and methods provided herein and are not tobe construed in any way as limiting their scope.

Preparation and Characterization of the Compounds Described HereinPreparation of the Compounds

The compounds provided herein can be prepared from readily availablestarting materials using methods known in the art, such as the methodsdescribed in Mauger et al., Eur. Pat. Appl., 1746097, 24 Jan. 2007, andthe methods described in Nitsche et al., Journal of Medicinal Chemistry,56(21), 8389-8403; 2013. Where typical or preferred process conditions(i.e., reaction temperatures, times, mole ratios of reactants, solvents,pressures, etc.) are given, other process conditions can also be usedunless otherwise stated. Optimum reaction conditions may vary with theparticular reactants or solvents used, but such conditions can bedetermined by those skilled in the art by routine optimizationprocedures.

Preparation of Substituted 2-mercaptobenzimidazoles

To a solution of aryl 1,2-diamine (1.0 eq) in dry pyridine (0.1M) wasadded carbon disulfide (1.5 eq) at room temperature. The flask wasflushed with argon and stirred at 50° C. overnight under argonatmosphere. The mixture was cooled down, concentrated and purified bycolumn chromatography on silica gel to afford the corresponding2-mercaptobenzimidazole.

General Procedure A: Example 1. Preparation of(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione1

In a dry flask, 2-mercaptobenzimidazole (4.78 g, 31.82 mmol) wasdissolved in dry CH₃CN:DMF (1:1, 0.05M) and cooled to 0° C. under argonatmosphere. NaH (1.40 g, 35.00 mmol) was added portionwise over 2minutes at 0° C. and kept at this temperature until gas evolutionceased. The mixture was then refluxed for 30 minutes prior to be cooledto room temperature. A solution of 5-nitro-2-furaldehyde (4.71 g, 33.38mmol) in dry CH₃CN (0.1M) was added dropwise at room temperature andstirred overnight at 70° C. The reacting mixture cooled down andquenched by addition of water, extracted with AcOEt (3×), dried overMgSO₄, filtered and concentrated. Purification by chromatography onsilica gel or recrystallization from EtOH afforded the corresponding5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde (6.3 g, 88%yield).

To a solution of 5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde(1.0 eq) in EtOH (0.05M) was added 3-isopropylthiazolidine-2,4-dione(1.1 eq) followed by piperidine (1.1 eq) at room temperature. Themixture was stirred overnight at room temperature (heating might berequire in some cases). The solution was concentrated and purified bycolumn chromatography on silica gel or by recrystallization from EtOH toafford 1.

General Procedure B:

Step 1: To a solution of5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde (1 eq) int-BuOH:Water (2.6:1, 0.05M) was added 2-methyl-2-butene (4.0 eq),NaH₂PO₄ (1.1 eq) and NaClO₂ (3.0 eq) at room temperature and stirredovernight. The reacting mixture was quenched with sat. NaHCO₃ and theaqueous layer washed with AcOEt. 1N HCl was added to the aqueous layer(pH 2), and extracted with AcOEt (3×). The combined organic layers weredried over MgSO₄, filtered and concentrated to provide5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylic acid.

Step 2: To a solution of5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylic acid (1 eq) in DMF(0.1M) was added the amine (1.3 eq), HATU (1.3 eq) and DIPEA (2.0 eq) atroom temperature and stirred overnight. The mixture was concentrated andpurified by column chromatography on silica gel.

General Procedure C:

NaBH(OAc)₃ (1.3 eq) was added to a solution of5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde (1.0 eq), Amine(1.1 eq), AcOH (1.5 eq) in DCM:THF (1:1, 0.05M) and stirred overnight atroom temperature. The reacting mixture was quenched with sat. NaHCO₃,extracted with AcOEt (3×), dried over MgSO₄, filtered and concentrated.Purification by chromatography on silica gel provided the correspondingproduct.

General Procedure D:

Example 2. Preparation of(Z)-5-(4-((1H-benzo[d]imidazol-2-yl)thio)benzylidene)-3-isopropylthiazolidine-2,4-dione64

Step 1: CuI (18 mg, 96 μmol), 1,10-Phenanthroline (35 mg, 192 μmol), andK₂CO₃ (0.53 g, 3.84 mmol) were placed in an oven dried sealed flask andpurged with argon. Dry DMF (2 ml) was then added followed by2-mercaptobenzimidazole (288 mg, 1.92 mmol) and 4-iodobenzaldehyde (446mg, 1.92 mmol). The mixture was stirred at 140° C. for 18 hours. Afterbeing cooled down, water was added and the aqueous layer extracted withAcOEt (3×). The combined organic layers were dried over MgSO₄, filteredand concentrated. Purification by column chromatography on silica gel(20 to 75% AcOEt in hexanes) afforded4-((1H-benzo[d]imidazol-2-yl)thio)benzaldehyde (425 mg, 87% yield).

Step 2: Prepared following general procedure A. ¹H NMR (500 MHz, CDCl₃):δ (ppm)=7.68 (1H, s), 7.57 (2H, dd, J=6.0, 3.0 Hz), 7.50 (2H, d, J=8.5Hz), 7.35 (2H, d, J=8.5 Hz), 7.28 (2H, dd, J=6.0, 3.0 Hz), 4.67 (1H,sep, J=7.0 Hz), 1.47 (6H, d, J=7.0 Hz).

General Procedure E: Alkylation of 2,4-thiazolidinedione

To a solution of 2,4-thiazolidinedione (1 eq) in DMF (0.1M) wassuccessively added K₂CO₃ (2.0 eq) and the alkyl halide (1.05 eq). Thereacting mixture was stirred at 70° C. until completion. The reactionwas cooled down, water was added and the aqueous layer extracted withAcOEt (3×). The combined organic layers were dried over MgSO₄, filteredand concentrated. Purification by column chromatography on silica gelprovided the desired alkylated 2,4-thiazolidinedione.

General Procedure F:

Example 3. Preparation of(Z)-3-isopropyl-5-((5-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione18

MeI (110 mg, 778 μmol) was added to a solution of(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione(150 mg, 389 μmol) and K₂CO₃ (108 mg, 778 μmol) in DMF (2 ml) at roomtemperature. The mixture was stirred overnight prior to be quenched withwater. The aqueous layer was extracted with AcOEt (3×) and the combinedorganic layers dried over MgSO₄, filtered and concentrated. Purificationby column chromatography on silica gel (10 to 25% AcOEt in hexanes)afforded 18 (142 mg, 91% yield). ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.75(1H, d, J=8.0 Hz), 7.50 (1H, s), 7.27-7.36 (3H, m), 6.91 (1H, d, J=3.5Hz), 6.75 (1H, d, J=3.5 Hz), 4.62 (1H, sep, J=7.0 Hz), 4.00 (3H, s),1.44 (6H, d, J=7.0 Hz).

Example 4.(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)imidazolidine-2,4-dione2

Compound 2 was prepared following general procedure A using hydantoin.1H NMR (500 MHz, DMSO-d₆): δ (ppm)=11.35 (1H, brs), 10.52 (1H, brs),7.51 (2H, br), 7.18 (2H, m), 7.16 (1H, d, J=3.5 Hz), 7.10 (1H, d, J=3.5Hz), 6.33 (1H, s).

Example 5.(Z)-5-((5-(benzo[d]thiazol-2-ylthio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione3

Compound 3 was prepared following general procedure A using2-mercaptobenzothiazole. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.94 (1H, d,J=8.0 Hz), 7.74 (1H, d, J=8.0 Hz), 7.60 (1H, s), 7.45 (1H, t, J=8.0 Hz),7.34 (1H, t, J=8.0 Hz), 7.06 (1H, d, J=3.5 Hz), 6.87 (1H, d, J=3.5 Hz).

Example 6. Preparation of(Z)-5-((5-((6-chloro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione4

Compound 4 was prepared following general procedure A using6-chloro-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=7.34-7.38 (3H, m), 7.07 (1H, dd, J=8.5, 2.0 Hz), 6.89 (1H, d,J=3.5 Hz), 6.64 (1H, d, J=3.5 Hz), 4.54 (1H, sep, 7.0 Hz), 1.37 (6H, d,J=7.0 Hz).

Example 7. Preparation of(Z)-3-isopropyl-5-((5-((6-methoxy-H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione5

Compound 5 was prepared following general procedure A using6-methoxy-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=7.41 (1H, d, J=8.5 Hz), 7.30 (1H, d, J=2.0 Hz), 6.96 (1H, d, J=2.5Hz), 6.92 (1H, d, J=3.5 Hz), 6.85 (1H, dd, J=8.5, 2.5 Hz), 6.62 (1H, dd,J=3.5, 2.0 Hz), 4.61 (1H, sep, J=7.0 Hz), 3.79 (3H, s), 1.44 (6H, d,J=7.0 Hz).

Example 8.(Z)-5-((5-(benzo[d]oxazol-2-ylthio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione6

Compound 5 was prepared following general procedure A using2-mercaptobenzoxazole. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.64 (1H, m),7.60 (1H, m), 7.46 (1H, m), 7.31 (2H, m), 7.05 (1H, d, J=3.5 Hz), 6.86(1H, d, J=3.5 Hz), 4.64 (1H, sep, J=7.0 Hz), 1.45 (6H, d, J=7.0 Hz).

Example 9. Preparation of(Z)-5-((5-((6-chloro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione7

Step 1: A mixture of 1,3-phenyldiamine (1.36 g, 7.51 mmol),5-(hydroxymethyl)furan-2-carbaldehyde (0.95 g, 7.51 mmol) and DDQ (1.70g, 7.51 mmol) in ethanol (30 ml) was stirred at reflux overnight underargon. Sat. NaHCO₃ was added and the aqueous layer extracted with AcOEt(3×). The combined organic layers were dried over MgSO₄, filtered andconcentrated. Purification by column chromatography on silica gel (30 to60% acetone in hexane) provided(5-(1H-benzo[d]imidazol-2-yl)furan-2-yl)methanol (700 mg, 44% yield).

Step 2: Dess-Martin Periodinane (1.52 g, 3.60 mmol) was added to asolution of (5-(1H-benzo[d]imidazol-2-yl)furan-2-yl)methanol (700 mg,3.27 mmol) in DCM (30 ml) at 0° C. After 2 hours, sat. NaHCO₃ was addedand the aqueous layer extracted with AcOEt (3×). The combined organiclayers were dried over MgSO₄, filtered and concentrated. Purification bycolumn chromatography on silica gel (20 to 60% acetone in hexanes)provided 5-(1H-benzo[d]imidazol-2-yl)furan-2-carbaldehyde (600 mg, 87%yield).

Step 3: Prepared following general procedure A. ¹H NMR (500 MHz, CDCl₃):δ (ppm)=7.65-7.80 (3H, m), 7.34 (1H, d, J=3.5 Hz), 7.36 (2H, m), 6.95(1H, d, J=3.5 Hz), 4.69 (1H, sep, J=7.0 Hz), 1.50 (6H, d, J=7.0 Hz).

Example 10. Preparation of(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylimidazolidine-2,4-dione8

Compound 8 was prepared following general procedure A using3-isopropylimidazolidine-2,4-dione. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=9.22 (1H, brs), 7.59 (2H, br), 7.22 (2H, m), 6.82 (1H, d, J=3.5Hz), 6.51 (1H, d, J=3.5 Hz), 6.32 (1H, s), 4.33 (1H, sep, J=7.0 Hz),1.42 (6H, d, J=7.0 Hz).

Example 11. Preparation of(E)-3-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)pyrrolidine-2,5-dione9

A mixture of 5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde (50mg, 205 μmol) and 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione(74 mg, 205 μmol) in EtOH (5 ml) was stirred at 50° C. overnight. Themixture was concentrated and purified by reverse phase (25 to 75% CH3CNin water) to afford 9 (66 mg, 99% yield). ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=12.72 (1H, brs), 11.44 (1H, brs), 7.64 (1H, m), 7.61 (2H, m), 7.42(1H, d, J=7.5 Hz), 7.13 (2H, m), 7.09 (1H, d, J=3.5 Hz).

Example 12. Preparation of(Z)-5-((5-((3H-imidazo[4,5-b]pyridin-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione10

Prepared following general procedure A using3H-imidazo[4,5-b]pyridine-2-thiol. ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=13.20 (1H, brs), 8.28 (1H, d, J=4.5 Hz), 7.90 (1H, d, J=7.0 Hz),7.71 (1H, s), 7.27 (1H, d, J=3.5 Hz), 7.24 (1H, d, J=3.5 Hz), 7.21 (1H,dd, J=7.0, 4.5 Hz), 4.47 (1H, sep, J=7.0 Hz), 1.34 (6H, d, J=7.0 Hz).

Example 13. Preparation of(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)thiophen-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione11

Step 1: To a solution of 2-mercaptobenzimidazole (500 mg, 3.33 mmol) andK₂CO₃ (506 mg, 3.66 mmol) in DMF (6.5 ml) was added5-bromothiophene-2-carbaldehyde (636 mg, 3.33 mmol) at room temperature.The mixture was stirred at 120° C. overnight. The reacting mixture wasquenched with water, extracted with AcOEt (3×), dried over MgSO₄,filtered and concentrated. Purification by chromatography on silica gel(20 to 50% AcOEt in hexanes) provided5-((1H-benzo[d]imidazol-2-yl)thio)thiophene-2-carbaldehyde (302 mg, 35%yield).

Step 2: Prepared following general procedure A. ¹H NMR (500 MHz, CDCl₃):δ (ppm)=9.60 (1H, brs), 7.82 (1H, s), 7.45 (1H, d, J=4.0 Hz), 7.20-7.27(5H, m), 4.65 (1H, sep, J=7.0 Hz), 1.47 (6H, d, J=7.0 Hz).

Example 14. Preparation of(Z)-1-(3-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)-3-phenylurea12

Step 1: Literature precedent was followed, as described in: TetrahedronLetters 2011, 52, 3347-3352.

Step 2: Prepared following general procedure A. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.94 (1H, brs), 7.85 (1H, s), 7.69 (1H, br),7.55-7.60 (4H, m), 7.43 (1H, m), 7.20 (2H, m), 4.49 (1H, sep, J=7.0 Hz),1.37 (6H, d, J=7.0 Hz).

Example 15. Preparation of(Z)-2-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)aceticAcid 13

To a solution of 14 (200 mg, 437 μmol) in DCM (2.2 ml) was added TFA(335 μl) at room temperature. Stirred for 4 hours then concentrated toprovide 13 (174 mg, 99% yield). LCMS (M+1)=402, >95% purity.

Example 16. Preparation of (Z)-tert-butyl2-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)acetate14

Compound 14 was prepared following general procedure A and E usingtert-butyl 2-(2,4-dioxothiazolidin-3-yl)acetate. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.84 (1H, brs), 7.82 (1H, s), 7.55 (1H, d, J=7.5 Hz),7.42 (1H, d, J=7.5 Hz), 7.28 (1H, d, J=3.5 Hz), 7.23 (1H, d, J=3.5 Hz),7.14-7.18 (2H, m), 4.31 (2H, s), 1.39 (9H, s).

Example 17. Preparation of (Z)-methyl2-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)acetate15

Compound 15 was prepared following general procedure A and E usingmethyl 2-(2,4-dioxothiazolidin-3-yl)acetate. LCMS (M+1)=416, >95%purity.

Example 18. Preparation of(Z)-5-((5-((1H-imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione16

Compound 16 was prepared following general procedure A starting from2-mercaptoimidazole. ¹H NMR (500 MHz, DMSO-d6): δ (ppm)=12.92 (1H, brs),7.60 (1H, s), 7.20 (2H, br), 7.12 (1H, d, J=3.5 Hz), 6.87 (1H, d, J=3.5Hz), 4.47 (1H, sep, J=7.0 Hz), 1.36 (6H, d, J=7.0 Hz).

Example 19. Preparation of(Z)-3-isopropyl-5-((5-(pyridin-2-ylthio)furan-2-yl)methylene)thiazolidine-2,4-dione17

Compound 17 was prepared following general procedure A starting from2-mercaptopyridine. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=8.45 (1H, d, J=4.5Hz), 7.58 (1H, s), 7.57 (1H, dt, J=8.0, 1.5 Hz), 7.11 (1H, dd, J=5.0,1.5 Hz), 7.00 (1H, d, J=8.0 Hz), 6.93 (1H, d, J=3.5 Hz), 6.84 (1H, d,J=3.5 Hz), 4.64 (1H, sep, J=7.0 Hz), 1.46 (6H, d, J=7.0 Hz).

Example 20. Preparation of(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-(3-aminopropyl)thiazolidine-2,4-dione2,2,2-trifluoroacetate 19

Compound 19 was prepared following general procedure A and E startingfrom tert-butyl (3-bromopropyl)carbamate to provide (Z)-tert-butyl(3-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)carbamate.Boc deprotection: TFA (177 μl, 2.30 mmol) was added to (Z)-tert-butyl(3-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)carbamate(230 mg, 459 μmol) in DCM (2.5 ml) at 0° C. The reacting mixture wasstirred at room temperature for 5 hours. Concentration and removal ofTFA by azeotropic distillation with toluene provided 19 (182 mg, 99%yield). LCMS (M+1)=401, >90% purity.

Example 21. Preparation of(Z)-1-(3-(5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)-3-phenylurea20

Phenylisocyanate (1.5 eq) was added to a solution of 19 (1 eq) and DIPEA(2.5 eq) in DCM at room temperature. The mixture was stirred overnight,concentrated and purified by column chromatography to afford 20. LCMS(M+1)=520, >95% purity.

Example 22. Preparation of(Z)-1-ethyl-3-(3-(5-((5-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)urea21

Ethylisocyanate (1.5 eq) was added to a solution of 19 (1 eq) and DIPEA(2.5 eq) in DCM at room temperature. The mixture was stirred overnight,concentrated and purified by column chromatography to afford 21. LCMS(M+1)=472, >90% purity.

Example 23. Preparation of(Z)-5-((5-((6-chloro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylimidazolidine-2,4-dione22

Compound 22 was prepared following general procedure A using6-chloro-1H-benzo[d]imidazole-2-thiol and3-isopropylimidazolidine-2,4-dione. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=9.09 (1H, brs), 7.47 (2H, m), 7.22 (1H, dd, J=8.0, 2.5 Hz), 6.85(1H, d, J=3.5 Hz), 6.55 (1H, d, J=3.5 Hz), 6.36 (1H, s), 4.44 (1H, sep,J=7.0 Hz), 1.50 (6H, d, J=7.0 Hz).

Example 24. Preparation of(Z)-3-isopropyl-5-((5-((7-methyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione23

Compound 23 was prepared following general procedure A using7-methyl-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=7.67 (1H, s), 7.26 (1H, br), 7.21 (1H, d, J=3.5 Hz), 7.17 (1H, d,J=3.5 Hz), 7.08 (1H, t, J=7.0 Hz), 6.98 (1H, d, J=7.0 Hz), 4.46 (1H,sep, J=7.0 Hz), 2.49 (3H, s), 1.33 (6H, d, J=7.0 Hz).

Example 25. Preparation of(Z)-3-isopropyl-5-((5-((6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione24

Compound 22 was prepared following general procedure A using6-(trifluoromethyl)-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=13.23 (1H, brs), 7.93 (1H, br), 7.71 (1H, s), 7.62(1H, br), 7.51 (1H, br), 7.28 (1H, d, J=3.5 Hz), 7.25 (1H, J=3.5 Hz),4.45 (1H, sep, J=7.0 Hz), 1.33 (6H, d, J=7.0 Hz).

Example 26. Preparation of(Z)-5-((5-((5,6-dichloro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione25

Compound 25 was prepared following general procedure A using5,6-dichloro-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=7.53 (2H, s), 7.00 (1H, d, J=3.5 Hz), 6.61 (1H, d, J=3.5 Hz), 4.63(1H, sep, J=7.0 Hz), 1.46 (6H, d, J=7.0 Hz).

Example 27. Preparation ofN-(3-((Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-2,4-dioxothiazolidin-3-yl)propyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide27

(Z)-5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-(3-aminopropyl)thiazolidine-2,4-dione2,2,2-trifluoroacetate (21 mg, 42 μmol) was stirred in 5% TFA in DCM(0.5 ml) for 30 minutes. The mixture was concentrated and diluted in DMF(0.5 ml). Triethylamine (30 μl, 210 μmol) and biotin-NHS (29 mg, 84μmol) were added at room temperature and stirred overnight. Water wasadded and the aqueous layer was extracted with DCM (3×). The combinedorganic layers were dried over MgSO₄, filtered and concentrated.Purification by prep TLC on silica gel (12% MeOH in DCM) afforded 27 (20mg, 76% yield), LCMS (M+1)=627, >95% purity.

Example 28. Preparation of(Z)-5-((5-((7-chloro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione28

Compound 28 was prepared following general procedure A using7-chloro-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=7.69 (1H, s), 7.42 (1H, br), 7.25 (3H, m), 7.19 (1H, t, J=8.0 Hz),4.65 (1H, sep, J=7.0 Hz), 1.34 (6H, d, J=7.0 Hz).

Example 29. Preparation of(Z)-3-isopropyl-5-((5-((6-isopropyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione29

Compound 29 was prepared following general procedure A using6-isopropyl-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, CDCl₃): δ(ppm)=7.50 (1H, d J=8.5 Hz), 7.46 (1H, s), 7.41 (1H, brs), 7.16 (1H, dd,J=8.5, 1.5 Hz), 6.97 (1H, d, J=3.5 Hz), 6.72 (1H, d, J=3.5 Hz), 4.63(1H, sep, J=7.0 Hz), 3.00 (1H, sep, J=7.0 Hz), 1.45 (6H, d, J=7.0 Hz),1.27 (6H, d, J=7.0 Hz).

Example 30. Preparation of(Z)-3-isopropyl-5-((5-((7-methoxy-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione30

Compound 30 was prepared following general procedure A using7-methoxy-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=7.67 (1H, s), 7.21 (1H, m), 7.17 (1H, m), 7.11 (1H, m), 6.72 (1H,brs), 4.46 (1H, sep, J=7.0 Hz), 3.89 (3H, s), 1.33 (6H, d, J=7.0 Hz).

Example 31. Preparation of(5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methanol 40

To a solution of 5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carbaldehyde(115 mg, 0.471 mmol) in MeOH (5 ml) was added NaBH₄ (18 mg, 0.471 mmol)at 0° C. and stirred at room temperature for 2 hours. The reactingmixture was quenched with water, extracted with AcOEt (3×), dried overMgSO₄, filtered and concentrated. Purification by chromatography onsilica gel (50 to 100% AcOEt in hexanes) provided 40 (112 mg, 96%yield).

Example 32. Preparation of5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylic acid 41

Compound 41 was prepared following general procedure B. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=13.24 (1H, brs), 7.48 (2H, br), 7.35 (1H, s), 7.18(3H, m).

Example 33. Preparation of5-((1H-benzo[d]imidazol-2-yl)thio)-N-phenylfuran-2-carboxamide 42

Compound 42 was prepared following general procedure B. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.66 (1H, brs), 10.32 (1H, brs), 7.72 (2H, d, J=8.5Hz), 7.54 (1H, d, J=8.0 Hz), 7.49 (1H, d, J=3.5 Hz), 7.41 (1H, d, J=7.0Hz), 7.35 (2H, t, J=8.5 Hz), 7.25 (1H, d, J=3.5 Hz), 7.09-7.20 (3H, m).

Example 34. Preparation of5-((1H-benzo[d]imidazol-2-yl)thio)-N-isopropylfuran-2-carboxamide 43

Compound 43 was prepared following general procedure B. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.60 (1H, brs), 8.30 (1H, d, J=8.5 Hz), 7.52 (1H, d,J=7.0 Hz), 7.40 (1H, d, J=7.0 Hz), 7.24 (1H, d, J=3.5 Hz), 7.14-7.18(2H, m), 4.06 (1H, sep, J=7.5 Hz), 1.12 (6H, d, J=7.5 Hz).

Example 35. Preparation of(5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)(morpholino)methanone 44

Compound 44 was prepared following general procedure B. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.74 (1H, brs), 7.52 (1H, d, J=7.5 Hz), 7.42 (1H, d,J=7.5 Hz), 7.13-7.18 (4H, m), 3.56-3.62 (8H, m).

Example 36. Preparation ofN-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methyl)aniline 45

Compound 45 was prepared following general procedure C. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.45 (2H, m), 7.20 (4H, m), 6.81 (2H, m), 6.68 (2H, m),6.30 (1H, m), 4.32 (2H, m).

Example 37. Preparation of4-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methyl)morpholine 47

Compound 47 was prepared following general procedure C. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.49 (2H, br), 7.19 (2H, m), 6.77 (1H, d, J=3.0 Hz),6.27 (1H, d, J=3.0 Hz), 3.73 (4H, m), 3.46 (2H, s), 2.50 (4H, m).

Example 38. Preparation of2-((5-((4-ethylpiperazin-1-yl)methyl)furan-2-yl)thio)-1H-benzo[d]imidazole48

Compound 48 was prepared following general procedure C. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=10.43 (1H, brs), 7.64 (1H, m), 7.31 (1H, m), 7.19 (2H,m), 6.79 (1H, d, J=3.0 Hz), 6.29 (1H, d, J=3.0 Hz), 3.53 (2H, s),2.53-2.70 (8H, m), 2.44 (2H, q, J=7.5 Hz), 1.09 (3H, t, J=7.5 Hz).

Example 39. Preparation of1-(5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)-N,N-dimethylmethanamine49

Compound 49 was prepared following general procedure C. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.46-7.50 (2H, m), 7.20 (2H, m), 6.81 (1H, d, J=3.5 Hz),6.33 (1H, d, J=3.5 Hz), 3.52 (2H, s), 2.33 (6H, s),

Example 40. Preparation of Methyl2-(((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methyl)amino)acetate50

Compound 50 was prepared following general procedure C. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.50 (2H, br), 7.18 (2H, m), 6.76 (1H, d, J=3.5 Hz),6.29 (1H, d, J=3.5 Hz), 3.85 (2H, s), 3.71 (1H, brs), 3.62 (3H, s), 3.49(2H, s).

Example 41. Preparation of Methyl5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylate 51

To a solution of 5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylicacid (26 mg, 0.10 mmol) and K₂CO₃ (18 mg, 0.13 mmol) in DMF (1 ml) wasadded MeI (7 μl, 0.11 mmol) at room temperature and stirred for 24 hoursat this temperature. The mixture was concentrated and purified byreverse phase (5 to 80% CH₃CN in water) to afford 51 (11 mg). LCMS(M+1)=275, >95% purity.

Example 42. Preparation of Methyl5-((1-methyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-carboxylate 52

Followed procedure F. ¹H NMR (500 MHz, DMSO-d6): δ (ppm)=7.60 (2H, m),7.41 (1H, d, J=3.5 Hz), 7.31 (1H, m), 7.22 (1H, m), 7.19 (1H, d, J=3.5Hz), 3.87 (3H, s), 3.80 (3H, s).

Example 43. Preparation of5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione53

Compound 53 was prepared following general procedure A using1,3-dimethylbarbituric acid. ¹H NMR (500 MHz, DMSO-d6): δ (ppm)=13.0(1H, brs), 8.51 (1H, d, J=4.0 Hz), 8.02 (1H, s), 7.52 (2H, br), 7.26(1H, d, J=4.0 Hz), 7.21 (2H, m), 3.22 (6H, s).

Example 44. Preparation of5-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione54

Compound 54 was prepared following general procedure A using barbituricacid. ¹H NMR (500 MHz, DMSO-d6): δ (ppm)=11.41 (1H, brs), 11.34 (1H,brs), 8.47 (1H, 4.0 Hz), 7.93 (1H, s), 7.50-7.55 (2H, br) 7.26 (1H, d,J=4.0 Hz), 7.19 (2H, m).

Example 45. Preparation of5-((5-((1-(3-aminopropyl)-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dionehydrochloride 55

Compound 55 was prepared following general procedure F using tert-butyl(3-bromopropyl)carbamate. Boc deprotection: The Boc protected amine (70mg) was dissolved in THF (1 ml) and a 4N HCl in dioxane solution (1 ml)was added at room temperature. The mixture was stirred overnight andconcentrated. Diethyl ether (5 ml) was added and the resultingsuspension filtered affording 55. LCMS (M+1)=443, >90% purity.

Example 46. Preparation of(Z)-3-isopropyl-5-((5-((6-(trifluoromethoxy)-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione56

Compound 56 was prepared following general procedure A using6-(trifluoromethoxy)-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.56 (1H, d, J=9.0 Hz), 7.46 (2H, s), 7.16 (1H, d, J=9.0Hz), 7.04 (1H, d, J=3.5 Hz), 6.75 (1H, d, J=3.5 Hz), 4.62 (1H, sep,J=7.0 Hz), 1.44 (6H, d, J=8.0 Hz).

Example 47. Preparation of(Z)-3-isopropyl-5-((5-((6-nitro-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)thiazolidine-2,4-dione57

Compound 57 was prepared following general procedure A using6-nitro-1H-benzo[d]imidazole-2-thiol. ¹H NMR (500 MHz, DMSO-d6): δ(ppm)=8.38 (1H, brs), 8.09 (1H, d, J=8.5 Hz), 7.27 (1H, s), 7.66 (1H, d,J=8.5 Hz), 7.33 (1H, d, J=3.5 Hz), 7.27 (1H, d, J=3.5 Hz), 4.47 (1H,sep, J=7.0 Hz), 1.34 (6H, d, J=7.0 Hz).

Example 48. Preparation of(Z)-5-((5-((6-acetyl-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione58

Compound 58 was prepared following general procedure A using1-(2-mercapto-1H-benzo[d]imidazol-6-yl)ethanone. ¹H NMR (500 MHz,CDCl₃): δ (ppm)=7.68 (1H, s), 7.39 (1H, d, J=8.5 Hz), 7.12 (1H, s), 7.07(1H, d, J=8.5 Hz), 6.60 (1H, d, J=3.5 Hz), 6.49 (1H, d, J=3.5 Hz), 4.12(1H, sep, J=7.0 Hz), 2.18 (3H, s), 0.97 (6H, d, J=7.0 Hz).

Example 49. Preparation ofN-(3-(2-((5-((Z)-(3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)propyl)-5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 59

Triethylamine (16 μl, 113 μmol) and biotin-NHS (20 mg, 56 μmol) wereadded to 55 (18 mg, 38 μmol) at room temperature and stirred overnight.The mixture was concentrated and purified by column chromatography onsilica gel (0 to 15% MeOH in DCM) to afford 59 (21 mg), LCMS(M+1)=669, >95% purity.

Example 50. Preparation of(Z)-5-((5-((6-amino-1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione60

A mixture of 57 (350 mg, 813 μmol) and tin chloride dehydrate (0.55 mg,2.44 mmol) in EtOH (20 ml) was stirred at reflux overnight. The mixturewas cooled down, partioned between DCM and water, and the aqueous layerextracted with DCM (3×). The combined organic layer was dried on MgSO₄,filtered and concentrated. Purification by column chromatography onsilica gel (0 to 15% MeOH in DCM) afforded 60 (256 mg), LCMS(M+1)=401, >95% purity.

Example 51. Preparation of(Z)—N-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-6-yl)benzamide61

Benzoyl chloride was added to a solution of 60 (5 μl, 41 μmol) and DIPEA(10 μl, 56 μmol) in DCM (2 ml) at room temperature. After 2 hours, themixture was concentrated and purified by isco (0 to 10% MeOH in DCM)affording 61 (7 mg) LCMS (M+1)=505, >90% purity.

Example 52. Preparation of(Z)—N-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-6-yl)acetamide62

Compound 63 was prepared according to the preparation of 61, usingacetyl chloride. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.74-7.79 (2H, m),7.45 (1H, m), 7.34 (1H, m), 7.28 (1H, m), 7.13 (1H, m), 6.94 (1H, m),6.65 (1H, m), 4.62 (1H, sep, J=7.0 Hz), 2.21 (3H, s), 1.46 (6H, d, J=7.0Hz).

Example 53. Preparation of (Z)-methyl2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazole-6-carboxylate63

Compound 63 was prepared following general procedure A using methyl2-mercapto-1H-benzo[d]imidazole-6-carboxylate. ¹H NMR (500 MHz, CDCl₃):δ (ppm)=8.21 (1H, br), 7.93 (1H, d, J=9.0 Hz), 7.52 (1H, br), 7.37 (1H,m), 7.00 (1H, d, J=3.5 Hz), 6.68 (1H, m), 4.62 (1H, sep, J=7.0 Hz), 3.92(3H, s), 1.46 (6H, d, J=7.0 Hz).

Example 54. Preparation of(Z)-5-(3-((1H-benzo[d]imidazol-2-yl)oxy)benzylidene)-3-isopropylthiazolidine-2,4-dione65

Step 1: Prepared following general procedure A.

Step 2: A mixture of 2-(methylsulfonyl)-1H-benzo[d]imidazole (101 mg,517 μmol),(Z)-5-(3-hydroxybenzylidene)-3-isopropylthiazolidine-2,4-dione (680 mg,2.58 mmol) and triethylamine (0.35 ml, 2.58 mmol) was stirred at 120° C.overnight. The reacting mixture was cooled down, concentrated andpurified by column chromatography on silica gel (10 to 40% AcOEt inhexanes) to afford 65 (78 mg). ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.77(1H, s), 7.46-7.51 (4H, m), 7.35 (2H, m), 7.22 (2H, m), 4.67 (1H, sep,J=7.0 Hz), 1.48 (6H, d, J=7.0 Hz).

Example 55. Preparation of5-((1-(3-aminopropyl)-1H-benzo[d]imidazol-2-yl)thio)-N-phenylfuran-2-carboxamidehydrochloride 66

Compound 66 was prepared following general procedure F using tert-butyl(3-bromopropyl)carbamate. Boc deprotection: followed conditionsdescribed for 55. LCMS (M+1)=393, >90% purity.

Example 56. Preparation of3-((5-((1H-benzo[d]imidazol-2-yl)thio)furan-2-yl)methyl)thiazolidine-2,4-dione67

Step 1: A solution of Boc₂O (2.0 eq), DMAP (0.1 eq) and triethylamine(3.0 eq) in DCM (0.05M) was stirred at room temperature overnight. Waterwas added and the aqueous layer extracted with DCM (3×). The combinedorganic layers were dried over MgSO₄, filtered and concentrated.Purification by column chromatography on silica gel (10 to 40% AcOEt inhexanes) afforded tert-butyl2-((5-formylfuran-2-yl)thio)-1H-benzo[d]imidazole-1-carboxylate.

To a solution of tert-butyl2-((5-formylfuran-2-yl)thio)-1H-benzo[d]imidazole-1-carboxylate (1 eq)in MeOH (0.05 M) was added NaBH₄ (1.3 eq) at 0° C. The reacting mixturewas stirred for 2 hours at room temperature prior to be quenched byaddition of water. The aqueous layer was extracted with DCM (3×), andthe combined organic layers dried over MgSO₄, filtered and concentrated.

Step 2: Diisopropyl azodicarboxylate (87 μl, 417 μmol) was addeddropwise at 0° C. to a solution of tert-butyl2-((5-(hydroxymethyl)furan-2-yl)thio)-1H-benzo[d]imidazole-1-carboxylate(125 mg, 361 μmol), thiazolidine-2,4-dione (46 mg, 370 μmol) andtriphenylphosphine (109 mg, 415 μmol) in dry THF (0.025M) under argon.The reacting mixture was stirred at 60° C. for 3 hours. Water was addedand the aqueous layer extracted with AcOEt (3×). The combined organiclayers were dried over MgSO₄, filtered and concentrated. Purification bycolumn chromatography on silica gel (20 to 40% AcOEt in hexanes)afforded tert-butyl2-((5-((2,4-dioxothiazolidin-3-yl)methyl)furan-2-yl)thio)-1H-benzo[d]imidazole-1-carboxylate(140 mg). The resulting product (70 mg) was dissolved in THF (3 ml) anda solution of 4N HCl in dioxane (3 ml) was added at 0° C. The reactingmixture was stirred at room temperature overnight. Sat. NaHCO₃ was added(pH8) and the aqueous layer extracted with AcOEt (3×). The combinedorganic layers were dried over MgSO₄, filtered and concentrated.Purification by column chromatography on silica gel (30 to 75% AcOEt inhexanes) afforded 67. ¹H NMR (500 MHz, CDCl₃): δ (ppm)=7.55 (2H, m),7.21 (2H, m), 6.73 (1H, d, J=3.5 Hz,), 3.38 (1H, d, J=3.5 Hz), 4.76 (2H,s), 3.98 (2H, s).

Example 57. Preparation of(Z)-5-((6-((1H-benzo[d]imidazol-2-yl)thio)benzofuran-2-yl)methylene)-3-isopropylthiazolidine-2,4-dione68

Step 1: PCC (1.3 eq) was added to a solution of(6-bromobenzofuran-2-yl)methanol (1 eq) in DCM (0.05 M) at 0° C. After 5hours, the mixture was filtered over celite, concentrated and purifiedby column chromatography on silica gel (0 to 30% AcOEt in hexanes) toafford 6-bromobenzofuran-2-carbaldehyde.

Step 2: Prepared following general procedure D.

Step 3: Prepared following general procedure A. ¹H NMR (500 MHz,DMSO-d6): δ (ppm)=12.74 (1H, brs), 7.94 (1H, m), 7.88 (1H, s), 7.80 (1H,d, J=8.5 Hz), 7.56-7.58 (2H, m), 7.44 (1H, dd, J=8.0, 1.5 Hz), 7.40 (1H,d, J=7.0 Hz), 7.15-7.21 (2H, m), 4.51 (1H, sep, J=7.0 Hz), 1.38 (6H, d,J=7.0 Hz).

Example 58. Preparation of(Z)—N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-2-(2-(2-(2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)acetamido)ethoxy)ethoxy)acetamide69

Step 1: HATU (303 mg, 797 μmol) and DIPEA (214 μl, 1227 μmol) were addedto a solution of Lenalidomide (159 mg, 613 μmol) and2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-oic acid (242 mg, 920μmol) in DMF (0.1 M) at room temperature. The mixture was stirredovernight prior to be quenched with sat. NaHCO₃. The aqueous layer wasextracted with AcOEt (3×), dried over MgSO₄, filtered and concentrated.The crude was purified by short plug on silica gel (50 to 75% Acetone inhexane to afford tert-butyl(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamate.The resulting product was dissolved in THF (5 ml) and a 4N HCl solutionin dioxane (5 ml) was added. The resulting mixture was stirred overnightand concentrated to furnish the corresponding Boc deprotected amine HClsalt.

Step 2: HATU (14 mg, 35 μmol) and DIPEA (10 μl, 55 μmol) were added to asolution of2-(2-(2-aminoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide(10 mg, 23 μmol) and(Z)-2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)aceticacid (12 mg, 27 μmol) in DMF (0.5 ml) at room temperature. The mixturewas stirred overnight, concentrated and purified by prep TLC (5% MeOH inDCM) to afford 69 (14 mg). LCMS (M+1)=831, >95% purity.

Example 59. Preparation of(Z)—N-(2-((3-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)propyl)amino)-2-oxoethyl)-3-(3-methyl-3H-diazirin-3-yl)-N-(prop-2-yn-1l-yl)propanamide71

Step 1: PyBOP (2.95 g, 5.66 mmol) and DIPEA (1.97 ml, 11.32 mmol) wereadded to 3-(3-methyl-3H-diazirin-3-yl)propanoic acid (0.87 g, 6.70 mmol,prepared following Org. Lett. 2013, 15, 5060-5063) and ethyl2-(prop-2-yn-1-ylamino)acetate (0.80 g, 5.66 mmol, prepared followingSynthesis 2009, 3, 488-494) in DMF (10 ml) at room temperature. Thereacting mixture was stirred overnight, concentrated and purified bycolumn chromatography on silica gel (25% AcOEt in hexanes) to provideethyl2-(3-(3-methyl-3H-diazirin-3-yl)-N-(prop-2-yn-1-yl)propanamido)acetate(1.04 g). The resulting product was dissolved in MeOH (15 ml) and asolution of NaOH (389 mg, 2 eq) in water (3 ml) was added at 0° C. Thereacting mixture was stirred overnight at room temperature, thenpartioned between water and DCM and brought to pH2 with 6N HCl. Theaqueous layer was extracted with DCM (3×), the combined organic layersdried over MgSO₄, filtered and concentrated providing2-(3-(3-methyl-3H-diazirin-3-yl)-N-(prop-2-yn-1-yl)propanamido)aceticacid (880 mg).

Step 2: HATU (20 mg, 53 μmol) and DIPEA (16 μl, 88 μmol) were added to55 (21 mg, 44 μmol) and2-(3-(3-methyl-3H-diazirin-3-yl)-N-(prop-2-yn-1-yl)propanamido)aceticacid (11 mg, 48 μmol) in DMF (0.5 ml) at room temperature. The mixturewas stirred overnight, then concentrated and purified by reverse phase(5 to 80% CH₃CN in water) providing 71. LCMS (M+1)=648, >90% purity.

Example 60. Preparation of(Z)—N-(2-((3-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)propyl)amino)-2-oxoethyl)-N-(prop-2-yn-1-yl)pentanamide70

Compound 70 was prepared according to the synthesis of 71 above,starting from valeric acid. LCMS (M+1)=622.

Example 61. Preparation of(Z)—N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)acetamide72

Step 1: Prepared following general procedure F.

Step 2: (Z)-tert-butyl2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)acetate(101 mg) was stirred in a 15% TFA/DCM solution (10 ml) overnight. Themixture was concentrated and used as is.

Step 3: HATU (33 mg, 88 μmol) and DIPEA (24 μl, 135 μmol) were added toa solution of(Z)-2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)aceticacid (30 mg, 68 μmol) and tert-butyl(2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (30 mg, 101 μmol) in DMF (1ml). The reacting mixture was stirred overnight at room temperature,concentrated and purified by column chromatography on silica gel (25 to75% Acetone in hexanes) to afford (Z)-tert-butyl(2-(2-(2-(2-(2-((5-((3-isopropyl-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)acetamido)ethoxy)ethoxy)ethyl)carbamate.The resulting product (33 mg) was stirred in 10% TFA/DCM (0.5 ml) for 3hours and concentrated providing 72. LCMS (M+1)=574, >95% purity.

Example 62. Preparation of(Z)-4-benzoyl-N-(3-(2-((5-((3-(but-3-yn-1-yl)-2,4-dioxothiazolidin-5-ylidene)methyl)furan-2-yl)thio)-1H-benzo[d]imidazol-1-yl)propyl)benzamide73

Step 1: Prepared according to general procedure A and E.

Step 2: Prepared according to the synthesis of 55.

Step 3: Prepared according to the synthesis of 71, using4-benzoylbenzoic acid. LCMS (M+1)=661, >95% purity.

Characterization of the Compounds Example 1. Solubility and Half-Life ofCompound 1

Exemplary solubility and half-life of compound 1 are shown in Table 1.

TABLE 1 Solubility and half-life of compound 1 Solubility at 37 °C.Half-life (μM) (minute) Aqueous solubility 80.2 (simulated intestinalfluid) Aqueous solubility <1 (PBS, pH 7.4) Aqueous solubility 62.7(simulated gastric fluid) Intrinsic clearance 22 (liver microsomes,human)

Compound Screening

More than 40,000 compounds were screened by combining unbiased SmallMolecule Microarray (SMMs) binding assays involving c-Myc with acell-based transcriptional readout. SMMs have been proven to be ageneral, robust, and scalable screening platform for discoveringprotein-small molecule interactions that lead to modulators of proteinfunction [10]. Purified 6×His-tagged c-Myc was incubated with SMMscontaining the compounds. Binding was detected using an Alexa647-labeledantibody against the 6×His-tag. Z-scores were computed for each compoundusing fluorescence intensities across three replicates as describedpreviously [10]. 313 compounds scored as selective assay positives.

Biological Assays of the Compounds Described Herein Example 1. c-MycReporter Gene Assay of Exemplary Compounds Described Herein

Select compounds described herein that were SMM assay positives wereevaluated in several versions of a c-Myc reporter gene assay, includinga commercial assay from Qiagen. The compounds' activities against c-Mycwere measured as a Firefly/Renilla ratio, using the Myc reporter assay(Qiagen) in HEK293T cells after treatment with the compounds for 16hours. Exemplary results are shown in Table 2. Compound 1 was a potentinhibitor with an IC₅₀ value of 0.67 μM (FIG. 1B and Table 2).

TABLE 2 IC₅₀ values of exemplary compounds described herein in the c-Mycreporter assay and viability data in select cell lines. Viability wasassessed by CELL TITER GLO assay (Promega). Results expressed as a mean+/− SEM (n = 3). c-Myc reporter IC₅₀ Viability in Viability in Viabilityin Eu- assay IC₅₀ standard Namalwa NCIH1975 Myc Arf −/− Compound # (μM)(μM) cells (μM) cells (μM) cells (μM) cLogP 1 0.67 — 21.14 24.91 10.25.2 2 7.5 0.74 >50 >50 >50 2.5 3 5.72 0.74 31.12 >50 >50 5.7 4 0.79 0.7412.44 17.32 11.01 6 5 1.19 0.74 42.15 34.53 >50 5.5 6 9.39 0.7437.23 >50 >50 5.1 7 >40 0.74 20.06 45.31 >50 4.6 8 0.83 0.74 >50 >5011.79 3.8 9 9.02 0.74 >50 >50 >50 2.4 10 5.6 0.74 >50 >50 33.13 4.4 111.62 0.84 — — — 5.7 13 inactive 0.84 — — — 3.6 14 1.96 0.84 — — — 5.2 153.26 0.84 — — — 3.9 16 20.8 0.84 — — — 3.6 17 7.67 0.84 — — — 4.3 181.67 0.84 — — — 5.2 19 6.52 0.84 — — — 3.8 20 1.22 0.84 — — — 5.6 216.77 0.84 — — — 4.5 22 1.05 0.74 16.54 45.27 6.09 4.57 23 1.5 0.74 33.9328.18 10.49 5.71 24 0.64 0.74 7.94 12.47 11.21 6.23 25 0.63 0.74 3.957.88 5.51 6.62 26 33.65 0.74 >50 >50 >50 3.31 27 2.28 0.74 12.17 >5026.04 1.61 28 0.98 0.74 9.41 15.58 5.36 6 29 0.64 0.74 15.27 19.95 13.056.64 30 1.63 0.74 72.03 56.3 11.14 5.51 31 2.22 3.00 — — — 5.74 32 6.243.00 — — — 4.24 33 2.77 3.00 — — — 4.77 34 7.01 3.00 — — — 5.52 35 11.93.00 — — — 6.28 36 >100 3.00 — — — 3.37 37 >100 3.00 — — — 4.7 38 >1003.00 — — — 2.5 39 >100 3.00 — — — 5.71 40 >40 0.74 >50 >50 14.11 2.62 41non active 2.09 — — — 3.42 42 3.32 2.09 — — — 4.19 43 7.9 2.09 — — —3.23 44 non active 2.09 — — — 2.32 45 4.66 2.09 — — — 4.61 46 57.47 2.09— — — 3.87 47 32.9 2.09 — — — 3.41 48 10.23 2.09 — — — 4.5 49 59.37 2.09— — — 3.5 50 75.9 2.09 — — — 2.99 51 non active 2.09 — — — 3.66 52 nottested 2.09 — — — 3.68 53 26.81 2.09 — — — 3.8 54 non active 2.09 — — —2.31 55 not tested — — — — 56 0.44 0.26 — — — 6.6 57 0.36 0.26 — — — 5.158 0.26 0.26 — — — 4.9 59 not tested — not tested not tested not tested60 4.56 0.68 not tested not tested not tested 4.7 61 0.4 0.68 not testednot tested not tested 6.3 62 0.93 0.68 not tested not tested not tested4.8 63 1.49 0.68 not tested not tested not tested 5.3 64 1.82 0.68 nottested not tested not tested 6.1 65 0.99 0.68 not tested not tested nottested 5.2 66 not tested — not tested not tested not tested 3.77 6729.97 0.68 not tested not tested not tested 3.4 68 0.54 0.68 not testednot tested not tested 6.6 69 not tested — not tested not tested nottested 3.9 70 not tested — not tested not tested not tested — 71 nottested — not tested not tested not tested — 72 not tested — not testednot tested not tested — 73 not tested — not tested not tested not tested—

Example 2. Cell Viability Assay of Exemplary Compounds Described Herein

The effect of compound 1 on cell viability in several cancer cell lineswere determined. The cancer cell lines employed in the assay includedthose corresponding to hematopoietic and solid tumors. Exemplary resultsare shown in FIGS. 2A to 2E, where viability was assessed by CELL TITERGLO assay (Promega). Compound 1 was also submitted in a blinded fashionto the National Cancer Institute's CTD cancer cell line profilingpipeline, which enabled sensitivity profiling in about 800 cancer celllines with annotation of specific genomic lesions that impart on humancancers (FIGS. 3A to 3B). Compound 1 demonstrated an effect in cellviability in a variety of cancer cell lines, consistent with the notionthat Myc is a key oncoprotein in a broad range of cancers. The effectsof other compounds described herein on cell viability in several cancercell lines were also determined, and exemplary results are shown inTable 2, where viability was assessed by CELL TITER GLO assay (Promega).

Example 3. Target Identification Experiments of Exemplary CompoundsDescribed Herein

In order to explore the mechanism of action of compound 1, preliminarytarget identification experiments involving affinity-based pull downswere carried out. Compound 1 was modified to append a short linker offof the thiazolidine-2,4-dione moiety, which had been shown to betolerated during an evaluation of select compounds (Table 2). Compound19 contains a short linker off of the thiazolidine-2,4-dione moiety andwas found to have an IC₅₀ value of 7.3 μM in Myc reporter assay. Thestructure of compound 19 allowed for linking compound 1 to beads(AFFI-GEL 102, Bio-Rad) (FIG. 4). Incubating the loaded beads withnuclear lysate, and 1 and 5 μM of compound 1, which was unbound to thebeads and acted a soluble competitor, followed by a pull down of thebeads and subsequent analysis by Western blot of c-Myc levels, it wasobserved that there was less c-Myc pulled down in the presence of 5 μMof compound 1 as a soluble competitor (FIG. 5A), suggesting thatcompound 1 is capable of binding to Myc-associated complexes in celllysates.

A similar approach that linked the beads onto the right part (e.g., anitrogen atom of the benzimidazolyl moiety) of the compounds also showeddecreased levels of c-Myc when compound 1 was added as a solublecompetitor (FIG. 5B). The linkage site to the bead via the nitrogen atomof the benzimidazolyl moiety was the original site of attachment to thesmall-molecule microarray and represented the orientation in theoriginal screen. This orientation was shown to be superior to the onethat corresponds to the linkage site to the bead via the nitrogen atomof the thiazolidine-2,4-dione moiety, from the perspective of pullingdown Myc.

REFERENCES

-   1. Vita et al., Semin. Cancer Biol., 16, 318-330, (2006).-   2. Dang, Mol. Cell Biol., 19, 1-11 (1999).-   3. Eilers et al., Genes Dev., 22, 2755-2766 (2008).-   4. van Riggelen et al., Nat. Rev. Cancer, 10, 301-309 (2010).-   5. Dang et al., Semin. Cancer Biol., 16, 253-264 (2006).-   6. Boxer et al., Oncogene, 20, 5595-5610 (2002).-   7. Frost et al., Am. J. Clin. Pathol., 121, 384-392 (2004).-   8. Felsher et al., Mol. Cell, 4, 199-207 (1999).-   9. Soucek et al., Genes Dev., 5, 504-513 (2013).-   10. Frye, Nat. Chem. Biol., 6, 159-161 (2010).-   11. Leskov, Oncogene, 32, 1066-1072 (2013).

EQUIVALENTS AND SCOPE

In the claims articles such as “a,” “an,” and “the” may mean one or morethan one unless indicated to the contrary or otherwise evident from thecontext. Claims or descriptions that include “or” between one or moremembers of a group are considered satisfied if one, more than one, orall of the group members are present in, employed in, or otherwiserelevant to a given product or process unless indicated to the contraryor otherwise evident from the context. The invention includesembodiments in which exactly one member of the group is present in,employed in, or otherwise relevant to a given product or process. Theinvention includes embodiments in which more than one, or all of thegroup members are present in, employed in, or otherwise relevant to agiven product or process.

Furthermore, the invention encompasses all variations, combinations, andpermutations in which one or more limitations, elements, clauses, anddescriptive terms from one or more of the listed claims is introducedinto another claim. For example, any claim that is dependent on anotherclaim can be modified to include one or more limitations found in anyother claim that is dependent on the same base claim. Where elements arepresented as lists, e.g., in Markush group format, each subgroup of theelements is also disclosed, and any element(s) can be removed from thegroup. It should it be understood that, in general, where the invention,or aspects of the invention, is/are referred to as comprising particularelements and/or features, certain embodiments of the invention oraspects of the invention consist, or consist essentially of, suchelements and/or features. For purposes of simplicity, those embodimentshave not been specifically set forth in haec verba herein. It is alsonoted that the terms “comprising” and “containing” are intended to beopen and permits the inclusion of additional elements or steps. Whereranges are given, endpoints are included. Furthermore, unless otherwiseindicated or otherwise evident from the context and understanding of oneof ordinary skill in the art, values that are expressed as ranges canassume any specific value or sub-range within the stated ranges indifferent embodiments of the invention, to the tenth of the unit of thelower limit of the range, unless the context clearly dictates otherwise.

This application refers to various issued patents, published patentapplications, journal articles, and other publications, all of which areincorporated herein by reference. If there is a conflict between any ofthe incorporated references and the instant specification, thespecification shall control. In addition, any particular embodiment ofthe present invention that falls within the prior art may be explicitlyexcluded from any one or more of the claims. Because such embodimentsare deemed to be known to one of ordinary skill in the art, they may beexcluded even if the exclusion is not set forth explicitly herein. Anyparticular embodiment of the invention can be excluded from any claim,for any reason, whether or not related to the existence of prior art.

Those skilled in the art will recognize or be able to ascertain using nomore than routine experimentation many equivalents to the specificembodiments described herein. The scope of the present embodimentsdescribed herein is not intended to be limited to the above Description,but rather is as set forth in the appended claims. Those of ordinaryskill in the art will appreciate that various changes and modificationsto this description may be made without departing from the spirit orscope of the present invention, as defined in the following claims.

What is claimed is:
 1. A compound of Formula (I-a):

or a pharmaceutically acceptable salt thereof, wherein: each instance ofR^(A) is independently hydrogen, halogen, substituted or unsubstitutedalkyl, substituted or unsubstituted alkenyl, substituted orunsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, —OR^(a), —N(R^(a))₂,—SR^(a), —CN, —SCN, —C(═NR^(a))R^(a), —C(═NR^(a))OR^(a),—C(═NR^(a))N(R^(a))₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂, —NO₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)N(R^(a))₂,—N(R^(a))S(═O)R^(a), —N(R^(a))S(═O)OR^(a), —N(R^(a))S(═O)N(R^(a))₂,—N(R^(a))S(═O)₂R^(a), —N(R^(a))S(═O)₂OR^(a), —N(R^(a))S(═O)₂N(R^(a))₂,—OC(═O)R^(a), —OC(═O)OR^(a), or —OC(═O)N(R^(a))₂, or two instances ofR^(A) are joined to form a substituted or unsubstituted, carbocyclicring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted, aryl ring, or substituted or unsubstituted, heteroarylring; k is 0, 1, 2, or 3; L is —N—, —O—, —S—, or a bond; X^(a) is—NR^(B)—, —O—, or —S—; W^(a) is —C(R^(A))═, or —N═; R^(B) is hydrogen,substituted or unsubstituted C₁₋₆ alkyl, or a nitrogen protecting group;R^(D) is hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, —OR^(d1), —N(R^(d1))₂, —NO₂, —NR^(d1)C(═O)R^(d1),—NR^(d1)C(═O)OR^(d1), —NR^(d1)C(═O)N(R^(d1))₂, —OC(═O)R^(d1),—OC(═O)OR^(d1), —OC(═O)N(R^(d1))₂, —C(═O)R^(d1), —C(═O)OR^(d1),—C(═O)N(R^(d1))₂, —CH₂N(R^(d1))₂, or —CH₂OR^(d1); each instance of R^(a)is independently hydrogen, substituted or unsubstituted acyl,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(a) are joined to form a substituted or unsubstituted carbocyclylring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted aryl ring, or substituted or unsubstituted, heteroarylring; each instance of R^(d1) is independently hydrogen, substituted orunsubstituted acyl, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(d1) are joined to form a substituted or unsubstituted carbocyclylring, substituted or unsubstituted, heterocyclic ring, substituted orunsubstituted aryl ring, or substituted or unsubstituted, heteroarylring; and Ring A is a substituted or unsubstituted aryl, or substitutedor unsubstituted heteroaryl.
 2. The compound of claim 1, wherein thecompound is of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein: each instance ofR^(A) is independently halogen, substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, —OR^(a), —N(R^(a))₂, —SR^(a),—CN, —SCN, —C(═NR^(a))R^(a), —C(═NR^(a))OR^(a), —C(═NR^(a))N(R^(a))₂,—C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂, —NO₂, —N(R^(a))C(═O)R^(a),—N(R^(a))C(═O)OR^(a), —N(R^(a))C(═O)N(R^(a))₂, —N(R^(a))S(═O)R^(a),—N(R^(a))S(═O)OR^(a), —N(R^(a))S(═O)N(R^(a))₂, —N(R^(a))S(═O)₂R^(a),—N(R^(a))S(═O)₂OR^(a), —N(R^(a))S(═O)₂N(R^(a))₂, —OC(═O)R^(a),—OC(═O)OR^(a), or —OC(═O)N(R^(a))₂, or two instances of R^(A) are joinedto form a substituted or unsubstituted, carbocyclic ring, substituted orunsubstituted, heterocyclic ring, substituted or unsubstituted, arylring, or substituted or unsubstituted, heteroaryl ring; each instance ofR^(a) is independently H, substituted or unsubstituted acyl, substitutedor unsubstituted alkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, substituted or unsubstitutedcarbocyclyl, substituted or unsubstituted heterocyclyl, substituted orunsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogenprotecting group when attached to a nitrogen atom, an oxygen protectinggroup when attached to an oxygen atom, or a sulfur protecting group whenattached to a sulfur atom, or two instances of R^(a) are joined to forma substituted or unsubstituted, heterocyclic ring, or substituted orunsubstituted, heteroaryl ring; k is 0, 1, 2, 3, or 4; R^(B) ishydrogen, substituted or unsubstituted C₁₋₆ alkyl, or a nitrogenprotecting group; X is —O— or —S—; the double bond labeled with “a” isin the (E)- or (Z)-configuration; and R^(C) is hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, —C(═O)R^(a),—C(═O)OR^(a), —C(═O)N(R^(a))₂, or a nitrogen protecting group.
 3. Thecompound of claim 1, wherein W^(a) is —N═.
 4. The compound of claim 1,wherein the compound is not of the formula:

or a pharmaceutically acceptable salt thereof.
 5. The compound of claim1, wherein the compound is not of the formula:


6. The compound of any one of claims 1-5, wherein the compound is of theformula:

or a pharmaceutically acceptable salt thereof.
 7. The compound of anyone of claims 1-5, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 8. The compound of anyone of claims 1-5, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 9. The compound of anyone of claims 1-5, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 10. The compound of anyone of claims 1-5, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 11. The compound of anyone of claims 1-5, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 12. The compound of anyone of claims 1-11, wherein at least one instance of R^(A) is halogen,—OR^(a), —N(R^(a))₂, —NO₂, —C(═O)R^(a), —C(═O)OR^(a), —C(═O)N(R^(a))₂,—N(R^(a))C(═O)R^(a), —N(R^(a))C(═O)N(R^(a))₂, or —N(R^(a))S(═O)₂R^(a).13. The compound of claim 12, wherein at least one instance of R^(A) isCl, —OMe, —OCF₃, —NH₂, —NHMe, —NMe₂, —NO₂, —C(═O)Me, —C(═O)OH,—C(═O)OMe, —C(═O)NH₂, —C(═O)NHMe, —C(═O)NHPh, —C(═O)-(1-morpholinyl),—NHC(═O)Me, —NHC(═O)Ph, —NHC(═O)NH(i-Pr), —NHC(═O)NHPh, —NHS(═O)₂Me, or—NHS(═O)₂Ph.
 14. The compound of any one of claims 1-11, wherein atleast one instance of R^(A) is substituted or unsubstituted alkyl. 15.The compound of claim 14, wherein at least one instance of R^(A) is Me.16. The compound of claim 14, wherein at least one instance of R^(A) is—CF₃, —CH₂OH, or i-Pr.
 17. The compound of any one of claims 1-5, 8 and11, wherein k is
 0. 18. The compound of any one of claims 1-5, 8, and11-16, wherein k is
 1. 19. The compound of any one of claims 1-5, 8, and11-16, wherein k is
 2. 20. The compound of any one of claims 1-10 and12-19, wherein R^(B) is hydrogen.
 21. The compound of any one of claims1-10 and 12-19, wherein R^(B) is substituted or unsubstituted C₁₋₆alkyl.
 22. The compound of claim 21, wherein R^(B) is of the formula:—(CH₂)_(a)N(R^(a1))₂, wherein: a is independently 1, 2, 3, or 4; andeach instance of R^(a1) is independently hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl.
 23. The compound of claim22, wherein: a is 3; and each instance of R^(a1) is hydrogen.
 24. Thecompound of claim 1, wherein R^(B) is of the formula:—(CH₂)_(a)NHC(═O)(CH₂)_(b)R^(b1), wherein: R^(b1) is H, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl, or —N(R^(b2))C(═O)R^(b3);each instance of a and b is independently 1, 2, 3, or 4; and eachinstance of R^(b2) and R^(b3) is independently H, substituted orunsubstituted acyl, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl.
 25. The compound of claim 24, wherein R^(b1) is a bicyclicheterocycle.
 26. The compound of claim 25, wherein R^(b1) is of theformula:

or a pharmaceutically acceptable salt thereof.
 27. The compound of claim1, wherein R^(B) is of the formula: —(CH₂)_(a)C(═O)NHR^(c1), wherein:R^(c1) is hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted alkynyl, substitutedor unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl.
 28. The compound of claim 27, wherein: R^(c1) is of theformula: —(CH₂)_(d)O(CH₂)_(e)O(CH₂)C(═O)NHR^(e1), wherein: R^(e1) isindependently hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted alkenyl, substituted or unsubstituted alkynyl,substituted or unsubstituted carbocyclyl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted aryl, substituted orunsubstituted heteroaryl; and each instance of d, e, or f isindependently 1, 2, 3, 4, 5, or
 6. 29. The compound of claim 28,wherein: R^(e1) is of the formula:


30. The compound of claim 1, wherein R^(B) is of the formula:—(CH₂)_(a)NHC(═O)R^(f1), wherein R^(f1) is independently hydrogen,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl.
 31. The compound of claim 30, wherein R^(f1) is substitutedphenyl.
 32. The compound of claim 30, wherein R^(f1) is of the formula:


33. The compound of claim 27, wherein: R^(c1) is of the formula:


34. The compound of claim 27, wherein R^(b1) is of the formula:


35. The compound of claim 22, wherein R^(b1) is of the formula:


36. The compound of claim 1, wherein R^(B) is Me or —(CH₂)₃NH₂.
 37. Thecompound of any one of claims 1-7 and 12-36, wherein X is —O—.
 38. Thecompound of any one of claims 1-7 and 12-36, wherein X is —S—.
 39. Thecompound of any one of claims 1-7 and 12-38, wherein the double bondlabeled with “a” is in the (E)-configuration.
 40. The compound of anyone of claims 1-7 and 12-38, wherein the double bond labeled with “a” isin the (Z)-configuration.
 41. The compound of any one of claims 1-40,wherein R^(C) is substituted or unsubstituted C₁₋₆ alkyl.
 42. Thecompound of claim 38, wherein R^(C) is i-Pr.
 43. The compound of claim38, wherein R^(C) is sec-Bu.
 44. The compound of claim 38, wherein R^(C)is —CH₂—CO₂H, —CH₂—CO₂Me, —CH₂—CO₂(t-Bu), —CH(Me)-CO₂Me, —CH(Me)-CO₂Et,


45. The compound of claim 38, wherein R^(C) is —(CH₂)₃—NH₂,—(CH₂)₃—NHC(═O)NHEt, —(CH₂)₃—NHC(═O)NHPh, or


46. The compound of any one of claims 1-38, wherein R^(C) is substitutedor unsubstituted phenyl.
 47. The compound of claim 1, wherein Ring A isof the formula:

or a pharmaceutically acceptable salt thereof, wherein: W is —NH—, —O—or —S—.
 48. The compound of claim 1, wherein Ring A is a monocyclic orbicyclic heteroaryl ring.
 49. The compound of claim 1, wherein Ring A isof the formula:

or a pharmaceutically acceptable salt thereof, wherein: Y is —O— or —S—.50. The compound of claim 47, wherein when W is —O—, then k is 1, 2, 3,or 4, and no instance of R^(A) is Me.
 51. The compound of claim 47,wherein when W is —O—, and k is 1, then no instance of R^(A) is Me. 52.The compound of claim 1, wherein R^(D) is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: X¹ is —S—, or—NR^(C)—, —CH₂—; and R^(C) is H, substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)N(R^(a))₂, or a nitrogen protecting group.
 53. The compound ofclaim 52, wherein R^(D) is of the formula:

or a pharmaceutically acceptable salt thereof.
 54. The compound of claim1, wherein R^(D) is of the formula: —CH₂OR^(F), —C(═O)OR^(F),—C(═O)N(R^(g1))₂, or —CH₂N(R^(g1))₂; R^(F) is H, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, substituted or unsubstituted heteroaryl; and R^(g1) is H,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, or two instances of R^(g1) are joined to form a substitutedor unsubstituted, carbocyclic ring, substituted or unsubstituted,heterocyclic ring, substituted or unsubstituted, aryl ring, orsubstituted or unsubstituted, heteroaryl ring.
 55. The compound of claim1, wherein R^(D) is of the formula:

or a pharmaceutically acceptable salt thereof.
 56. The compound of claim1, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 57. The compound of claim1, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 58. The compound of claim1, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 59. The compound of claim1, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 60. The compound of claim1, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 61. A compound of Formula(II):

or a pharmaceutically acceptable salt thereof, wherein: the double bondlabeled with “a” is in the (E)- or (Z)-configuration; R^(C) is hydrogen,substituted or unsubstituted acyl, substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, —C(═O)R^(a), —C(═O)OR^(a),—C(═O)N(R^(a))₂, or a nitrogen protecting group; each instance of R^(a)is independently hydrogen, substituted or unsubstituted acyl,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, a nitrogen protecting group when attached to a nitrogenatom, an oxygen protecting group when attached to an oxygen atom, or asulfur protecting group when attached to a sulfur atom, or two instancesof R^(a) are joined to form a substituted or unsubstituted, heterocyclicring, or substituted or unsubstituted, heteroaryl ring; and R^(E) is asubstituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl.
 62. The compound of claim 61, wherein R^(E) is of theformula:

or a pharmaceutically acceptable salt thereof, wherein: X is —O— or —S—;and Ring B is a substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl.
 63. The compound of claim 61,wherein R^(E) is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: X is —O— or —S—and Ring B is a substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl.
 64. The compound of claim 61,wherein Ring B is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: W¹ and Y¹ areindependently —N—, or —NR^(W)—, as valency permits; and R^(W) is H,substituted or unsubstituted alkyl, substituted or unsubstituted acyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted carbocyclyl, substituted orunsubstituted heterocyclyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, or a nitrogen protecting group.65. The compound of claim 61, wherein Ring B is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: Z is —N— or—CH—; and R^(G) is hydrogen, or substituted or unsubstituted alkyl. 66.The compound of claim 63 or 64, wherein Ring B is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: Y¹ and Z¹ areindependently —NR^(g)—, —CH—, or —O—; and R^(g) is hydrogen, orsubstituted or unsubstituted alkyl.
 67. The compound of claim 61,wherein R^(E) is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: X is —O— or —S—;and R^(X) is hydrogen, substituted or unsubstituted alkyl, substitutedor unsubstituted acyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted carbocyclyl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedaryl, or substituted or unsubstituted heteroaryl.
 68. The compound ofclaim 61, wherein R^(E) is of the formula:

or a pharmaceutically acceptable salt thereof, wherein: R^(f) ishydrogen, or substituted or unsubstituted alkyl.
 69. The compound ofclaim 61, wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.
 70. A pharmaceuticalcomposition comprising a compound of any one of claims 1-69, or apharmaceutically acceptable salt thereof, and optionally apharmaceutically acceptable excipient.
 71. The pharmaceuticalcomposition of claim 70 further comprising an additional pharmaceuticalagent.
 72. A method of treating a disease in a subject in need thereof,the method comprising administering to the subject an effective amountof a compound of any one of claims 1-69, or a pharmaceutical compositionof claim 70 or 72, wherein the disease is associated with Myc.
 73. Themethod of claim 72, wherein the disease is associated with increasedactivity of Myc.
 74. The method of claim 72 or 73, wherein the diseaseis associated with a mutant form of Myc.
 75. The method of any one ofclaims 72-74, wherein the disease is associated with somaticamplification of Myc.
 76. The method of any one of claims 72-75, whereinthe disease is associated with a chromosomal translocation.
 77. Themethod of any one of claims 72-76, wherein the disease is associatedwith overexpression of Myc.
 78. The method of any one of claims 72-77,wherein the disease is associated with enhanced translation of Myc. 79.The method of any one of claims 72-78, wherein the disease is associatedwith increased stability of Myc.
 80. A method of treating a disease in asubject in need thereof, the method comprising administering to thesubject an effective amount of a compound of any one of claims 1-69, ora pharmaceutical composition of claim 70 or 71, wherein the disease is aproliferative disease.
 81. The method of any one of claims 72-80,wherein the disease is cancer.
 82. The method of 81, wherein the diseaseis lung cancer, cervical cancer, breast cancer, or colorectal cancer.83. The method of 81, wherein the disease is ovarian cancer, pancreaticcancer, gastric cancer, or uterine cancer.
 84. The method of 81, whereinthe disease is hematological malignancy.
 85. The method of 81, whereinthe disease is lymphoma.
 86. The method of any one of claims 70-78,wherein the disease is benign neoplasm.
 87. The method of any one ofclaims 70-78, wherein the disease is pathological angiogenesis.
 88. Amethod of modulating the activity of Myc in a subject in need thereof,the method comprising administering to the subject a therapeuticallyeffective amount of a compound of any one of claims 1-69, or apharmaceutical composition of claim 70 or
 71. 89. The method of any oneof claims 70-88, wherein the Myc is c-Myc, L-Myc, or N-Myc.
 90. Themethod of any one of claims 70-88, wherein the subject is a human.
 91. Amethod of inducing apoptosis of a cell, the method comprising contactingthe cell with an effective amount of a compound of any one of claims1-69, or a pharmaceutical composition of claim 70 or
 71. 92. The methodof claim 91, wherein the cell is in vitro.
 93. The method of claim 91,wherein the cell is in vivo.
 94. A kit comprising: a compound of any oneof claims 1-69, or a pharmaceutical composition of claim 70 or 71; andinstructions for using the compound or pharmaceutical composition.